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Summary 
 
 Candida species are commonly part of the normal flora in humans; 
however, they are opportunistic fungal pathogens that are capable of causing a 
variety of infections in hospitalized and immunocompromised individuals. 
These infections range from superficial to systemic ones. Many Candida 
infections involve biofilm formation on the surfaces of implanted devices, such 
as catheters and prostheses, or host tissues. Candida biofilms are resistant to a 
range of antifungal agents in current clinical use but the basis of this drug 
resistance is not clear. The aim of this project was to investigate possible 
resistance mechanisms using two fungicidal agents, amphotericin B and 
caspofungin, a new drug reported to have anti-biofilm activity. 
 The activity of amphotericin B and caspofungin at different development 
phases of Candida biofilms was investigated in vitro. Amphotericin B at two 
times the MIC (for planktonic culture) had the least effect on Candida biofilms, 
but at a higher concentration (five times the MIC) it showed relatively high 
activity against biofilms of C. parapsilosis and C. glabrata, especially at the 
late development phase. Biofilms of C. albicans were more resistant to 
amphotericin B throughout development (except for the earliest stage) than 
the other Candida species. Caspofungin, at two times the MIC, generally exhibited 
a greater effect on Candida biofilms than amphotericin B although this was not 
observed with C. parapsilosis biofilms in some development phases. 
Caspofungin, at five times the MIC, was slightly less effective than at the lower 
concentration against C. tropicalis in all development phases tested. The 
species most susceptible to caspofungin throughout biofilm development was C. 
glabrata. In no case were biofilm cells of any Candida species completely killed 
by either amphotericin B or caspofungin.  
 The penetration of caspofungin through biofilms of different Candida 
species was evaluated using an in vitro filter disc bioassay.  Caspofungin 
penetration through biofilms of C. albicans SC5314 was initially faster than C. 
albicans GDH2346; however, after 6 h drug diffusion was greater with biofilms 
of strain GDH2346 (70.8% of the control value). Among other Candida species 
tested, the highest drug penetration was observed with C. glabrata and C. 
parapsilosis (81.2% and 73.3% of the control value, respectively), while the 
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lowest was seen with biofilms of C. krusei. Biofilms of C. tropicalis also showed 
poor penetration. Exposure of biofilms of any Candida species to caspofungin 
(or amphotericin B) in this assay failed to result in complete killing of biofilm 
cells. However, evaluation of caspofungin activity against biofilms was 
complicated by the paradoxical phenomenon (reduced activity of the drug at 
high concentrations, above the minimum inhibitory concentration). Scanning 
electron microscopy revealed that caspofungin caused more structural damage 
to biofilm cells and matrix than did amphotericin B; the highest degree of 
damage due to caspofungin was observed in biofilms of C. glabrata and C. 
krusei.  
 The presence of a small number of drug-tolerant or persister cells is one 
possible mechanism of biofilm drug resistance. Biofilms and planktonic cells of 
five Candida species were surveyed for the presence of persister cell 
populations after exposure to amphotericin B. None of the planktonic cultures 
(exponential or stationary phase) contained persister cells. However, persisters 
were found in biofilms of one of two strains of C. albicans tested and in 
biofilms of C. krusei and C. parapsilosis, but not in biofilms of C. glabrata or C. 
tropicalis. Live-dead staining with fluorescein diacetate confirmed these 
results which do, however, suggest that persister cells cannot solely account 
for drug resistance in Candida biofilms. 
 If microorganisms exposed to antimicrobial agents undergo a type of 
programmed cell death or apoptosis, persisters could be variant in which this 
process has been disabled. Here, specific staining methods were used to 
investigate the existence of apoptosis in Candida biofilms subjected to 
different concentrations of amphotericin B. Caspase activity, indicative of 
apoptosis, was detected with SR-FLICA and D2R fluorochrome-based staining 
reagents in all of these biofilms. The general inhibitor of mammalian caspases, 
Z-VAD-FMK, when used at a low concentration (2.5 µM), increased the viability 
of drug-treated biofilms up to 11.5-fold (P<0.001%). Seven specific caspase 
inhibitors had different effects on C. albicans biofilm viability, but inhibitors of 
caspases-1, -9, -5, -3, and -2 all significantly increased cell survival (40-fold, 8-
fold, 3.5-fold, 1.9-fold and 1.7-fold, respectively). On the other hand, histone 
deacetylase (HDA) inhibitors enhanced the activity of amphotericin B against 
biofilms of all three Candida species. Sodium butyrate and sodium valproate, 
for example, when added concurrently with amphotericin B, completely 
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eliminated biofilm populations of C. albicans. Overall, these results 
demonstrate an apoptotic process in amphotericin-treated biofilms of three 
Candida species. They also indicate that HDA inhibitors can enhance the action 
of the drug and in some cases even eradicate persister subpopulations, 
suggesting that histone acetylation might activate apoptosis in these cells.  
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1 Candida 
1.1  Background 
 Candida species are yeasts, or single-celled fungi, that commonly 
colonize different body sites such as the skin, oral cavity, oesophagus,  and 
gastrointestinal and genital tracts (Kumamoto & Vinces, 2005; Odds, 1988; 
Wingard & Leather, 2004). According to Odds (1988), most people carry a single 
strain of Candida at different body sites, as part of their normal flora. 
However, a few individuals may harbour more than one strain or species of 
Candida at the same time; this occurs more commonly in hospitalized and 
immunocompromised patients (McCullough et al., 1996).  Under normal 
circumstances, Candida species remain as commensals and do not produce 
clinical disease; however, they may become opportunistic pathogens under 
certain conditions (Odds, 1988). Although there are about 200 species of 
Candida, it is well established that only a few are pathogenic for humans; in 
fact, 65% of Candida species are unable to grow at a temperature of 37°C 
(Schauer & Hanschke, 1999). Six species are most frequently isolated in human 
infections, namely, C. albicans, C. tropicalis, C. glabrata, C. parapsilosis, C. 
krusei, and C. lusitaniae (AbiSaid, 1997).  
 C. albicans is the most significant and frequently isolated yeast 
pathogen. According to data from the US National Nosocomial Infections 
Surveillance System, approximately 50% of fungal nosocomial infections are 
caused by C. albicans (Calderone, 2002; Marcilla et al., 1998). C. albicans is 
also the predominant species in fungal biofilm infections of medical devices 
(He et al., 2006). In vitro, C. albicans biofilms exhibit resistance to a wide 
range of commonly used antifungals such as fluconazole, amphotericin B, 
nystatin, and ketoconazole, as well as the newer triazoles, ravuconazole and 
voriconazole (Chandra et al., 2001a; Chandra et al., 2001b; Hawser & Douglas, 
1995; Kuhn et al., 2002a; Kuhn et al., 2002b). However, in recent years there 
has been a shift from C. albicans to non-C. albicans Candida species (NCAC) so 
that approximately half of the reported cases of Candidaemia are now caused 
by NCAC. Non-C. albicans species such as C. glabrata, C. krusei, C. 
parapsilosis, C. tropicalis and the new species, C. dubliniensis, have been 
identified as important opportunistic pathogens; these species are sometimes 
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less susceptible than C. albicans to antifungal agents and may require a higher 
dosage for a clinical cure (Cheng et al., 2005; Yucesoy & Marol, 2003) .  
 C. tropicalis, unlike C. albicans, which can be found as a commensal, is 
almost always associated with the development of fungal infections (Wingard 
et al., 1979). An increase in the incidence of C. tropicalis has been recognized 
recently; it accounts for 4 to 24% of all Candida species isolated (AbiSaid, 1997; 
Price et al., 1994; Wingard, 1995). With regard to its pathogenicity and 
virulence, data from animal models suggest that it is at least as virulent as C. 
albicans (Wingard, 1995).  C. tropicalis has the potential to cause severe 
invasive disease, with multiorgan involvement in neutropenic patients, and it is 
associated with a high mortality rate (33-90%) (Powderly et al., 1988; Wingard 
et al., 1979; Wingard, 1995). Furthermore, this species has been found to be 
less susceptible than C. albicans to antifungal agents such as fluconazole and 
amphotericin B (Powderly et al., 1988; Rex et al., 1995; White et al., 1998). 
 C. glabrata is the second  most common cause of systemic candidosis 
and candiduria after C. albicans in the United States (Occhipinti et al., 1994; 
Pfaller et al., 1999b). It is also the NCAC species that is most commonly 
isolated from the oral cavities of HIV–infected patients (Sangeorzan et al., 
1994; Schoofs et al., 1998). This species contributes to mortality in 
approximately 21% of pediatric patients with bloodstream infections (Fridkin et 
al., 2006) and it is known for its decreased susceptibility to azoles (Magill et 
al., 2006).  
 C. parapsilosis has become the second most frequently recovered 
Candida species from blood cultures in Europe, Latin America, and Canada, and 
is ranked third in the United States (Yucesoy & Marol, 2003). C. parapsilosis has 
also been shown to be the Candida species most commonly recovered from the 
hands of health workers and can adhere strongly to the surfaces of 
intravascular catheters and prosthetic devices (De Bernardis et al., 1999; 
Hedderwick et al., 2000; Levin et al., 1998).  In addition, C. parapsilosis has 
become the NCAC species most commonly isolated in neonatal intensive-care 
units (Rangel-Frausto et al., 1999). 
 C. krusei is a relatively uncommon pathogen accounting for 2 to 4% of 
Candidaemia cases (Calderone, 2002). C. krusei fungaemia commonly occurs in 
haematology patients with severe neutropenia due to bone marrow 
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transplantation or leukaemia. In these patients, C. krusei fungaemia is 
associated with high mortality rates of approximately 60 to 93%, and infection 
is often disseminated (Abbas et al., 2000; Merz et al., 1986; Nguyen et al., 
1996). This species is known to be resistant to fluconazole (Rex et al., 2000); 
however, some investigators have also noticed reduced susceptibility to other 
antifungal drugs among isolates of C. krusei, suggesting that C. krusei is a 
multidrug-resistant pathogen (Berrouane et al., 1996; Kao et al., 1999). Most 
recently, C. krusei has been implicated in disseminated disease in patients 
receiving caspofungin (Pelletier et al., 2005).  
1.2  Morphology 
 Colonies of Candida species on Sabouraud dextrose agar are normally 
white to cream coloured, grow rapidly and mature in 3 days at 25°C. The 
microscopic features of Candida species show species-related variations. All 
species grow in the logarithmic phase as oval-to-oblong, budding cells (yeasts). 
These cells occur singly, or in clusters or chains. Most members of the genus 
Candida also produce a filamentous type of growth involving pseudohyphae 
which are essentially chains of elongated yeast cells. Candida albicans and the 
closely related C. dubliniensis have the ability to form both pseudohyphae and 
true hyphae (Fig. 1). The early stage in the formation of a true hypha is known 
as a germ tube. In addition, Candida albicans and C. dubliniensis can also 
produce chlamydospores; these cells are larger and more rounded than yeast 
cells and their physiological status is uncertain (Calderone, 2002; Larone, 
1995). 
1.3  Candida cell wall structure 
 The cell wall is vital both to the biology of the yeast and to its 
interactions with host cells in health and disease. It protects the fungus from 
host defence mechanisms and it is responsible for maintaining the unique 
shapes that characterize fungal growth (Marcilla et al., 1998). The surface of 
the organism is the site of the physical interactions between the fungus and 
host tissues that lead to adherence, and between the fungus and the immune 
system that lead to clearance (Cannon & Chaffin, 1999). The surface layers of 
the fungal cell are composed of an outer cell wall and an inner cell membrane 
(Aguilar-Uscanga & Francois, 2003). The cell wall is an active structure that can  
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Figure 1. Growth forms of Candida species: yeast, pseudohyphae, and 
hyphae  
Candida albicans can exist in three forms that have distinct shapes: yeast cells, 
pseudohyphae and true hyphae. Yeast cells are round to ovoid in shape and 
separate readily from each other. Pseudohyphae are elongated yeast cells that 
remain attached to one another at the constricted septation site and usually 
grow in a branching pattern. True hyphae are long and highly polarized, with 
parallel sides and septa, and no obvious constrictions between cells. 
 
True hyphae 
Yeast 
Pseudohyphae 
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adapt to physiological changes. Its composition is unique; therefore it is an 
ideal target for new antifungal drugs since it is not present in mammalian cells 
(Marcilla et al., 1998). The cell wall of C. albicans makes up 30% of the dry 
weight of the cell; about 80 to 90% of the cell wall is composed of 
carbohydrate, 6 to 25% of protein and 1 to 7% of lipid (Chaffin et al., 1998). 
The carbohydrates include branched polymers of glucose (β-1,3-D-glucans and 
β-1,6-D-glucans), unbranched polymers of N-acetyl-D-glucosamine (chitin) and 
polymers of mannose (mannan), covalently bound to proteins (Calderone, 2002; 
Chaffin et al., 1998; Marcilla et al., 1998). In C. albicans, β-glucans account for 
50 to 60% by weight of the fungal cell wall while mannoproteins account for 
approximately 40% of the total cell wall polysaccharide (Calderone, 2002). 
Glucan and chitin polymers are responsible for the rigidity of the cell wall and 
also for cell morphology. The cell wall polymers in Candida species are linked 
together by covalent bonds, in addition to hydrogen and hydrophobic bonds. 
Covalent linkages between glucan and chitin, and between mannoproteins and 
β-glucan, have been described. Furthermore, β-1,3 and β-1,6 glucan are also 
linked to proteins by phosphodiester linkages. It is believed that the fungal cell 
wall is composed of building blocks of mannoproteins, which are associated 
through glycosyl phosphatidylinositol (GPI) anchor remnants with β-1,6 glucan, 
which in turn is linked to β-1,3 glucan and chitin (Figure 2) (Bowman & Free, 
2006; Klis et al., 2001; Smits et al., 2001). 
1.4  Candida infections 
 Over the last few decades the prevalence of opportunistic Candida 
infections has increased. This rise is largely attributed to the extensive use of 
immunosuppressive and cytotoxic drugs, widespread use of broad-spectrum 
antibiotics (permitting fungal overgrowth), and increased use of invasive 
devices (catheters, prostheses, and valves) (Douglas, 2003; Kumamoto & 
Vinces, 2005). These opportunistic fungi are potential pathogens in patients 
with certain predisposing factors, e.g. patients with AIDS, organ transplants, 
prolonged antibiotic use, diabetes mellitus, malnutrition, and obstructive 
uropathy (Wainstein et al., 1995). Candida species are capable of causing a 
variety of infections, ranging from the superficial to systemic (Calderone, 2002; 
Odds, 1988). 
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Figure 2. Schematic of fungal cell wall.  
GPI, glycophosphatidylinositol. Reprinted from Selitrennikoff (2001) by 
permission of the publisher, American Society for Microbiology. 
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1.4.1 Superficial candidosis 
 Candida infections of the skin are referred to as cutaneous candidosis, 
whereas infections on mucous membranes of the mouth, oropharynx or vagina 
are termed mucosal candidosis. The most common superficial infections mainly 
take the form of mucosal candidosis: vulvovaginal candidosis or oropharyngeal 
candidosis (Fidel & Sobel, 1996). Vulvovaginal candidosis occurs most 
frequently in women of childbearing age. It has been estimated that 75% of all 
adult women will experience at least one vaginal infection episode during their 
lifetime (Odds, 1988). Candida species can be found as commensals in the 
vagina in 10 to 25% of all women (Fidel & Sobel, 1996). Predisposing factors for 
Candida overgrowth include pregnancy, antibiotic use, immunosuppressive 
therapy, hormone replacement therapy or uncontrolled diabetes mellitus 
(Arendorf & Walker, 1987; Bulad et al., 2004). A study by Moreira and Paula 
(2006) on patients with vulvovaginal candidosis showed that C. albicans is the 
most frequently isolated species, with 90% of isolation, followed by C. glabrata 
with 6% and C. parapsilosis and C. tropicalis each with 2%.   
 Oropharyngeal candidosis (OPC) refers to Candida infection in the mouth 
and throat. The most common types of OPC are oral thrush and denture-
induced stomatitis. Oral thrush is characterized by soft, white or cream-
coloured deposits on mucosal membranes.  This infection most frequently 
occurs in newborns, the elderly, and diabetics. In the absence of other known 
causes of immunosuppression, oral thrush in an adult is highly predictive of 
human immunodeficiency virus (HIV) infection (Dronda et al., 1996).  Candida-
associated denture stomatitis is prevalent in approximately 11 to 67% of 
denture wearers. The upper denture provides a surface to which Candida can 
adhere. In the oral cavity, Candida species usually co-exist with commensal 
bacteria. Studies by Budtz-Jorgensen (1990) have shown that in denture plaque 
of patients with Candida-induced denture stomatitis, 93% of the plaque biofilm 
is composed of yeasts and the remainder comprises oral bacteria. Despite 
antifungal therapy to treat denture stomatitis, infection is usually re-
established soon after the treatment ceases, suggesting that denture plaque 
may serve as a protected reservoir of C. albicans (Budtz-jorgensen, 1990). 
Resolution of the infection may sometimes occur by simply removing the 
dentures (Calderone, 2002).  
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 Two forms of OPC are commonly encountered among HIV patients: 
pseudomembranous and erythematous candidosis. Pseudomembranous OPC 
consists of smooth, white, papular lesions. Erythematous OPC is characterized 
by smooth red patches on the hard or soft palate, oropharynx, buccal mucosa, 
and dorsal tongue (Becksague & Jarvis, 1993; Cheng et al., 2005; Edmond et 
al., 1999). It has been estimated that 90% of HIV patients develop OPC in 
various stages of their disease (de Repentigny et al., 2004). 
1.4.2 Invasive candidosis 
 Candida species now rank as the fourth most common cause of 
nosocomial bloodstream infections in the United States (Edmond et al., 1999). 
Candidaemia is the most common form of invasive candidosis and usually occurs 
in individuals with reduced function of the immune system and those 
hospitalized with serious underlying conditions (Pfaller & Diekema, 2007). 
Despite available antifungal therapy, the rate of morbidity and mortality 
associated with candidaemia remains high: about 30 to 70% among cancer 
patients (Horn et al., 1985; Viscoli et al., 1999) and 26 to 75% among non-
cancer patients (Cheng et al., 2005; Komshian et al., 1989; Phillips et al., 
1997). Several studies have suggested that many if not most incidents of 
candidaemia are catheter related (Pfaller & Diekema, 2007). The largest 
prospective treatment study of patients with candidaemia implicated a 
catheter in 72% of them (Rex et al., 1994). In invasive candidosis, 60 to 75% of 
infections are caused by C. albicans. Although the incidence of non-C. albicans 
species as a cause of infection is increasing in both invasive and mucosal 
candidosis, C. albicans remains the most prevalent aetiological agent of 
Candida infection (Jabra-Rizk et al., 2004; Slavin et al., 2004; Wingard & 
Leather, 2004). 
 
2 Virulence factors of Candida species 
 Like other pathogens, in order to establish an infection, opportunistic 
pathogens have to evade the immune system, survive, divide in the host 
environment and spread to new tissues. C. albicans expresses several virulence 
factors that contribute to pathogenesis. These factors include morphogenesis 
(the reversible transition between unicellular yeast cells and filamentous 
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growth forms), hydrolytic enzyme production, adhesion (production of host 
recognition biomolecules), and phenotypic switching (Calderone & Fonzi, 
2001). 
2.1  Morphogenesis 
 Morphogenesis refers to the transition between various growth 
morphologies. The fungal pathogen, C. albicans, shows considerable 
morphogenetic flexibility. This organism has the ability to reversibly convert 
between the yeast form and the filamentous form (hyphal or pseudohyphal 
states).  This transition is thought to contribute to the ability to grow on 
surfaces and invade tissues (Calderone & Fonzi, 2001; Yang, 2003). Of all 
Candida species, only C. albicans and C. dubliniensis have the ability to 
undergo both types of filamentous growth and are defined as polymorphic in 
their growth patterns (Calderone & Fonzi, 2001). Virulence is attenuated in 
mutants that are unable to switch from the yeast form to the hyphal form. For 
example, mutant strains of C. albicans that were defective in germ-tube 
formation showed decreased tissue invasion in an immunosuppressed animal 
model (Riggle et al., 1999). The various cellular forms of C. albicans can be 
induced by many different environmental factors, such as mammalian serum, 
high temperatures (37°C), and neutral pH (Brown & Gow, 1999; Brown et al., 
1999). Moreover, hyphae are formed in response to nutrient deprivation and 
filamentous growth is considered an important adaptive response that enables 
the fungus to forage for nutrients more effectively (Brown & Gow, 1999; 
Calderone & Fonzi, 2001; Palecek et al., 2002).  
 Several signalling pathways control morphogenesis in C. albicans. These 
include the mitogen-activated protein kinase (MAPK) and Ras-cAMP signalling 
pathways that are thought to activate filamentous growth in response to 
starvation and/or serum signals (Brown, 2001; Ernst, 2000; Whiteway, 2000). 
The MAPK and Ras-cAMP pathways regulate the transcription factors Cph1 and 
Efg1, respectively (Liu et al., 1994; Stoldt et al., 1997). Under most 
experimental conditions, yeast-hypha morphogenesis is blocked in a C. albicans 
cph1/cph1, efg1/efg1 double mutant. This indicates that the transduction of 
most environmental signals is dependent on Ras-cAMP or MAPK signalling (Lo et 
al., 1997). Tripathi and colleagues (2002) have reported that amino acid 
starvation induces pseudohyphal growth in C. albicans and this morphogenesis 
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response is dependent upon CaGcn4, a functional homologue of S. cerevisiae 
Gcn4. About 30% of C. albicans wild-type cells (containing a functional CaGcn4 
locus) formed filamentous projections, whereas the gcn4/gcn4 mutant cells 
only formed buds (Tripathi et al., 2002). Another study by Wightman et al. 
(2004) suggested that Nim1-kinases, Gin4 and HsI1, act as negative regulators 
of pseudohyphal development. Hyphal forms can be inhibited by farnesol, a 
quorum-sensing molecule (Hornby et al., 2001). Also, down regulation of Nrg1 
(a DNA-binding repressor protein) synthesis induces filamentous growth in C. 
albicans (Braun et al., 2001). The hyphal and pseudohyphal forms can revert 
back to the yeast form but the mechanisms controlling this transition are not 
well understood (Whiteway & Oberholzer, 2004). Several studies have shown 
that most lesions in infected tissues are populated by both morphological 
forms, suggesting that both contribute to the development and progression of 
disease (Calderone & Fonzi, 2001). 
2.2  Production of extracellular hydrolytic enzymes 
 The three most important hydrolytic enzymes produced by C. albicans 
and linked directly to virulence are secreted aspartic proteinases (SAPs), 
phospholipases, and lipases. Secreted hydrolytic enzymes can contribute to 
host tissue invasion by digesting or distorting host cell membranes, degrading 
host surface molecules to enhance adhesion, or digesting cells and molecules of 
the host immune system to avoid or resist antimicrobial attack (Calderone, 
2002).  
2.2.1 Aspartic proteinases 
 Secreted aspartic proteinases degrade many human proteins at lesion 
sites; such proteins include albumin, haemoglobin, keratin, and secretory 
immunoglobulin A. To date, 10 different SAP genes (SAP1-10) have been 
identified in C. albicans and their proteolytic activity has been linked to tissue 
invasion (Naglik et al., 2003). The production of SAPs is not limited to C. 
albicans only and their presence has been demonstrated in C.tropicalis, C. 
parapsilosis, C. dubliniensis, and C. guilliermondii (Calderone & Fonzi, 2001; 
Calderone, 2002). In vitro studies have shown that SAP1, 2, and 3 genes are 
expressed by yeast cells only, whereas expression  of  SAP4, 5, and 6  is limited 
to the hyphal form (Hube et al., 1998; Yang, 2003).  The expression of SAP7 has 
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never been observed under any laboratory growth conditions. SAP8 transcript 
has been detected in yeast cells grown at 25°C in a defined growth medium 
and SAP9 is expressed in later growth phases (Monod et al., 1998; Yang, 2003). 
2.2.2  Phospholipases and lipases 
 The activity of phospholipases has been reported in several fungal 
pathogens including Candida species, Cryptococcus neoformans, and 
Aspergillus fumigatus (Birch et al., 1996; Chen et al., 1997; Yang, 2003). 
According to the specific ester bond cleaved, these enzymes have been divided 
into four types of phospholipases: phospholipase A (PLA), phospholipase B 
(PLB), phospholipase C (PLC), and phospholipase D (PLD) (Calderone & Fonzi, 
2001; Yang, 2003). The major phospholipase in C. albicans is phospholipase B; 
it has both hydrolase (fatty acid release) and lysophospholipase-transacylase 
activities (Leidich et al., 1998). Two PLB genes, PLB1 and PLB2, have been 
identified and cloned; only PLB1 has been associated with virulence. In an 
intravenous murine model for hematogenously disseminated candidosis, the 
virulence of C. albicans mutants lacking PLB1 was significantly attenuated and 
the mutants showed a dramatically reduced ability to penetrate host cells 
(Leidich et al., 1998). A separate study indicated that a PLB1-disrupted mutant 
of C. albicans was less invasive and caused reduced inflammatory response in 
an oral-intragastric infant-mouse model (Ghannoum, 2000). These findings 
suggest that phospholipase secretion may contribute to the virulence of C. 
albicans. Non-C. albicans species such as C. tropicalis, C. parapsilosis, and C. 
glabrata have also been shown to secrete phospholipases, albeit at lower levels 
(Ghannoum, 2000).  
 In comparison to proteinases and phospholipases, other secreted 
hydrolytic enzymes of C. albicans such as lipases or esterases, have been rather 
neglected until recently. Extracellular lipase activity of pathogenic Candida 
species was first detected by Werner (1966) and a secreted esterase was later 
characterized by Tsuboi et al. (1996). The esterase was induced by lipids such 
as Tween 80 and showed a high activity on α-naphthyl palmitate at pH 5.5. 
However, it was not able to hydrolyze triolein, tripalmitin, and α-lecithin, and 
it was therefore characterized as a monoester hydrolase. C. albicans was able 
to grow in media with triolein as a sole source of carbon, suggesting that other 
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lipolytic enzymes must exist (Sheridan & Ratledge, 1996). Subsequently, a 
range of lipase genes (LIP1-10) were identified in C. albicans (Hube et al., 
2000) and in other Candida species such as C. parapsilosis, C.tropicalis, and C. 
krusei (Fu et al., 1997; Neugnot et al., 2002). It has been found that lipase 
gene expression depends on the stage of infection rather than on the organ 
localization (Hube et al., 2000).  
2.3  Adhesion 
 One of the most important virulence factors of Candida species is their 
ability to adhere using a variety of mechanisms, permitting the yeast to anchor 
at a site and establish the process of colonization and biofilm formation (Cotter 
& Kavanagh, 2000). Candida species can adhere to host cells, as well as to the 
surfaces of medical devices, and form biofilms; this results in an increase in 
antifungal resistance (Chandra et al., 2001a; Hawser & Douglas, 1995). There is 
a positive correlation between the virulence of different Candida species and 
their ability to form biofilms (Hawser & Douglas, 1994). Adhesion of the yeast 
form of the fungus to epithelial cells can involve several kinds of adhesin–
receptor interactions, including protein-protein, protein-carbohydrate, and 
carbohydrate-carbohydrate interactions (Cutler, 1991; Staddon et al., 1990). C. 
albicans and other species seem to bind and interact not only with human 
epithelial surfaces but also with human proteins of the blood and internal 
tissues (Calderone & Gow, 2002). 
2.3.1 Adhesins 
 The components of the organism that promote host recognition and 
adherence are usually referred to as adhesins. The adhesins of C. albicans are 
usually polysaccharide or glycoprotein in nature (Calderone & Gow, 2002). 
Candida albicans possesses multiple adhesins and there may be more than one 
adhesin that recognizes a host ligand or cell (Cannon & Chaffin, 1999). Many 
studies in vitro have shown that a number of environmental signals appear to 
regulate the expression of Candida adhesins, including the availability of sugar 
(McCourtie & Douglas, 1984; Pizzo et al., 2000), iron (Baillie & Douglas, 1998b), 
and temperature (Kennedy & Sandin, 1988). 
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 C. albicans has a family of at least nine ALS (agglutinin-like sequence) 
genes that encode cell-surface glycosylated proteins. These proteins have 
homology with the S. cerevisiae α–agglutinin protein that is required for cell-
cell recognition during mating (Calderone & Fonzi, 2001). In C. albicans and 
other related species, these proteins are thought to play a role in adhesion to 
host surfaces (Calderone & Gow, 2002). Als1p and Als5p in C. albicans have an 
adhesin function in relation to human buccal epithelial cells and fibronectin, 
respectively (Hoyer, 2001). Kamai and colleagues (2002) showed that Als1p has 
an important role in the adherence of the organism to the oral mucosa during 
the early stages of infection. Recently, it has been demonstrated that an 
Als3/Als3 mutant strain of C. albicans had an obvious defect in biofilm 
formation on silicone elastomer discs; the mutant biofilm was structurally 
weakened and had approximately half the biofilm of a wild-type biofilm  (Zhao 
et al., 2006). 
 A hypha cell wall-specific protein (Hwp1) was found on the surface of 
germ tubes and true hyphae, but not on yeasts or pseudohyphae of C. albicans 
(Sundstrom et al., 2002). Hwp1 is encoded by a gene that was originally 
isolated as a cDNA that encoded a hypha-specific antigen. The gene encodes an 
outer surface mannoprotein that is believed to be oriented with its amino-
terminal domain surface-exposed and carboxyl terminus most probably 
covalently integrated with cell wall β-glucan (Staab et al., 1996). The structure 
of the protein suggests that it is linked through a GPI-anchor to cell wall β-
glucan (Staab & Sundstrom, 1998). In subsequent work, Staab et al. (1999) 
showed that Hwp1 functions as a substrate for mammalian transglutaminases, 
suggesting that the protein is involved in the formation of stable complexes 
with buccal epithelial cells. It has been reported that an hwp1/hwp1 mutant 
strain of C. albicans was greatly impaired in its ability to form stable 
attachments to human buccal epithelial cells. Also, this mutant showed 
reduced virulence in a mouse model of systemic candidosis compared with the 
HWP1/HWP1 strain (Staab et al., 1999). 
 More recently, the role of Hwp1 in C. albicans biofilm formation has 
been investigated. A study by Nobile et al. (2006) demonstrated a requirement 
for Hwp1 for normal biofilm formation by C. albicans in vitro and in vivo. In an 
in vitro model, a hwp1/hwp1 mutant produced a thin biofilm that lacked much 
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of the hyphal mass found in wild-type biofilms. Further, in a rat venous 
catheter model, the hwp1/hwp1 mutant was severely deficient in biofilm 
formation, yielding only yeast microcolonies (Nobile et al., 2006). These 
findings suggest that Hwp1 is critical for adhesion and biofilm formation. 
 The integrin-like protein Int1 of Candida has been shown to have a role 
in adhesion and in morphogenesis. Disruption of the INT1 gene in C. albicans 
reduced yeast adhesion to human epithelial cells by approximately 40%. 
Moreover, in a mouse model, the mutation in INT1 reduced the virulence of C. 
albicans (Kinneberg et al., 1999). 
2.3.2 Receptors 
 Fibronectin was one of the first molecules to be recognized as a receptor 
for C. albicans (Skerl et al., 1984). Fibronectin is an extracellular matrix 
glycoprotein to which a number of microorganisms adhere avidly (Pendrak & 
Klotz, 1995). The induction of a fibronectin-binding mannoprotein of C. 
albicans was demonstrated when cells were grown in a medium that contains 
0.1% haemoglobin (Yan et al., 1996; Yan et al., 1998). In disseminated 
candidosis, the fibronectin adhesin may be responsible for the adherence of the 
microorganism to intravascular structures such as endothelial cells or the 
subendothelial extracellular matrix (Pendrak & Klotz, 1995). The presence of 
adsorbed fibronectin as a target protein for epithelial attachment of C. 
tropicalis was also confirmed (Bendel & Hostetter, 1993). 
 The complement fragment iC3b has also been implicated as a ligand 
associated with epithelial and endothelial cell adherence (Gustafson et al., 
1991). Heidenreich and Dierich (1985) were the first to describe the binding of 
sheep erythrocytes coated with human iC3b or C3d to germ tubes of C. 
albicans. They concluded that germ tubes had surface receptors for bound 
complement components that functioned similarly to the human complement 
receptor 2 (CR2) and the human CR3 of host defence cells in their recognition 
of C3d and iC3b. Later, Calderone et al. (1988) identified, in extracts of C. 
albicans pseudohyphae but not yeasts, two proteins of approximately 62 and 70 
kDa that bind the C3d fragment of C3. The finding of C3 receptors, exclusively 
on the more pathogenic Candida species, is highly predictive of their 
involvement in disease processes (Calderone et al., 1988).  Jimenez-Lucho et 
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al. (1990) suggested that yeast cells of C. albicans and other fungi bind 
specifically to the glycosphingolipid, lactosylceramide. Lactosylceramide is a 
major glycosphingolipid in human glioma brain cells and was the only lipid to 
which the yeasts bound. As lactosylceramide is widely distributed in epithelial 
tissues, this glycosphingolipid could be a receptor for yeast colonization and 
disseminated disease in humans (Jimenez-Lucho et al., 1990). 
 Lectin-like Candida adhesins that recognize glycosides containing L-
fucose- or N-acetyl-D-glucosamine have been identified (Critchley & Douglas, 
1987a; Critchley & Douglas, 1987b). The binding of some C. albicans strains to 
buccal epithelial cells was inhibited by fucose, but in other strains it was 
inhibited by N-acetyl-D-glucosamine or D-glucosamine, suggesting strain-
specific receptors. Furthermore, fucoside-binding adhesin has been purified 
and shown to have an affinity for glycosphingolipid receptors carrying the H 
blood-group antigen, suggesting that blood group antigens may act as epithelial 
cell receptors for C. albicans (Tosh & Douglas, 1992). The purified adhesin was 
devoid of carbohydrate and inhibited yeast adhesion to buccal epithelial cells 
by 80% at an adhesin concentration of 10 µg/ml. In subsequent work, the 
binding of the purified adhesin (fucoside-binding protein), crude adhesin 
(extracellular polymeric material), and intact yeast cells of different strains of 
C. albicans to glycosphingolipid receptors was investigated by a chromatogram 
overlay assay. All preparations from five C. albicans strains bound to glycolipids 
carrying the H blood group antigen. However, one strain, GDH2023, showed a 
completely different binding pattern and bound only to glycolipids containing 
N-acetyl-D-glucosamine (Cameron & Douglas, 1996). These results confirmed 
earlier findings about the receptor specificity of the strains made on the basis 
of adhesion inhibition studies (Critchley & Douglas, 1987b). 
2.4  Phenotypic switching  
 This phenomenon could have important implications in pathogenesis and 
is considered to be an attribute of virulence in C. albicans and other species of 
Candida; switching has been reported in C. glabrata, C.tropicalis, and C. 
parapsilosis as well as C. albicans (Soll, 2002). Colonies of C. albicans can 
switch among variant phenotypes including smooth, rough, star, stippled, 
irregular wrinkled, and fuzzy at high frequency (10-4 to 10-1) (Slutsky et al., 
1985). Switching can be stimulated by low doses of UV light and the reversion 
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of the variant colonies (phenotypes) to the original parental phenotype occurs 
at high frequency (Calderone & Fonzi, 2001; Pomes et al., 1985). Phenotypic 
switching may involve changes in the expression of cell surface antigens, 
enzyme production, and even drug sensitivity. However, the basic mechanism 
of phenotypic switching and the involvement of this phenomenon in the 
virulence of C. albicans are not clear. One of the most studied phenotypic 
switching processes is the white-opaque system in C. albicans strain WO-1 
(Slutsky et al., 1987). In this system, smooth, white, hemispherical colonies 
(white phase) can switch to flat, gray colonies (opaque phase). A number of 
differences exist between these two colony types, including cell shape (white 
cells are round-ovoid and opaque cells are elongated or bean-shaped), cell 
surface structure (pimples are found on opaque cells only), and germination at 
37°C (by white cells only unless the opaque cells are grown on human skin 
epithelial cells). Opaque cells have a greater ability to colonize the skin in a 
mouse model of cutaneous infection and a higher frequency of mating than do 
white-phase cells (Kvaal et al., 1999; Miller & Johnson, 2002). However, 
opaque cells are less virulent than white cells in a systemic mouse model (Kvaal 
et al., 1999). Furthermore, these two phenotypes show different gene 
expression; OPA1 and SAP3 are expressed specifically in opaque cells, whereas 
SAP2, WH11, and EFG1 are expressed in white cells (Srikantha & Soll, 1993). 
Phenotypic switching has been found to affect adhesion to human epithelial 
cells. The adhesion of white and opaque cells of strain WO-1 to buccal 
epithelium were dramatically different; white cells were significantly more 
adhesive than opaque cells (Kennedy et al., 1988). 
 Recently the correlation between phenotype switching and biofilm 
formation has been investigated. Biofilms formed by 100% white cells of C. 
albicans were dense and composed of a mixture of yeast cells and hyphae, 
whereas biofilms formed by 100% opaque cells were thin and fragile, and made 
up almost entirely of cells that had extended conjugation tubes. However, the 
thickness of biofilms formed by 90% white and 10% opaque cells was twice that 
of biofilms formed by 100% white cells; the minority opaque cells stimulated 
biofilm development by white cells. This finding reveals a novel form of 
communication between switch phenotypes (Daniels et al., 2006).    
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 The effect of phenotype switching on biofilm formation in C. parapsilosis 
was also investigated. Cells from crepe and concentric phenotypes were 
pseudohyphal, whereas cells from smooth and crater phenotypes were mostly 
yeast-like. On polystyrene surfaces, the concentric phenotype produced up to 
two-fold more biofilm than the crepe and crater phenotypes. Smooth 
phenotypes produced the least biofilm (Laffey & Butler, 2005). 
 
3 Antifungal drugs 
 The antifungal agents that are currently available for the treatment of 
systemic fungal infections are grouped according to their site of action in 
fungal cells into four major classes: the polyenes, azoles, pyrimidine 
analogues, and echinocandins. 
3.1  Polyenes 
 Polyenes are all produced by species of Streptomyces and include 
amphotericin B (Fig. 3A ) and nystatin, which are considered to be fungicidal 
(Jabra-Rizk et al., 2004; Wingard & Leather, 2004). The polyenes cause the 
fungal cell to die by binding to the sterol, ergosterol, in the fungal cell 
membrane. This binding leads to membrane disruption, increased permeability, 
leakage of cytoplasmic contents, and cell death (Fig. 4).  Amphotericin B has a 
very broad spectrum of antifungal activity and it has been the drug of choice 
for treatment of invasive fungal infections for many years. Most fungi are 
susceptible to amphotericin B, including most Candida and Aspergillus species 
(Slavin et al., 2004; Wingard & Leather, 2004). However, some species exhibit 
reduced susceptibility or resistance including C. lusitaniae, C. guilliermondii, 
Trichosporon beigelii, A. terreus, A. flavus and Fusarium spp. (Polak & 
Hartman, 1991; Slavin et al., 2004; Wingard & Leather, 2004). 
 Frequent toxicities and a narrow therapeutic window are major 
limitations to the clinical use of amphotericin B (Slavin et al., 2004; Wingard & 
Leather, 2004). Infusional toxicity occurs in approximately 50-60% of treated 
patients and renal failure in 80% of patients receiving a 2-week course (Slavin 
et al., 2004). Amphotericin shows poor tolerability, especially with patients  
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Figure 3. Chemical structures of antifungal drugs: amphotericin B and 
fluconazole 
 
B. Fluconazole 
A. Amphotericin B 
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Figure 4.  Mechanism of action of polyenes on the fungal cell membrane 
Polyene antifungals such as amphotericin B act by binding to ergosterol in the 
cell membrane. This binding results in depolarization of the membrane and 
formation of pores that increase permeability and leakage of vital cytoplasmic 
components (mono- or divalent cations), eventually leading to death of the 
organism.  Reprinted by courtesy of www.doctorfungus.org. 
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requiring long-term courses of doses above 0.5 mg/kg per day (Slavin et al., 
2004; Wingard & Leather, 2004). 
 Lipid formulations of amphotericin B were developed to ensure less 
infusional and renal toxicity, and greater tolerability; these preparations 
permit higher doses of amphotericin B to be used in clinical practice (Slavin et 
al., 2004; Wingard & Leather, 2004). 
3.2  Azoles  
 The azoles, first described in the late 1960s, are totally synthetic. This 
class includes the imidazoles (clotrimazole, miconazole, and ketoconazole) and 
the triazoles (fluconazole, itraconazole, and voriconazole) (Jabra-Rizk et al., 
2004; Wingard & Leather, 2004). The azoles inhibit the biosynthesis of 
ergosterol through their interactions with the enzyme lanosterol demethylase, 
which is responsible for the conversion of lanosterol to ergosterol. This leads to 
a reduced content of ergosterol in the fungal cell membrane and ultimately 
inhibition and fungal death (Fig. 5). Azole antifungal agents have a fungistatic, 
broad-spectrum activity against most yeasts and filamentous fungi (Slavin et 
al., 2004; Wingard & Leather, 2004). Among the most commonly used azoles is 
fluconazole (Fig. 3B), available as both oral and intravenous formulations. 
Fluconazole is a very effective drug for the treatment of most yeast infections, 
particularly oropharyngeal and vaginal candidosis. Fluconazole is also 
recommended as a first choice for the treatment of invasive Candida infections 
in non-neutropenic patients such as solid-organ transplant patients, surgical 
and ICU patients, or for those with urinary tract infections due to susceptible 
Candida species. Furthermore, fluconazole can successfully treat Candidaemia 
in neutropenic patients, as long as the patient is stable and the infection is not 
due to Candida species less susceptible to fluconazole (Rex et al., 1994). 
Several species are resistant to fluconazole; almost all C. krusei isolates are 
intrinsically resistant and about 50% of C. glabrata isolates show reduced 
susceptibility to the drug (Jabra-Rizk et al., 2004; Slavin et al., 2004). 
Fluconazole is safe, with a very low incidence of side effects, and is well 
tolerated (Slavin et al., 2004; Wingard & Leather, 2004). Furthermore, it has 
efficacy against moulds.  
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Figure 5.  Mechanism of action of azoles on the fungal cell membrane 
Azole antifungals inhibit the fungal cytochrome P450 14-α-lanosterol 
demethylase, thereby interrupting the synthesis of ergosterol. Inhibition of this 
critical enzyme in the ergosterol synthesis pathway leads to the depletion of 
ergosterol in the cell membrane and accumulation of toxic intermediate 
sterols, causing increased membrane permeability and inhibition of fungal 
growth. Reprinted by courtesy of www.doctorfungus.org. 
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 Voriconazole is one of the newest triazoles available and it has the 
broadest spectrum activity of all the licensed azoles. It exhibits activity against 
Candida (including fluconazole-resistant species), Aspergillus and Fusarium 
species, but not against zygomycetes. Voriconazole has two toxicity effects 
that are not seen with other azoles. It causes photopsia, a visual disturbance, 
in up to 30-45% of recipients and photosensitivity, in up to 5% of patients 
receiving the drug. In addition to its toxicities, drug interaction is a very 
important issue to be considered (Jabra-Rizk et al., 2004; Wingard & Leather, 
2004). 
 Posaconazole is an extended-spectrum triazole that was approved in 
2006. It is active against Candida species, Aspergillus species, and is the only 
azole with reliable antifungal activity against Zygomycetes. It is also effective 
against Candida isolates resistant to itraconazole, fluconazole, and 
voriconazole (Greer, 2007; Keating, 2005; Torres et al., 2005) and has activity 
comparable to fluconazole in treating oropharyngeal candidosis in HIV-positive 
patients (Vazquez et al., 2006). Ravuconazole is the latest azole agent to 
undergo clinical development. It shows a broad spectrum of activity against 
fungal pathogens including Candida, Aspergillus, Cryptococcus species, and 
dermatophytes (Pfaller et al., 2004) it also exhibits good activity against 
fluconazole- or itraconazole-resistant isolates of C. albicans and C. dubliniensis 
(Pfaller et al., 1999a). 
3.3  Pyrimidine analogues 
 5-Flucytosine (5-fluorocytosine; 5-FC) is a pyrimidine analogue that was 
originally developed in the 1950s as a potential antineoplastic agent and later 
was found to have antifungal activity (Fig. 6A).  After its transport into the 
fungal cell, it is deaminated to the active form, 5-fluorouracil (5-FU), and 
ultimately leads to the disruption of DNA and protein synthesis (Fig. 7) (Polak & 
Hartman, 1991; Wingard & Leather, 2004). Flucytosine has a narrow spectrum 
of activity against Candida and Cryptococcus species (Wingard & Leather, 
2004). Most moulds including Aspergillus spp. are resistant (Maschmeyer & 
Glasmacher, 2005; Slavin et al., 2004; Wingard & Leather, 2004).  
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Figure 6. Chemical structures of antifungal drugs: flucytosine and 
caspofungin 
A. Flucytosine 
B. Caspofungin 
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Figure 7. Mechanism of action of 5-flucytosine on the fungal cell 
5-Flucytosine is transported into susceptible fungal cells by a specific enzyme 
cytosine permease and converted in the cytoplasm by cytosine deaminase to 5-
fluorouracil (5-FU).  5-FU undergoes further steps of activation and finally 
interacts as FUTP with RNA biosynthesis and causes miscoding and halts protein 
synthesis. Additionally, 5-FU is converted to dTMP which inhibits DNA synthesis 
by blocking the function of thymidylate synthetase. Reprinted by courtesy of 
www.doctorfungus.org. 
5-FC, 5-fluorocytosine; 5-FU, 5-fluorouracil; FdUMP, 5-fluorodeoxyuridine;
FUMP, 5-fluorouridine monophosphate; FUDP, 5-fluorouridine diphosphate;
FUTP, 5-fluorouridine triphosphate; dUMP, deoxyuridine monophosphate
dTMP, deoxythymidine monophosphate
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3.4  Echinocandins 
 The echinocandins and their analogues, the pneumocandins, are semi-
synthetic cyclic lipopeptides and represent a new class of antifungal agents 
that have a unique mechanism of action. They inhibit the synthesis of β-1,3-D-
glucan, an essential component of the fungal cell wall (Fig. 8). This component 
is absent in mammalian cells, which increases the drug’s specificity and 
reduces its toxicity for mammalian cells (Maschmeyer & Glasmacher, 2005; 
Slavin et al., 2004; Wingard & Leather, 2004). Echinocandins have fungicidal 
activity against Candida spp. and fungistatic activity against Aspergillus spp. In 
vitro, echinocandins demonstrate excellent activity, against amphotericin B- 
resistant and azole-resistant Candida and Aspergillus species (Espinel-Ingroff, 
2003; Maschmeyer & Glasmacher, 2005; Wingard & Leather, 2004) but have no 
activity against fungi that lack significant β-glucan in their cell walls, such as  
Cryptococcus and Trichosporon species (Espinel-Ingroff, 2003; Slavin et al., 
2004).  The inhibition is effective and specific, and short exposure leads to cell 
death (Maschmeyer & Glasmacher, 2005). This class of drugs now includes 
anidulafungin and micafungin, as well as caspofungin. However, caspofungin 
(Fig. 6B) was the first echinocandin licensed for treatment of fungal infections. 
It has demonstrated excellent pharmacokinetic properties and exhibited good 
safety profiles (Chandra et al., 2001a; Kuhn et al., 2002a; Mukherjee et al., 
2005). 
 
4 Biofilms 
 In Nature, biofilms are the most common form of microbial growth; 
microorganisms are found attached to surfaces and not as free-floating 
(planktonic) cells (Chandra et al., 2001a; Douglas, 2003; Mukherjee et al., 
2005; O'Toole et al., 2000). Biofilms are a preferred mode of microbial 
existence as they provide protection for the cells against physical forces, pH 
changes, chemical attacks, and offer higher chances of survival in a low-nutrient 
environment (Jefferson, 2004). A biofilm is defined as a community of 
microorganisms that develops from a single species or from multiple species of 
bacteria or fungi attached to a surface.  
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Figure 8.  Mechanism of action of echinocandins on the fungal cell wall 
Echinocandins inhibit the enzyme β-1,3-glucan synthase. This inhibition results 
in depletion of glucan polymers in the fungal cell wall, resulting in an 
abnormally weak cell wall unable to withstand osmotic stress. Reprinted by 
courtesy of www.doctorfungus.org. 
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These microbes are embedded in a matrix, often slimy, of extracellular 
polymeric material (Donlan, 2001; Donlan & Costerton, 2002; Douglas, 2003; 
Kumamoto & Vinces, 2005) and exhibit a distinctive phenotype with regard to 
growth rate and gene transcription (Donlan & Costerton, 2002; Douglas, 2003).  
 A large number of studies have been carried out in order to understand 
bacterial biofilms and their role in disease (Chandra et al., 2001a; Douglas, 
2003; Jabra-Rizk et al., 2004; Mukherjee et al., 2005). In the seventeenth 
century, dental plaque on tooth surfaces was the first example of what we now 
call a biofilm to be recognized in medical systems (Marsh, 1995). Recent 
estimates suggest that some 65% of all human infections involve biofilms 
(Dominic et al., 2007; Ramage et al., 2005). Many of these infections are 
associated with implanted medical devices such as intravascular catheters, 
joint replacements, endotracheal tubes and prosthetic heart valves, which can 
act as surfaces for biofilm growth (Donlan, 2001). These devices can easily 
become contaminated. The infusion fluid itself or the catheter hub may be the 
source of infection but, more often, organisms are introduced from the 
patient’s skin or from the hands of health care workers.  Sometimes the distal 
tip of the catheter is contaminated during the insertion process; alternatively, 
organisms from another site in the body can travel via the blood and infect the 
catheter (Collin, 1999; Donlan & Costerton, 2002). Biofilm microorganisms can 
also be found in tissues taken from non-device-related chronic infections such 
as cystic fibrosis, native valve endocarditis, otitis media, chronic bacterial 
prostatitis and periodontitis (Mukherjee et al., 2005). The most common 
organisms isolated from catheter biofilms are C. albicans and a diversity of 
bacterial species including Staphylococcus aureus, S. epidermidis, 
Pseudomonas aeruginosa and Actinobacter species (Kumamoto & Vinces, 2005; 
Mukherjee et al., 2005). In the United States, several million vascular and 
urinary catheters and tens of thousands of prosthetic heart valves are used 
annually (Chandra et al., 2001a; Kuhn et al., 2002a; Kumamoto & Vinces, 
2005). Infections of catheters are not only expensive in terms of catheter 
replacement but may also cause a bacteraemia or fungaemia with a mortality 
rate of up to 40% (Cheng et al., 2005; Nguyen et al., 1995). The use of central 
venous catheters (CVCs) in current clinical practice is responsible for more than 
90% of bloodstream infections (Odetola et al., 2003), resulting in 10-25% 
mortality among these patients (Nicastri et al., 2001; Veenstra et al., 1999) . 
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4.1  Candida biofilms 
 Little attention has been given to medically relevant fungal biofilms in 
comparison to bacterial biofilms and their role in disease.  All Candida species 
are opportunistic pathogens and their emergence as important nosocomial 
pathogens is related to specific risk factors. These factors include 
immunosuppressive therapy, antibiotic therapy, and the use of indwelling 
devices such as intravenous catheters (Calderone, 2002; Nucci et al., 1998). 
Approximately 50% of all nosocomial infections are medical device-related 
infections and about 10% of these infections are due to Candida spp. 
(Kumamoto & Vinces, 2005). In a prospective study of catheter colonization, C. 
albicans represented the second highest colonization to invasive infection rate 
(Crump & Collignon, 2000). Even with current antifungal therapy, the mortality 
of patients with systemic candidosis can be as high as 40% (Dominic et al., 
2007). 
 Superficial Candida infections related to implanted devices are much 
less serious, but are the most frequently encountered and can be problematic 
(Douglas, 2003; Jabra-Rizk et al., 2004; Mukherjee et al., 2005). One of the 
most common is denture stomatitis, a Candida infection of the oral mucosa 
that is promoted by a close-fitting upper denture and is present in up to 65% of 
edentulous persons (Chandra et al., 2001a; Jabra-Rizk et al., 2004; O'Toole et 
al., 2000).  
 A description of Candida biofilms on specific devices is presented in 
Table 1 (Ramage et al., 2006; Kojic et al., 2004).  Non-device-related 
infections can also involve biofilms; these include Candida endocarditis and 
Candida vaginitis  (Donlan & Costerton, 2002; Douglas, 2003).  
4.2  Model biofilm systems 
 A variety of biofilm models have been developed by different groups of 
researchers to investigate the properties of Candida biofilms in vitro. Almost 
all of these models have been adapted from methods reported previously for 
bacteria.  
 Hawser and Douglas (1994) initially described a simple method, involving 
growth of adherent populations on the surfaces of small discs cut from 
catheters. Growth of biofilms was monitored quantitatively by a colorimetric  
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Table 1. Some of the implantable devices on which Candida biofilms 
develop most frequently 
 
Device Annual use in 
the United States
Infection risk 
(%)
Central and peripheral 5 million 3-8 albicans
venous catheters glabrata
parapsilosis
Hemodialysis and albicans
peritoneal  dialysis parapsilosis
catheters
Urinary catheters Tens of 
millions
10-30 albicans
Endotracheal tubes Millions 10-25 albicans
albicans
glabrata
parapsilosis
tropicalis
Breast implants 130 000 1-2 albicans
parapsilosis
albicans
glabrata
Neurosurgical shunts 40 000 6-15 albicans
albicans
tropicalis
albicans
glabrata
240 000 1-20
Intracardiac prosthetic 
devices
400 000 1-3
Dentures > 1 million 5-10
Main Candida 
species
Prosthetic joints 600 000 1-3
Voice prostheses Thousands 50-100
 
Reprinted from Ramage et al. (2006) by permission of the publisher, John Wiley 
and Sons; and from Kojic et al. (2004) by permission of the publisher, American 
Society for Microbiology. 
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assay involving the reduction of a tetrazolium salt, or by [3H] leucine 
incorporation. Subsequent in vitro model systems have included procedures 
with a variety of different acrylic strips and discs, glass slides, microtitre 
plates, cylindrical cellulose filters, perfused biofilm fermenters, polycarbonate 
membrane filters, and tissue culture flasks; these models have produced 
biofilms formed under both static and flow conditions (Al-Fattani & Douglas, 
2004; Baillie & Douglas, 1998a; Baillie & Douglas, 1999a; Chandra et al., 2001a; 
Honraet et al., 2005; Ramage & Lopez-Ribot, 2005). Among the various systems 
described, the 96-well microtitre plate method permits rapid processing of a 
large number of samples and has therefore been widely used. It has proved 
particularly valuable for determination and standardization of antifungal 
susceptibility testing in Candida biofilms (Ramage et al., 2001b; Ramage et al., 
2001c). Studies with different model systems have also identified factors 
affecting Candida biofilm development and phenotypic properties associated 
with this mode of growth.  
 More recently, two different animal models of catheter-associated 
Candida infections have been described, and visualization of the resulting 
biofilms formed in vivo has revealed structural features similar to those of 
biofilms formed in vitro (Andes et al., 2004; Schinabeck et al., 2004). These 
findings suggest that in vitro model systems can replicate in vivo events and 
therefore that the observations made may be clinically relevant (Ramage et 
al., 2005).  
4.2.1 Quantitative analysis of biofilm growth 
 Several methods have been used to measure the growth of Candida 
biofilms. Commonly used methods are: (a) uptake of radioactively labelled 
leucine; (b) determination of metabolic activity via reduction of tetrazolium 
salts by mitochondrial dehydrogenases or ferric reductase; (c) absorption of 
crystal violet dye, (d) determination of dry weight, (e) viable cell counts; and 
(f) measurement of ATP-bioluminescence (Baillie & Douglas, 1999b; Chandra et 
al., 2001b; Hawser & Douglas, 1994; Nikawa et al., 1996; Ramage et al., 
2001b). 
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4.3  Factors affecting biofilm formation 
 A number of environmental and growth factors can greatly influence the 
ability of Candida to form biofilms in vitro, including the Candida species, the 
nature of the surface colonized, the host-derived conditioning film, the liquid 
flow, and the type of nutrients available.  
4.3.1 Candida species and strain  
 Different Candida species show some correlation between their ability to 
form biofilms and their pathogenicity when tested in the catheter disc system. 
Isolates of C. parapsilosis, C. pseudotropicalis and C. glabrata all gave 
considerably less biofilm growth than the more pathogenic C. albicans (Hawser 
& Douglas, 1994). Recently, it has been confirmed that C. albicans isolates 
consistently produce more biofilm in vitro than non-C. albicans isolates (Kuhn 
et al., 2002a). 
4.3.2 Nature of colonized surface 
 The chemical nature and properties of the colonized surface play an 
important role in biofilm formation (Hawser & Douglas, 1994; Mukherjee et al., 
2005). In the catheter disc model system, the type of material used affected 
biofilm formation by C. albicans. Biofilm formation was slightly greater on 
latex or silicone elastomer than on polyvinylchloride, but was significantly 
reduced on polyurethane or 100% silicone (Hawser & Douglas, 1994). 
4.3.3 Presence of conditioning film 
  In vivo, catheters and other implants rapidly adsorb host proteins which 
form a conditioning film on the implant surface. Preincubation of PVC catheter 
discs in vitro with fibrinogen or collagen improved the formation of biofilms by 
C. albicans (Douglas, 2003; Mukherjee et al., 2005). Likewise, conditioning 
films of serum or saliva enhanced biofilm formation on denture acrylic 
(Chandra et al., 2001b; Nikawa et al., 1996). 
4.3.4 Liquid flow 
 In vivo, development of biofilms is frequently subjected to a liquid flow. 
This can be achieved in vitro by gentle shaking of the growing biofilm on a 
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catheter disc in liquid medium, to produce a flow of liquid over the surface of 
the cells (Hawser et al., 1998). More sophisticated flow systems include biofilm 
formation on cylindrical cellulose filters (Baillie & Douglas, 1998b; Baillie & 
Douglas, 1999a), in the perfused biofilm fermenter (Baillie & Douglas, 1999b), 
or in a modified Robbins device (Al-Fattani & Douglas, 2006). Biofilms of C. 
albicans incubated under these conditions produce substantially more matrix 
material than those incubated statically. 
4.3.5 Growth media and different nutrients 
 Nutrients play an important role in biofilm formation. The effect of 
different carbohydrates on C. albicans biofilm formation was examined and it 
was shown that biofilm formation reached a maximum after 48 h in a medium 
containing 500 mM galactose or 50 mM glucose and then declined; however, the 
cell yield was lower in the low-glucose medium (Hawser & Douglas, 1994). C. 
tropicalis and C. parapsilosis seem to form biofilms quite readily when grown 
in medium containing 8% glucose (Shin et al., 2002). 
4.4  Structure of Candida biofilms 
 The biofilm development cycle includes adhesion of planktonic cells to 
the surface, growth and secretion of extracellular polymers (forming the 
mature biofilm with mushroom-shaped microcolonies) and cell detachment 
(Fig. 9). The architecture of biofilms formed by Candida species shares several 
properties with bacterial biofilms (Chandra et al., 2001a; Douglas, 2003; Jabra-
Rizk et al., 2004; O'Toole et al., 2000). However, many fully mature Candida 
biofilms have a mixture of morphological forms and consist of a dense network 
of yeasts and filaments in a matrix of extracellular polymeric material. Some 
non-C. albicans species such as C. glabrata (Chandra & Ghannoum, 2004; Kuhn 
et al., 2002a) and some isolates of C. parapsilosis (Laffey & Butler, 2005) form 
biofilms that contain yeast cells with no filaments. 
 Biofilm formation by C. albicans proceeds in three distinct 
developmental phases: initial adherence, followed by proliferation, and  
maturation over a period of 24 to 48 h (Chandra et al., 2001a; Hawser & 
Douglas, 1994; Ramage et al., 2001a). Scanning electron microscopy was shown 
that mature biofilms of C. albicans grown on catheter material consist of  
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Figure 9. Different stages in the biofilm life cycle 
1. Initial reversible attachment of free swimming micro-organisms to surface  
2. Permanent chemical attachment, single layer, microorganisms begin making 
slime  
3. Early vertical development  
4. Maturing biofilms (mushroom-shaped microcolonies) with multiple layers and 
channels between the microcolonies 
5. Mature biofilm with seeding / dispersal of more free swimming micro-
organisms  
Reprinted by courtesy of Center for Biofilm Engineering, Montana State 
University, USA (www.erc.montana.edu). 
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yeasts, hyphae and pseudohyphae arranged in a bilayer structure; there is a 
dense, basal yeast layer that anchors the biofilm to the catheter surface, and 
an overlying but more open, hyphal layer (Douglas, 2003; Kuhn et al., 2002a) 
(Fig. 10). Subsequent studies indicated that in vivo biofilms are structurally 
similar to those described in vitro model except for numerous host cells 
including red blood cells, platelets, macrophages and neutrophils that are 
embedded in the matrix (Andes et al., 2004; Schinabeck et al., 2004).  
Recent advances in confocal laser scanning microscopy (CLSM), provided 
the opportunity to visualize living biofilms in a fully hydrated condition. C. 
albicans biofilms were observed as three-dimensional structures consisting of 
microcolonies of yeasts and hyphae surrounded by a matrix of extracellular 
polymeric material and separated by water channels to facilitate nutrient 
circulation and disposal of waste products (Chandra et al., 2001a; Douglas, 
2003; Kumamoto & Vinces, 2005). The CLSM technique has also shown that 
Candida biofilms can range in thickness from 25 µm to more than 450 µm 
(Chandra et al., 2001a). 
 Quorum sensing appears to play an important role in Candida biofilm 
formation and to date two quorum sensing molecules have been identified: 
farnesol and tyrosol (Alem et al., 2006; Ramage et al., 2002b). This strategy of 
cell-cell communication contributes to the biofilm’s wellbeing by preventing 
unnecessary overpopulation and controlling competition for nutrients; it also 
has important implications in the infectious process, especially for 
dissemination and for the establishment of distal sites of infection (Nickerson 
et al., 2006; Ramage et al., 2002b). Quorum sensing systems may regulate the 
active detachment of cells by the production of enzymes to break down the 
biofilm extracellular polymeric matrix (Ghannoum & OToole, 2004; Kruppa, 
2009).    
 The matrix composition of C. albicans biofilms has been studied and 
compared with the extracellular polymeric material collected from culture 
supernatants of planktonically grown organisms. Both materials contained 
carbohydrate, protein, phosphorus and hexosamine. However, the matrix had 
considerably less carbohydrate (41%), and protein (5%). It also had a higher 
proportion of glucose (16%) than mannose and contained galactose (Baillie & 
Douglas, 2000). In a recent study, the biofilm matrix of C. tropicalis was  
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Figure 10. Stages in the formation of a Candida albicans biofilm on a 
polyvinylchloride (PVC) catheter surface  
(a) Catheter surface with an adsorbed conditioning film of host proteins (black 
dots). (b) Initial yeast (red) adhesion to the surface. (c) Formation of the basal 
layers of yeast microcolonies. These anchor each microcolony to the surface. 
(d) Completion of microcolony formation by addition of the upper, mainly 
hyphal layer and matrix material (yellow) that surrounds both yeasts (red) and 
hyphae (green). Mature biofilms contain numerous microcolonies with 
interspersed water channels to allow circulation of nutrients. On other surfaces 
(e.g. cellulose fibres) microcolonies consisting entirely of yeast cells are 
produced. Reprinted from Douglas (2003) by permission of the publisher, 
Elsevier. 
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analyzed and shown to contain large amounts of hexosamine (27.4%) with 
smaller proportions of carbohydrate (3.3%, including 0.5% glucose), protein, 
and phosphorus (Al-Fattani & Douglas, 2006). 
4.5  Mixed-species biofilms 
 Biofilms that are formed by a mixture of Candida species and bacteria 
(polymicrobial biofilms) are probably common in vivo (El-Azizi et al., 2004). In 
vitro, various studies suggest that extensive interactions between these species 
occur. For example, the catheter disc model has been used to investigate 
mixed–species biofilms consisting of C. albicans and Staphylococcus 
epidermidis. Two strains of S. epidermidis were used: a slime-producing wild-
type and a slime-negative mutant. Both strains of S. epidermidis showed 
numerous physical interactions with both yeast and hyphal forms of C. albicans 
(Adam et al., 2002).  Moreover, drug susceptibility studies suggested that 
fungal cells can modulate the action of antibiotics, and bacteria can affect 
antifungal activity in these biofilms. The presence of C. albicans in the biofilm 
increased the resistance of slime-negative staphylococci to vancomycin, 
whereas Candida resistance to fluconazole was enhanced in the presence of 
slime-producing staphylococci (Adam et al., 2002).  
 Antagonistic interactions have been observed in mixed-species biofilms 
consisting of Pseudomonas aeruginosa and C. albicans. In vitro studies showed 
that P. aeruginosa formed a dense biofilm on C. albicans hyphae, and killed the 
fungus. However, the bacteria were unable to bind to, or kill, yeast-form C. 
albicans (Hogan & Kolter, 2002). Subsequent studies showed that P. aeruginosa 
excretes a compound structurally similar to the quorum sensing molecule, 
farnesol, which inhibits yeast-hyphal morphogenesis (Hogan et al., 2004). 
4.6  Biofilm resistance to antimicrobial agents 
 Microbial biofilms not only serve as a nidus for disease but are also 
notoriously resistant to a wide range of antimicrobial agents (Donlan, 2001; 
Hoyle & Costerton, 1991; Jabra-Rizk et al., 2004). In vitro, bacterial cells in a 
biofilm are 10-1000 times more resistant to antibiotics than planktonic cells 
(Donlan & Costerton, 2002). Similar findings with Candida biofilms were first 
reported in 1995 (Hawser & Douglas, 1995). Clinically important antifungal 
agents, including amphotericin B, fluconazole, flucytosine, itraconozole, and 
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ketoconazole were tested against different Candida species. All these agents 
showed much less activity against C. albicans biofilms than against planktonic 
cells. Concentrations of antifungal agent required to reduce metabolic activity 
by 50% were five to eight times higher than for planktonic cells, and 30-2000 
times higher than the corresponding minimum inhibitory concentrations. 
Biofilms of non-C. albicans species such as C. tropicalis, C. parapsilosis, C. 
krusei, and C. glabrata were also drug resistant (Hawser & Douglas, 1995). 
Subsequent studies have demonstrated drug resistance for Candida biofilms 
grown in a variety of model systems in vitro (Baillie & Douglas, 1998b; Chandra 
et al., 2001a; Chandra et al., 2001b; Mukherjee & Chandra, 2004; Ramage et 
al., 2001b). Moreover, with in vivo animal models, Candida biofilms showed a 
resistant phenotype similar to that of biofilms formed in vitro (Kuhn et al., 
2002b).  
 Since antifungal therapy is often ineffective, biofilm-associated 
infections are problematic and removal of the infected device is 
recommended. However, in the case of infected heart valves, central nervous 
system shunts and joint prostheses, removal may result in serious implications 
for the patient (Jabra-Rizk et al., 2004). Therefore, there is an obvious 
requirement for antifungal drugs that are active against this type of infection. 
Recently, two classes of antifungal agents, namely, lipid formulations of 
amphotericin B (liposomal AMB and AMB lipid complex) and the echinocandins, 
have shown activity against Candida biofilms. The mechanism behind their 
unique activity is unclear (Kuhn et al., 2002b). 
4.7  Possible mechanisms of biofilm drug resistance 
 The mechanisms of biofilm-associated resistance to antimicrobial agents 
are not fully understood. In bacteria, resistance appears to be multifactorial 
and may vary with the bacteria present in the biofilm and the  nature of the 
antimicrobial agent being administered (Mah & O'Toole, 2001).  With Candida 
biofilms, at least four factors have been considered to be responsible for 
increased resistance to antimicrobial agents. These are: a) restricted drug 
diffusion through the matrix of extracellular polymeric material, b) phenotypic 
differences resulting from low growth rate or nutrient depletion, c) surface 
contact-induced gene expression and d) the presence of “persister” cells 
(Douglas, 2003; Mukherjee & Chandra, 2004; Ramage et al., 2005). Cell density 
  Introduction 
 
  
 
38 
(Perumal et al., 2007), membrane sterols (Mukherjee et al., 2003), and cell 
wall glucans (Nett et al., 2007b) could also play a role. To date, most evidence 
suggests that drug resistance in Candida biofilms may be due to a combination 
of two or more of these mechanisms. 
4.7.1 Restricted drug diffusion 
 The production of extracellular polymeric matrix is one of the 
distinguishing characteristics of biofilms. It has long been supposed that this 
matrix might act as a barrier to the diffusion of antimicrobial agents. This was 
investigated in C. albicans by comparing the susceptibility profiles of biofilms 
grown under liquid flow conditions (maximal matrix production) with those of 
biofilms grown under static conditions (minimal matrix production). Both types 
of biofilm were resistant to antifungal drugs with no significant differences 
(Baillie & Douglas, 2000); this suggests that drug resistance is unrelated to the 
extent of matrix formation. However, other studies with biofilms produced 
under flow conditions showed that resuspended cells (which had previously lost 
most of their matrix) were 20% less resistant to amphotericin B than the intact 
biofilms (Baillie & Douglas, 1998a; Baillie & Douglas, 1998b). These results with 
resuspended biofilm cells were subsequently confirmed elsewhere (Ramage et 
al., 2002a).  
 More recently, a filter disc assay was used to examine the penetration of 
antifungal drugs (flucytosine, fluconazole, amphotericin B, and voriconazole) 
into single- and mixed-species biofilms containing Candida. In single-species 
Candida biofilms, fluconazole penetration was more rapid than penetration by 
flucytosine. Each drug showed similar diffusion rates through biofilms of three 
strains of C. albicans. However, the rates of drug diffusion through biofilms of 
C. glabrata or C. krusei were faster than those through biofilms of C. 
parapsilosis or C. tropicalis. In all cases, after 3 to 6 h the drug concentration 
at the distal edge of the biofilm was very high but failed to yield complete 
killing of biofilm cells. In mixed-species biofilms containing C. albicans and S. 
epidermidis, the diffusion of all four antifungal agents was very slow. In these 
experiments, the drug concentrations at the distal edges of the biofilms 
substantially exceeded the MIC. Thus, although the presence of bacteria and 
bacterial matrix material undoubtedly retarded the penetration of the 
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antifungal drugs, poor penetration does not account for the drug resistance of 
Candida biofilm cells, even in these mixed-species biofilms (Al-Fattani & 
Douglas, 2004).  
 Subsequently, the same research group used a different model biofilm 
system to investigate further the role of the matrix in biofilm resistance to 
antifungal agents. Biofilms of C. albicans were grown under conditions of 
continuous flow in a modified Robbins device (Al-Fattani & Douglas, 2006). 
These biofilms produced more matrix material than those grown statically and 
were significantly more resistant to amphotericin B. Biofilms of C. tropicalis 
produced copious amounts of matrix material and were completely resistant to 
amphotericin B and fluconazole. Mixed-species biofilms containing C. albicans 
and a slimy strain of S. epidermidis, when grown statically or in the modified 
Robbins device, were completely resistant to both drugs. On the other hand, 
mixed-species biofilms of C. albicans and a slime-negative mutant of S. 
epidermidis were completely drug resistant only when grown under flow 
conditions (Al-Fattani & Douglas, 2006).  Overall, these results suggest that the 
matrix might play a significant role in biofilm drug resistance, especially when 
biofilms are grown under flow conditions similar to those found in catheter 
infections in vivo. 
4.7.2 Slow growth rate and nutrient limitation 
 Biofilm cells, especially those at the bottom of the biofilm, are expected 
to experience some form of nutrient limitation, which in turn slows their 
growth rate. A slow growth rate is often associated with phenotypic changes 
such as alteration in cell surface composition that may affect the susceptibility 
of the microorganisms to antimicrobial agents. Moreover, various studies have 
shown that antimicrobial agents are more effective in killing rapidly growing 
cells (Mah & O'Toole, 2001). Therefore, growth rate could be an important 
modulator of drug activity in biofilms (Donlan & Costerton, 2002; Mah & 
O'Toole, 2001). To examine the effect of growth rate with C. albicans, a 
perfused biofilm fermentor was used to produce biofilms at different growth 
rates. The susceptibility of the biofilm cells to amphotericin B was then 
compared with that of planktonic organisms grown at the same rate in a 
chemostat. The results showed that biofilm cells were resistant to 
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amphotericin B at all growth rates tested, while planktonic cells were resistant 
only at low growth rates (Baillie & Douglas, 1998a). Therefore, biofilm 
resistance depends on some other feature of the biofilm mode of growth and is 
not only the result of a low growth rate. 
 Subsequent studies demonstrated that drug resistance is associated with 
an increase in the metabolic activity of the developing biofilm (Chandra et al., 
2001a; Chandra et al., 2001b) and that drug resistance develops over time, 
coincident with biofilm maturation. A separate investigation by Baillie and 
Douglas (1998b), using the cylindrical cellulose filter model system, reported 
that glucose-limited and iron-limited biofilms grown at the same low rate were 
equally resistant to amphotericin B. In the same study, daughter cells from 
iron-limited biofilms were significantly more susceptible to the drug than those 
from glucose-limited biofilms. An acute disseminated infection produced by the 
release of such cells from an implant biofilm might therefore respond rapidly to 
amphotericin B treatment but the biofilm would be unaffected. 
4.7.3 Surface contact-induced gene expression 
 When cells attach to a surface and form a biofilm, they express an 
altered phenotype. There is a special interest in trying to identify the genes 
that are activated or repressed in biofilms as compared with planktonic cells, 
particularly genes that might contribute to increased resistance to 
antimicrobial agents. Antifungal resistance in planktonic cells of C. albicans has 
been associated with the expression of two different types of efflux pump, 
encoded by CDR and MDR genes, respectively. Recent studies have 
demonstrated that both CDR and MDR genes are upregulated during biofilm 
formation and development. However, mutant strains lacking one or both 
pumps were highly susceptible to fluconazole when growing planktonically but 
still retained the resistant phenotype during biofilm growth (Ramage et al., 
2002a). A separate study investigated the antifungal susceptibilities of biofilms 
developed by C. albicans Cdr1/Cdr2 and Cdr1/Cdr2/Mdr1 double and triple 
mutants. Biofilms formed by these mutants were more susceptible to 
fluconazole at an early stage of biofilm development than the wild-type strain.  
At later time points (12 and 48 h), all the strains became resistant to 
fluconazole. These studies indicate that efflux pumps are differently expressed 
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during biofilm formation and that they contribute to azole resistance in the 
early phase of biofilm formation but not in the later phases (Mukherjee et al., 
2003). 
4.7.4 Existence of “persister” cells 
 A recently proposed hypothesis for the resistance of bacterial biofilms is 
that a subpopulation of microorganisms in a biofilm differentiates into a unique 
and highly protected phenotypic state in the presence of a bactericidal agent, 
similar to spore formation (Spoering & Lewis, 2001; Stewart & Costerton, 
2001). Persisters were first noted in planktonic cultures by Joseph Bigger (1944) 
in one of the first studies on the mechanism of penicillin action. The persister 
phenomenon has recently received increased attention in the context of 
biofilms where persisting cells have the added protection of an extracellular 
matrix (Spoering & Lewis, 2001).  
 Persisters, which might consist of 1% or less of the original population, 
remain dormant (neither grow nor die) despite continued exposure to an 
antimicrobial drug (Lewis, 2005). These cells can withstand drug concentrations 
substantially above the MIC and represent special survivor cells that are 
phenotypic variants of the wild type, rather than mutants (Keren et al., 2004b; 
Lewis, 2000). The immune system is able to clear any planktonic persisters 
whereas in a biofilm, persisters are protected by the matrix against immune 
cells. Biofilm persisters are formed by all bacterial species studied, and are 
present at 0.1-1% in biofilms of Pseudomonas aeruginosa, Escherichia coli, or 
Staphylococcus aureus, for example (Keren et al., 2004b). Bacteria produce 
multidrug-tolerant persister cells in both planktonic and biofilm populations 
(Brooun et al., 2000; Keren et al., 2004b; Spoering & Lewis, 2001). A biphasic 
pattern of killing is a defining feature demonstrating the presence of persisters 
in bacterial populations; the majority of the population is rapidly killed, 
whereas a small fraction of the cells are unaffected even by prolonged 
antibiotic treatment (Brooun et al., 2000; Stewart, 2002). 
 The existence of such cells in Candida species has been reported 
recently. Certain cells at the base of a C. albicans biofilm were shown to have 
increased resistance to the antiseptic, chlorhexidine (Suci & Tyler, 2003). In 
addition, small subpopulations in biofilms of both C. albicans and C. tropicalis 
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were found to be 4 to 533 times more tolerant of high concentrations of metal 
chelating agents than the corresponding planktonic cell populations (Harrison 
et al., 2007). Increased resistance to amphotericin B was also detected in a 
subpopulation of C. albicans biofilms which remained adhering to the surface 
of a tubular flow cell after most cells were washed away. These cells were 
resistant to amphotericin B  at ten times the concentration that eliminated 
planktonic populations, and the high level of resistance appeared to correlate 
with differential regulation of the ergosterol and β-1,3 glucan genes ERG1, 
ERG25, SKN1, and KRE1 (Khot et al., 2006).  
 A separate study by LaFleur and colleagues (2006) demonstrated that a 
subpopulation of cells within C. albicans biofilms exhibited multidrug 
tolerance. In this investigation, biofilms of C. albicans exhibited a biphasic 
killing pattern in response to two microbicidal agents, amphotericin B and 
chlorhexidine, indicating the presence of persisters. The extent of killing with a 
combination of amphotericin B and chlorhexidine was similar to that obtained 
with individually added antimicrobials, and it was thus concluded that surviving 
persisters form a multidrug-tolerant subpopulation. Unlike bacterial 
populations, surviving C. albicans persisters were detected only in biofilms, and 
not in planktonic, exponentially growing or stationary-phase populations. 
Reinoculation of cells that survived killing by amphotericin B produced a new 
biofilm with a new subpopulation of persisters, suggesting that C. albicans 
persisters are not mutants, but phenotypic variants of the wild type. Given that 
persisters were produced only in the biofilm, mutants defective in biofilm 
formation were examined for persister production. Interestingly, all biofilm-
defective mutants treated with high concentrations of amphotericin B were 
able to produce normal levels of persisters. This result may indicate that 
attachment rather than formation of a complex biofilm architecture initiates 
persister formation. 
 Mammalian cells with serious damage may undergo programmed cell 
death or apoptosis. In this respect, it has been suggested that treatment of 
microorganisms with antimicrobial agents triggers a programmed suicide 
mechanism, resulting in death from apoptosis (Gilbert et al., 2002; Lewis, 
2005). Persisters may represent cells with defective programmed cell death 
rather than inherent resistance to the agent (Jabra-Rizk et al., 2004), i.e., 
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inhibition of programmed cell death allows the cells to exhibit tolerance to 
antimicrobial drugs (Lewis, 2005). 
 
5 Apoptosis 
 Cell death is a completely normal process in living organisms and plays a 
major role in physiological processes of multicellular organisms, particularly 
during embryogenesis and metamorphosis (Lockshin & Zakeri, 2001). The term 
programmed cell death was first introduced in 1964, to describe a process 
whereby cell death during development is not accidental in nature but follows 
a sequence of controlled and regulated steps leading to locally and temporally 
defined self destruction (Lockshin & Williams, 1964).  In 1972, Kerr and 
coworkers coined the term ‘apoptosis’ to describe the processes leading to 
controlled cellular self destruction. Apoptosis is involved in various biological 
processes such as development, differentiation, proliferation/homoeostasis, 
regulation and function of the immune system, and in the removal of defective 
and therefore harmful cells (Wyllie et al., 1980). Defects in apoptosis can 
result in uncontrolled cell proliferation (such as in cancer), autoimmune 
diseases and spreading of viral infections, while excessive apoptosis can cause 
neurodegenerative disorders, AIDS, and ischemic heart diseases (Thompson, 
1995).   
5.1  Apoptosis in mammalian cells 
 Apoptosis is characterized by cell shrinkage (the cell shows deformation 
and loses contact with its neighbouring cells), chromatin condensation, nuclear 
fragmentation, plasma membrane blebbing, and cell fragmentation into 
compact membrane-enclosed structures called ‘apoptotic bodies’. The 
apoptotic bodies are engulfed by macrophages (in mammals) or by 
neighbouring cells, without causing an inflammatory response (Griffin & 
Hardwick, 1997). Apoptosis is quite different from the necrotic mode of cell 
death in which the cells suffer a major insult, resulting in a loss of membrane 
integrity, swelling and rupture of the cells. During necrosis, the cellular 
contents are released in an uncontrolled way into the cell's environment and 
this results in damage to the surrounding cells, inflammatory responses and, 
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potentially, serious health problems (Lawen, 2003; Leist & Jaattela, 2001; Van 
Cruchten & Van Den Broeck, 2002) (Fig. 11). 
 Apoptosis can be triggered by a wide variety of stimuli from outside 
(extrinsic inducers) or inside (intrinsic inducers) the cell. Extrinsic signals may 
include toxins, hormones, growth factors, or cytokines (Cobb & Schaefer, 1997; 
Kirby, 2004) while intrinsic signalling can be initiated by a cell in response to 
stress such as DNA damage (e.g. by radiation or chemotherapeutic drugs) or 
starvation, as well as to oxidative stress (Kaufmann & Earnshaw, 2000; Wang, 
2001). The key effectors that modulate apoptosis are cysteinyl aspartate-
specific proteases (caspases). Strictly defined, cell death can only be classified 
to follow a classical apoptosis mode if execution of cell death is dependent on 
caspase activity (Leist & Jaattela, 2001). These caspases exist within the cell in 
an inactive form and they can be cleaved to form active enzymes following the 
induction of apoptosis. Once the initiator caspases have been activated, a 
sequential activation of caspases takes place. These enzymes cleave other 
caspases and non-caspase substrates such as proteins of the DNA repair system, 
resulting in the mediation and amplification of the death signal and eventually 
in the execution of cell death with all the characteristic features of apoptosis 
(Earnshaw, 1999). However, there are also potential negative regulators of 
apoptosis including Bcl-2 family proteins and inhibitor-of-apoptosis proteins 
(White, 1996).  
5.2  Apoptosis in yeasts  
 Recent studies indicate that yeasts undergo programmed cell death for 
several good reasons. For example, the death of aged, infertile, damaged, or 
virus-infected yeast cells may ensure the survival of the rest of the population 
(Buttner et al., 2006). A large number of exogenous stimuli have also been 
found to induce apoptosis-like cell death in yeasts (Madeo et al., 2004). These 
include stress stimuli such as hydrogen peroxide, acetic acid, hyperosmotic 
stress, ultraviolet irradiation, mating pheromone exposure, amino acid 
starvation, aspirin, and some antifungal drugs (Almeida et al., 2008; Frohlich & 
Madeo, 2000; Gourlay et al., 2006; Hiramoto et al., 2003; Madeo et al., 1997; 
Silva et al., 2005).  
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Figure 11.  Hallmarks of the apoptotic and necrotic cell death process 
Apoptosis includes cellular shrinking, chromatin condensation and margination 
at the nuclear periphery with the eventual formation of membrane-bound 
apoptotic bodies which contain organelles, cytosol and nuclear fragments. 
These bodies are phagocytosed without triggering inflammatory processes. The 
necrotic cell swells, becomes leaky and finally is disrupted and releases its 
contents into the surrounding tissue resulting in inflammation. Reprinted from 
Van Cruchten & Van Den Broeck (2002) by permission of the publisher, John 
Wiley and Sons. 
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Phillips and colleagues (2003) reported that planktonically grown cells of C. 
albicans, when treated with low concentrations of amphotericin B or H2O2, 
exhibit cellular changes reminiscent of mammalian apoptosis. These include 
nuclear fragmentation, chromatin condensation, phosphatidylserine 
externalization, reactive oxygen species accumulation, and arrest in G2/M cell 
cycle phases. In Saccharomyces cerevisiae, one caspase-like protease 
(metacaspase Mca1p) has been identified that functions similarly to caspases in 
mammalian cells  (Madeo et al., 2002). Several studies have demonstrated that 
apoptosis in S. cerevisiae may be dependent on the activity of the metacaspase 
Mca1p (also known as MCA1 or YCA1) (Bettiga et al., 2004; Khan et al., 2005; 
Madeo et al., 2002). However, in other studies, the apoptotic killing response 
was shown to be Mca1p-independent, indicating the presence of additional 
caspase-like activity in S. cerevisiae (Hardwick & Cheng, 2004; Hauptmann et 
al., 2006; Herker et al., 2004; Vachova & Palkova, 2005; Wissing et al., 2004). 
More recently, Cao et al. (2009) have found that C. albicans contains a putative 
metacaspase CaMCA1 which shows homology to S. cerevisiae metacaspase. The 
deletion of CaMCA1 resulted in decreased caspase activity and in resistance to 
oxidative stress (Cao et al., 2009). 
 Histone acetylation and deacetylation play critical roles in eukaryotic 
gene transcriptional regulation (Grunstein, 1997; Howe et al., 1999). 
Acetylation is generally associated with activation, whereas lack of acetylation 
tends to correlate with repression; these two processes work together to 
achieve appropriate levels of transcription (Sterner & Berger, 2000). Histone 
deacetylases (HDAs) selectively regulate chromatin structure, which in turn 
affects the folding patterns and interactions between DNA and DNA-binding 
proteins (Grozinger & Schreiber, 2002; Mai et al., 2007). To date, more than 50 
non-histone proteins have been identified as substrates for one or another of 
the HDAs. These substrates include proteins with regulatory roles in cell 
proliferation, cell migration, and cell death (Dokmanovic et al., 2007). HDA 
inhibitors such as valproic acid, trichostatin A, and butyric acid are known to 
induce apoptosis in mammalian cells (Kawagoe et al., 2002). In fungi, histone 
deacetylases are also important regulators of many cellular functions and HDA 
inhibitors have been found to affect a number of processes in these organisms 
(Kurdistani & Grunstein, 2003; Mai et al., 2007; Simonetti et al., 2007; Smith & 
Edlind, 2002). Valproic acid induces YCA1-dependent apoptosis in S. cerevisiae 
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(Mitsui et al., 2005). In C. albicans, HDA inhibitors have been reported to 
enhance sensitivity to azoles and other antifungal agents (Mai et al., 2007; 
Smith & Edlind, 2002), to inhibit adhesion and serum-induced germ-tube 
formation (Noverr & Huffnagle, 2004; Simonetti et al., 2007), and to promote 
colony-type switching (Klar et al., 2001; Srikantha et al., 2001).  
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6 Aims and Objectives of Research 
 Most hospital-acquired implant-based infections attributable to fungi are 
caused by Candida albicans and other closely related Candida species. These 
organisms are able to form adherent biofilms on the surfaces of catheters, joint 
replacements, prosthetic heart valves, and other medical devices. Candida 
biofilm-associated infections are resistant to a range of antifungal agents in 
current clinical use. As a result, antifungal therapy is often ineffective and 
removal of these devices is recommended. However, in the case of infected 
heart valves, central nervous system shunts and joint prostheses, removal may 
result in serious consequences for the patient. The basis of biofilm drug 
resistance is poorly understood. The aim of this project was to investigate 
possible resistance mechanisms, with particular emphasis on restricted drug 
penetration through the biofilm matrix and the existence of persisters in 
Candida biofilms. Research concentrated on two fungicidal agents: 
amphotericin B which has long been used for the treatment of systemic 
infections, and caspofungin, a newly licensed drug reported to show some 
activity against biofilms. 
Specific objectives were the following: 
1. To compare the susceptibility to amphotericin B and caspofungin of 
 Candida biofilms at different developmental phases in vitro. 
2. To determine the penetration of caspofungin through biofilms of 
 different Candida species using a filter disc assay. 
3. To investigate the presence of persister (drug-tolerant) cells in 
 planktonic cultures and biofilms of Candida species by means of 
 fluorescein staining and viability measurements. 
4. To explore the existence of apoptosis in Candida biofilms and to 
 determine the effect of apoptosis activators and inhibitors on drug 
 resistance.  
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1 Candida species 
 Six Candida isolates were used in this study. C. albicans GDH2346 was 
originally isolated from a patient with denture stomatitis at Glasgow Dental 
Hospital. C. albicans SC5314 was kindly provided by Professor Neil. A. R. Gow, 
University of Aberdeen, Aberdeen, Scotland. C. glabrata AAHB12, C. tropicalis 
AAHB73, and C. parapsilosis AAHB4479 were isolated from patients with line 
infections at Crosshouse Hospital, Kilmarnock, Scotland. C. krusei was obtained 
from a clinical specimen and came from the Regional Mycology Reference 
Laboratory, Glasgow, Scotland. 
 All isolates were maintained on slopes of Sabouraud dextrose agar (SDA; 
Difco) and stored at 2 to 8°C. Fresh slopes were prepared at 2-monthly 
intervals from long-term stocks held in 50% glycerol at -70°C. 
 
2 Growth media 
2.1  Sabouraud dextrose agar 
 Sabouraud dextrose agar (SDA; Oxoid; 65g/litre) was autoclaved for 15 
min at 121°C. The final pH was 5.6 ± 0.2. After autoclaving and cooling to 
50°C, the medium was dispensed in petri dishes or universal bottles for slope 
cultures. This medium was used to maintain Candida isolates.  
2.2   Yeast nitrogen base 
 Yeast nitrogen base medium (YNB; Difco) was supplemented with 50 mM 
glucose as a carbon source. This medium was used as a standard liquid medium 
for growth of planktonic cells and biofilms. One litre of this medium contained 
of 6.7 g of yeast nitrogen base and 9 g of glucose (50 mM) and the final pH was 
5.4. The medium was autoclaved at 10 p.s.i for 10 min. 
2.3   YNB agar with 50mM or 200mM glucose 
 YNB containing 50 mM glucose was prepared as described earlier (section 
2.2). Agar powder (12 g/litre; Duchefa) was added before autoclaving. The 
medium was dispensed into petri dishes. YNB agar with 50 mM glucose was used 
for drug penetration assays. YNB agar supplemented with 200 mM glucose 
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(36g/litre) was used for lawn production by the indicator strain during drug 
penetration assays and for viable cell counts. 
2.4  YNB agar containing antifungal agents 
 Using a sterile filtration unit (Sartorius Minisart; pore size, 0.2 µm), the 
drug solution was filtered into culture medium (YNB agar containing 50 mM 
glucose) buffered with 0.165 M morpholinepropanesulfonic acid (MOPS; 34.53 
g/litre; Sigma) to pH 7, and kept molten at 50°C. The medium was dispensed in 
petri dishes and used for drug penetration assays. 
2.5   RPMI 1640 buffered with MOPS 
 RPMI 1640 liquid medium (with L-glutamine; Cambrex) was buffered with 
MOPS (34.53 g/litre; Sigma) to pH 7 at 25°C (National Committee for Clinical 
Laboratory Standards, 1995). The medium was then filter sterilized using a 
sterile filtration unit (Sartorius Minisart; pore size, 0.2 µm) and stored at 4°C. 
This medium was used for MIC determinations.  
2.6  RPMI 1640 buffered with HEPES 
 RPMI 1640 liquid medium (with L-glutamine; Cambrex) was buffered with 
HEPES [4-(2-Hydroxyethyl) piperazine-1-ethanesulforic acid, sodium salt; 16.4 
g/litre] to pH 7 at 25°C (National Committee for Clinical Laboratory Standards, 
1995). The medium was then filter sterilized using a sterile filtration unit 
(Sartorius Minisart; pore size, 0.2 µm) and stored at 4°C. This medium was used 
for killing curve assays.  
 
3 Chemicals 
3.1   Antifungal agents 
3.1.1 Fluconazole 
 Stock solutions of fluconazole (800 µg/ml; Sigma) were prepared in 
sterile water and filter sterilized. Small volumes of the solution were dispensed 
into sterile vials and stored at -20°C. 
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3.1.2 Amphotericin B 
 Stock solutions of amphotericin B (8000 µg/ml or 40 mg/ml; Sigma) were 
dissolved in dimethyl sulphoxide (DMSO) and filter sterilized. Small volumes of 
the solution were dispensed into sterile vials and stored at -20°C. Amphotericin 
B is light sensitive and therefore aliquots were protected in foil. 
3.1.3 Caspofungin 
 Stock solutions of caspofungin (800 µg/ml; Merck) were prepared in 
sterile water and filter sterilized. Small volumes of the solution were dispensed 
into sterile vials and stored at -20°C. 
3.2   Tetrazolium salt XTT 
 The tetrazolium salt, XTT [2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-
tetrazolium-5-carboxanilide] was used as an indicator of cell viability. XTT is 
reduced by mitochondrial dehydrogenases to a brown-coloured tetrazolium 
formazan product.  The dye formed is water soluble and the dye intensity can be 
read at a given wavelength with a spectrophotometer.  The intensity of the dye is 
proportional to the number of metabolically active cells.  
3.3  Live-dead cell staining  
3.3.1 Fluorescein diacetate 
 Fluorescein diacetate (3,6-Diacetoxyfluoran; Di-O-acetylfluorescein; 
Sigma) is a fluorescent dye used to distinguish dead yeast cells from living 
cells. This dye specifically stains dead yeast cells with a green fluorescence.  
3.4  Apoptosis inhibitors (Caspase inhibitors) 
3.4.1 Z-VAD-FMK 
 Stock solutions (14.7 mM) of the general caspase inhibitor, Z-VAD-FMK 
(Calbiochem) were prepared in DMSO and stored in small aliquots at -20°C.  
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3.4.2 Caspase inhibitor set III 
 Caspase Inhibitor Set III was supplied by the manufacturer (Calbiochem) 
as 2 mM solutions in DMSO and consisted of: caspase-1 inhibitor VI (Z-YVAD-
FMK); caspase-2 inhibitor I (Z-VDVAD-FMK); caspase-3 inhibitor II (Z-DEVD-FMK); 
caspase-5 inhibitor I (Z-WEHD-FMK); caspase-6 inhibitor I (Z-VEID-FMK); 
caspase-8 inhibitor II (Z-IETD-FMK); and caspase-9 inhibitor I (Z-LEHD-FMK). 
Caspase Inhibitors were stored at -20°C. 
3.5   Apoptosis inducers (Histone deacetylase inhibitors) 
3.5.1 Sodium butyrate 
 Stock solutions of sodium butyrate (1 M; Sigma) were prepared in sterile 
water. Small volumes of the solution were dispensed into sterile vials and 
stored at -20°C. 
3.5.2 Sodium valproate 
 Stock solutions of sodium valproate (1 mg/ml; Sigma) were prepared in 
sterile water. Small volumes of the solution were dispensed into sterile vials 
and stored at -20°C. 
3.5.3 Trichostatin A 
 Stock solutions of trichostatin A (10 mg/ml; Calbiochem) were prepared 
in DMSO and stored in small aliquots at -20°C.  
3.5.4 Apicidin 
 Stock solutions of apicidin (10 mg/ml; Calbiochem) were prepared in 
DMSO and stored in small aliquots at -20°C.  
3.6  Apoptosis detection kits 
3.6.1 SR-FLICA 
 An SR-FLICA (Sulforhodamine-Fluorescent Labelled Inhibitors of 
Caspases) apoptosis detection assay (Immunochemistry Technologies) was used 
to detect apoptotic cells. The SR-VAD-FMK FLICA reagent comprises 3 
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segments: a red fluorescent label (Sulforhodamine; SR); an amino acid peptide 
inhibitor sequence targeted by all active caspases (VAD); and a 
fluoromethylketone group (FMK) which acts as a leaving group and helps form a 
covalent bond with the active caspase enzyme. SR-VAD-FMK irreversibly binds 
to many activated caspases (caspase-1, -3, -4, -5, -6, -7, -8, and -9). The FLICA 
reagent is supplied as a highly concentrated lyophilized powder. It is 
reconstituted in 50 µl DMSO forming a 150-fold stock concentrate and then 
diluted 1 in 5 in PBS to form a final 30-fold concentrated working solution. For 
best results, the working solution is used the same day that it is prepared; 
however, the stock concentrate can be stored at -20ºC for 6 months. 
3.6.2 CaspSCREEN apoptosis detection 
 A CaspSCREENTM kit (Biovision Research Products, CA) was also used to 
detect caspase activity. The assay is based on the cleavage of (aspartyl)2-
Rhodamine 110 (D2R), a reported substrate for members of the caspase family 
of proteases. The caspase substrate D2R is non-fluorescent; however, upon 
cleavage by cellular activated caspases, the released rhodamine 110 gives rise 
to a green fluorescence that can be measured by flow cytometry or by using a 
fluorescence microscope.  
3.7  Pepstatin A 
 Pepstatin A (Sigma) was dissolved at a concentration of 1 mg/ml in 
methanol containing 10 % (v/v) acetic acid. Small volumes of the solution were 
dispensed in sterile vials and stored at -20°C. 
 
4 Antifungal susceptibility of Candida planktonic cells 
4.1  Inoculum preparation 
 Using the NCCLS method (National Committee for Clinical Laboratory 
Standards, 1995), five colonies of >1 mm diameter from 24 h cultures grown on 
SDA plates at 37 ºC were suspended in 5 ml of sterile saline (0.85% w/v). The 
resulting suspension was vortexed for 15 s and the cell density was adjusted to 
a reading of 0.5 at 530 nm using a spectrophotometer. This procedure yielded a 
Candida stock suspension of 1 x 106 to 5 x 106 cells per ml. A working 
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suspension was made via a 1:50 dilution followed by a 1:20 dilution of the stock 
suspension with RPMI 1640 medium to obtain a concentration double that of 
the test inoculum (1 x 103 to 5 x 103 cells/ml).  
4.2   Broth microdilution 
 The broth microdilution method was performed according to the NCCLS 
guidelines (National Committee for Clinical Laboratory Standards, 1995).  
4.2.1 Minimum inhibitory concentration (MIC) 
  The MIC assay was performed in U-shaped wells of sterile 96-well plates 
(Costar; Corning Inc, USA). Serial dilutions of antifungal agents (amphotericin 
B, caspofungin) were prepared at double the final concentration in RPMI 1640 
medium buffered with 0.165 M MOPS (pH 7); the dilutions ranged from 0.06 to 
16 µg/ml. The Candida inoculum was prepared as described previously (Section 
4.1). Antifungal solutions (100 µl) were dispensed in the wells of a microtitre 
plate. The inoculum suspension (100 µl) was then added to each well of the 
microtitre plate. This results in a 1:2 dilution of both the antifungal agent and 
the inoculum. Control wells contained inoculum suspension and medium 
without drug. The plates were incubated at 37˚C for 48 h. The MIC end point 
for the tested drugs was defined as the lowest concentration resulting in no 
visible growth in the wells (100% inhibition).  
4.2.2 Minimum fungicidal concentration (MFC) 
 The minimum inhibitory concentration (MIC) of amphotericin B for C. 
albicans GDH2346 was determined following the method described previously 
(Section 4.2.1). After the MIC was read, 100 µl samples from each well at or 
above the MIC were transferred to duplicate SDA agar plates (90 mm diameter) 
and spread evenly. The plates were incubated at 37˚C and read after 48 h. The 
minimum fungicidal concentration (MFC) was defined as the lowest drug 
concentration that caused total killing of cells. 
4.3   Killing curves 
 To further investigate the fungicidal activity of amphotericin B against 
C. albicans GDH2346, three to five colonies of C. albicans GDH2346 were 
picked from a 48-h plate culture and suspended in 10 ml of sterile distilled 
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water; the optical density was adjusted to 0.5 at 530 nm. One ml of this 
inoculum was added to either 9 ml of RPMI 1640 medium buffered with HEPES 
alone (control) or to 9 ml of the same buffered medium containing 
amphotericin B at final concentrations of one-half, one, two and four times the 
MIC. Cultures were then placed on a shaker and incubated at 37˚C. At time 
points 0, 2, 6 and 24 h following the inoculation of C. albicans into the 
solutions, a 100 µl aliquot from each test solution was removed. After 10-fold 
serial dilutions in RPMI, 50 µl aliquots from each dilution were spread on 
duplicate SDA plates. Plates were incubated at 37˚C. The total number of 
colony forming units (CFU) on each plate was determined after 48 h (Barchiesi 
et al., 2005). The results were used to construct killing curves of cell survival 
against time for each concentration of amphotericin B tested.  
 
5  Biofilm formation on catheter discs 
5.1  Catheter discs 
 Discs (surface area, 0.5 cm2; diameter, 0.8 cm) were cut from polyvinyl 
chloride (PVC) Faucher tubes (French gauge 36; Vygon, Cirencester, UK) using a 
metal punch (Fig. 12). The discs were sterilized by exposure to ultraviolet 
radiation (254nm; UVP Inc., USA) for 20 min on both sides. 
5.2   Biofilm inoculum 
 Candida isolates were grown in YNB medium containing 50 mM glucose. 
Batches of medium (50 ml in 250-ml Erlenmeyer flasks) were inoculated from 
slopes and incubated for 24 h at 37°C in an orbital shaker at 60 rpm. Aliquots of 
culture (10ml) were transferred to universal bottles and centrifuged at 3000 
rpm for 4 min. Cell pellets were washed twice in 0.15 M phosphate-buffered 
saline (PBS; pH 7.2; Sigma) and resuspended in the same buffer. Cell 
suspensions were standardized to an optical density of 0.8 at 520 nm.  
5.3  Biofilm formation 
 Catheter discs (Section 5.1) were transferred aseptically into wells of 24-
well Costar tissue culture plates, with concave side facing up.  A standardized 
cell suspension (80 µl) was applied to the surface of each disc. The cells were  
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Figure 12.  Metal punch device and biofilm discs. 
Metal punch (A) used to cut polyvinyl chloride (PVC) discs (diameter, 0.8 cm) 
(C) from PVC Faucher tubes (B) for biofilm formation. 
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allowed to adhere to the discs for 1 h at 37°C. Nonadherent cells were 
removed by gentle washing with PBS (5 ml). Discs were then submerged into 1 
ml YNB medium containing 50 mM glucose in wells of fresh tissue culture 
plates. Plates were incubated for 48 h at 37°C (Fig. 13). 
5.4  Quantitative measurement of biofilm growth 
 Biofilm metabolic activity was measured colorimetrically using a 
tetrazolium salt (XTT) reduction assay. This salt is reduced by mitochondrial 
dehydrogenases to a brown-coloured tetrazolium formazan product, which is 
then determined spectrophotometrically. However, addition of the electron 
coupling agent menadione (Vitamin K3; 2-methyl-1,4-naphthoquinone; Sigma) is 
necessary. XTT solution (250 µg/ml; Sigma) was dissolved in sterile, pre-
warmed PBS containing 1% (w/v) glucose and 1 ml was added to each well of 
fresh plates containing the biofilm discs. Menadione solution (1 mM in acetone; 
4 µl) was also added to the wells to give a final concentration of 4 µM. The 
biofilms were then incubated for 5 h at 37°C in the dark. The solution 
containing XTT formazan in each well was transferred to a microfuge tube and 
clarified at 13000 rpm for 3 min. The supernatant was then transferred to a 
microcuvette for measuring formazan production at 492 nm (Fig. 14). 
5.5  Viable counts of biofilm cells 
 This method was used to measure the number of viable cells in biofilms.  
Biofilm cells were harvested from the discs by scraping and vigorous vortexing, 
washed twice in 0.15 M PBS, pH 7.2, and resuspended in more PBS. Ten-fold 
serial dilutions (10-1 to 10-6) of biofilm cell suspensions were prepared in PBS. 
Duplicate samples (0.1 ml) of the 10-5 and 10-6 dilutions were then spread on 
YNB agar containing 200 mM glucose and the plates were incubated for 24 – 48 
h at 37°C. The total number of CFU was counted and this number multiplied by 
the dilution factor to determine the concentration of cells per ml of original 
sample. 
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Figure 13. Costar tissue culture plate containing mature 48-h old biofilms 
grown on polyvinyl chloride catheter discs.  
Biofilm discs were submerged in 1 ml YNB growth medium with 50 mM glucose. 
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Figure 14. Tetrazolium salt (XTT) reduction assay used to measure biofilm 
cell viability. 
Metabolically active cells convert XTT to a brown-coloured formazan product. 
(A) Positive sample, after incubation for 5 h at 37ºC; (B) Negative control 
sample, colourless. 
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6 Antifungal susceptibility of Candida biofilms 
6.1  Susceptibility of biofilms on catheter discs 
 Stock solutions of the drugs were diluted in growth medium (YNB 
containing 50 mM glucose) buffered to pH 7 with MOPS buffer. Biofilms were 
grown on discs for 48 h at 37°C or for specific time periods and then 
transferred into wells containing 1 ml of buffered medium with defined 
concentrations of the test antifungal agents. Control discs were submerged in 
buffered medium free of drug. Discs were further incubated for 24 h at 37°C 
and the effect of the antifungal agent was measured by either the XTT 
reduction assay (Section 5.4) or by a viable cell count (Section 5.5). 
 
7 Antifungal activity at different developmental phases 
of Candida biofilms 
 Biofilms were grown on catheter discs for 8, 17, 24 or 35 h and then 
submerged into 1 ml of buffered YNB glucose (50 mM) medium containing 
different concentrations (2 times or 5 times the MIC) of antifungal agent. These 
were 2.6 and 6.5 µg/ml of amphotericin B for C. albicans GDH2346; 1.6 and 4 
µg/ml of amphotericin B for C. albicans SC5314; 4.6 and 11.5 µg/ml of 
amphotericin B for C. tropicalis; 2.4 and 6 µg/ml of amphotericin B for C. 
glabrata; 4.4 and 11 µg/ml of amphotericin B for C. parapsilosis; 0.8 and 2 
µg/ml of caspofungin for C. albicans GDH2346; 0.6 and 1.5 µg/ml of 
caspofungin for C. albicans SC5314; 0.9 and 2.25 µg/ml of caspofungin for C. 
tropicalis; 1.4 and 3.5 µg/ml of caspofungin for C. glabrata; 1.6 and 4 µg/ml of 
caspofungin for C. parapsilosis. Control discs were submerged in medium free 
of drug. Discs were further incubated for a total of 48 h at 37°C and metabolic 
activities of biofilm cells were measured using the XTT assay (Section 5.4). 
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8 Penetration of antifungal agents through Candida 
biofilms 
 This penetration assay was a modification of the filter disc method for 
bacterial biofilms as previously described by Anderl et al. (Anderl et al., 2000). 
One antifungal agent was used in this study: caspofungin. However for 
comparative purposes, some experiments (preparation of a standard curve for 
drug penetration and viability measurements) were carried out with 
amphotericin B. 
8.1  Biofilm formation on membrane filters 
 The biofilm inoculum was prepared as described in section 5.2 except 
that the cell suspension was adjusted to an optical density of 0.2 at 600 nm. 
Biofilms were grown on polycarbonate membrane filters (diameter, 25 mm; 
pore size, 0.2 µm; Whatman) which were sterilized by exposure to ultraviolet 
radiation for 15 min on both sides prior to inoculation.  The filters were placed 
aseptically on plates of YNB agar containing 50 mM glucose (Section 2.3). A 
standardized cell suspension (50 µl) was carefully deposited on the surface of 
each sterile membrane. All agar plates were incubated for 24 h at 37°C. The 
membrane-supported biofilms were then transferred to fresh YNB agar plates 
and reincubated for a further 24 h, giving a total incubation time of 48 h for 
biofilm formation. 
8.2   Drug penetration through biofilms 
 A drug concentration of 60 times the MIC for Candida albicans GDH2346 
was used in antifungal agent-supplemented YNB agar (Section 2.4), i.e., 24 
µg/ml for caspofungin. After 48 h of biofilm formation on membrane filters 
(section 8.1), smaller polycarbonate membrane filters (diameter, 13 mm; pore 
size, 0.2 µm; Whatman) were sterilized by exposure to ultraviolet radiation for 
15 min on both sides and then carefully placed on top of the 48-h biofilms. 
Paper concentration discs (diameter, 6 mm; Becton Dickinson) were also 
sterilized by exposure to ultraviolet radiation for 15 min on both sides and then 
moistened with 30 µl of growth medium prior to placement on top of the 13-
mm-diameter membranes. Wetting the discs helped to prevent the capillary 
action of the antifungal medium through the biofilms. The whole assembly –  
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the biofilm ‘sandwich’ - was transferred to an antifungal agent-containing agar 
plate using sterile forceps (Fig. 15). All plates were incubated for specific time 
periods, i.e., 60, 90, 120, 180, 240, or 360 min at 37°C.  
 The amount of antifungal agent that diffused into a concentration disc 
through the biofilm was determined by using the disc in a standard drug 
diffusion assay. Plates of YNB agar containing 200 mM glucose were seeded 
with 150 µl of a standardized suspension of planktonic C. albicans GDH 2346 
which was used as an indicator organism. The suspension was adjusted to an 
optical density of 1.0 at 520 nm prior to plating. The concentration discs were 
removed from the biofilm ‘sandwiches’ after the specified exposure time and 
placed on the seeded plates, which were then incubated for 24 h at 37°C. The 
zones of growth inhibition were measured and used to determine the 
concentration of active antifungal agent in the discs by reference to a standard 
curve prepared by using drug solutions of different concentrations but fixed 
volumes (Section 8.3). The assay was conducted in duplicate on two separate 
occasions for each Candida isolate tested. The control assays used for the 
experiment were concentration discs placed on the two-membrane system 
without the biofilm. To provide a normalized penetration curve, the drug 
concentration that diffuse through the biofilm (C) was divided by the drug 
concentration determined for the control (C0). 
8.3  Preparation of drug standard curves 
 Drug standard curves were prepared by using drug solutions of different 
concentrations but fixed volumes. The standard curve was constructed by 
plotting the log of the drug concentration used versus the diameter of the zone 
of growth inhibition. 
 Overnight planktonic cultures of C. albicans GDH2346 (used here as an 
indicator organism) were harvested by centrifugation at 3000 rpm for 5 min, 
washed twice in sterile PBS, and then adjusted to an optical density of 1.0 at 
520 nm in PBS. Plates of YNB agar containing 200 mM glucose were seeded with 
150 µl of this standardized suspension. Concentration discs were moistened 
with a fixed volume (30 µl) of drug solution before being transferred to the pre-
seeded plates. Plates were then incubated for 24 h at 37ºC. The zones of 
growth inhibition were measured (in mm) at four points around each disc and  
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Figure 15. The experimental system used to determine the penetration of 
antifungal agents through biofilms. 
 
The biofilm (B) is initially formed on a 25 mm-diameter membrane filter (A) 
resting on glucose YNB agar (not shown). A second, smaller filter (C) is placed 
on top of the biofilm, and a moistened concentration disc (D) is positioned on 
top of the second filter. After 48 h of biofilm formation, the entire assembly is 
transferred to antifungal-containing agar (E). All plates are incubated at 37ºC 
for time periods ranging from 60 to 360 min. 
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the mean value calculated. These values were plotted against the drug 
concentration used, to produce a standard curve. 
8.3.1 Caspofungin 
 A standard curve of caspofungin concentration against zone of growth 
inhibition (distance from edge of disc, mm) was prepared as described in 
section 8.3 with the following drug concentrations: 4, 8, 10, 20, 25, and 30 
µg/ml (Table 2 and Fig. 16). 
8.3.2 Amphotericin B 
 A standard curve of amphotericin B concentration against zone of growth 
inhibition (distance from edge of disc, mm) was prepared as described in 
section 8.3 with the following drug concentrations: 16, 20, 30, 40, 50, and 60 
µg/ml (Table 3 and Fig. 17). 
8.4  Drug susceptibility of biofilms on membrane filters 
 After biofilm formation on 25-mm-diameter membrane filters, biofilms 
were capped with sterile 13-mm-diameter filters, transferred to antifungal 
agent-containing agar, and incubated for 6 h at 37°C (the maximum exposure 
period in drug penetration assays) or 24 h. A drug concentration of 60 times the 
MIC for Candida albicans GDH2346 was used in the antifungal agent-
supplemented agar. The concentrations used were as follows: caspofungin, 24 
µg/ml and amphotericin B, 78 µg/ml. After incubation for the specified 
exposure time, biofilm cells were gently scraped from the membranes with a 
sterile scalpel and resuspended in 10 ml of PBS. Viable cell counts were carried 
out as described in Section 5.5. 
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Table 2. Zone of growth inhibition due to caspofungin on plates seeded with 
C. albicans GDH2346 a 
 
 
  
Zone of growth inhibition (distance from edge of disc, mm) 
produced by caspofungin at a concentration (µg/ml) of 
Disc b 2 4 8 10 20 25 30 c 
1 0.0 0.88 2.00 2.60 3.13 3.94 4.21 
2 0.0 1.00 2.03 2.44 3.86 3.70 4.00 
3 0.0 1.20 1.79 2.23 3.00 3.23 3.64 
4 0.0 0.95 2.30 2.37 3.62 3.15 3.89 
Total 0.0 4.03 8.12 9.64 13.61 14.02 15.74 
Mean d 0.0 1.01 2.03 2.41 3.40 3.51 3.94 
 
a Growth medium (YNB supplemented with 200 mM glucose) was seeded with 
150µl of a standard suspension of C. albicans. 
b  Blank paper concentration disc (4 for each drug concentration) were 
moistened with a fixed volume (30 µl) of drug solution. 
c  Different concentrations (µg/ml) of caspofungin were used to draw the 
standard curve. 
d  Data are means from two independent experiments done in duplicate. 
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Figure 16. Standard curve for caspofungin in drug penetration assay 
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Table 3. Zone of growth inhibition due to amphotericin B on plates seeded 
with C. albicans GDH2346 a 
 
 
  
Zone of growth inhibition (distance from edge of disc, mm) 
produced by amphotericin B at a concentration (µg/ml) of 
Disc b 10 16 20 30 40 50 60 c 
1 0.0 1.03 1.56 4.00 4.35 4.70 4.78 
2 0.0 1.25 1.95 3.64 4.33 4.10 5.00 
3 0.0 0.81 1.63 3.47 4.15 4.34 5.11 
4 0.0 0.97 1.52 3.89 3.68 4.14 4.40 
Total 0.0 4.06 6.66 15.00 16.51 17.28 19.29 
Mean d 0.0 1.02 1.67 3.75 4.13 4.32 4.82 
 
a Growth medium (YNB supplemented with 200 mM glucose) was seeded with 
150µl of a standard suspension of C. albicans. 
b  Blank paper concentration disc (4 for each drug concentration) were 
moistened with a fixed volume (30 µl) of drug solution. 
c  Different concentrations (µg/ml) of amphotericin B were used to draw the 
standard curve. 
d  Data are means from two independent experiments done in duplicate. 
  Materials & methods 
 
  
 
69 
 
    
 
 
 
Figure 17. Standard curve for amphotericin B in drug penetration assay  
 
 
0
1
2
3
4
5
6
10 100
Amphotericin B (µg/ml)
Zo
n
e 
o
f g
ro
w
th
 
in
hi
bi
tio
n
 
(m
m
)
  Materials & methods 
 
  
 
70 
9 Scanning electron microscopy of biofilms 
9.1  Standard SEM air-drying procedure 
 Biofilms formed on polycarbonate membranes were fixed with 2.5% (v/v) 
glutaraldehyde in PBS (pH 7.2) for 1 h at room temperature. The biofilms were 
then treated with 1% (w/v) osmium tetroxide (Sigma) for 1 h, washed three 
times in 3 ml of distilled water for 10 min, treated with 1% (w/v) uranyl 
acetate for 1 h, and finally washed twice in 3 ml of distilled water . Biofilms 
were dehydrated in a series of ethanol solutions (30%, 50%, 70%, 90% absolute 
ethanol, and dried absolute ethanol) for 10 minutes each. All samples were air 
dried in a desiccator overnight then mounted on aluminium stubs before being 
gold coated with a polaron coater, and viewed under a Philips 500 scanning 
electron microscope. 
9.2  Cationic dye procedure  
 To improve the preservation and visualization of matrix material in 
biofilms, a procedure involving cationic dyes (Erlandsen et al., 2004b) was 
used. Biofilms formed on polycarbonate membrane filters were fixed overnight 
at room temperature in a mixture of 2% paraformaldehyde and 2% 
glutaraldehyde in 0.15 M sodium cacodylate buffer, pH 7.4, and containing 
0.15% alcian blue or 0.15% ruthenium red (cationic dyes). After primary fixation 
in the aldehyde mixture with cationic dye additives, the samples were rinsed in 
0.15 M cacodylate buffer twice (5 min each) and immersed in 1% (w/v) osmium 
tetroxide in 0.15 M cacodylate buffer containing 1.5% (w/v) potassium 
ferrocyanide for 90–120 min. They were then washed five times with distilled 
water. Dehydration of the samples was achieved by immersion in an ascending 
ethanol series ranging, in 20% increments (30%, 50%, 70%, and 90% absolute 
ethanol) , followed by dried absolute ethanol, for 10 minutes each. The last 
step of dehydration was using 100% hexamethyldisilizane (Sigma) twice for 5 
min each time. All samples were air dried in a desiccator overnight then 
mounted on aluminium stubs before being gold coated with a polaron coater, 
and viewed under a Philips 500 scanning electron microscope. 
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10  Persister cells in Candida species 
10.1  Persister cells in planktonic cultures 
 All organisms were grown at 37°C with shaking in YNB medium 
containing 50 mM glucose (50 ml in 250-ml flasks). Exponential-phase cultures 
were incubated for 8 h (C. krusei, C. albicans, and C. tropicalis), 11 h (C. 
parapsilosis), or 18 h (C. glabrata). Stationary-phase cultures of all species 
were incubated for 48 h. Cells from samples (100 µl) of exponential- or 
stationary-phase cultures were harvested and washed twice in PBS. Washed 
cells were treated in microtitre plates with different concentrations of 
amphotericin B (5 to 100 µg/ml) in YNB glucose medium buffered to pH 7 with 
0.165 M MOPS. Control cells were treated similarly with buffered medium 
without amphotericin B. All cell suspensions were adjusted to a concentration 
(approximately 107 cells/ml) equivalent to that of resuspended biofilms. After 
incubation at 37°C for 24 h, the cells were washed twice and resuspended in 
PBS (100 µl). Viable counts were then carried out by serial dilution and plating 
on YNB agar containing 200 mM glucose (Section 5.5). Assays were carried out 
in duplicate and done at least twice on different days. 
10.2  Persister cells in biofilms 
 Organisms were grown in YNB medium containing 50 mM glucose and 
washed cell suspensions were adjusted to an optical density of 0.8 at 520 nm 
(Section 5.2). Biofilms were formed on PVC discs as described previously 
(Section 5.3). The biofilms were then treated with amphotericin B at 
concentrations ranging from 5 to 100 µg/ml. Mature (48-h) biofilms were 
transferred to fresh wells, submerged in YNB glucose medium (1 ml) containing 
different concentrations of amphotericin B and buffered to pH 7 with 0.165 M 
MOPS, and incubated at 37°C for 24 h. Control biofilms were incubated in 
buffered medium in the absence of amphotericin B. After incubation, biofilm 
cells were harvested from the discs by scraping and vigorous vortexing, washed 
twice in 0.15 M PBS, pH 7.2, and resuspended in more PBS (100 µl). Viable 
counts were then determined by the standard procedure of serial dilution 
followed by plating on YNB agar containing 200 mM glucose (Section 5.5). 
Assays were carried out in duplicate and done at least twice on different days. 
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10.3  Live-dead staining with fluorescein 
 Biofilms were grown on PVC catheter discs in YNB containing 50 mM 
glucose for 48 h at 37°C. Biofilm discs were then transferred into 1 ml of 
buffered YNB glucose (50 mM) medium plus 100 µg/ml fluorescein diacetate 
alone (control) or with amphotericin B (100 µg/ml) and fluorescein diacetate 
(100 µg/ml) and incubated  for 24 h at 37°C. The biofilm cells were then 
scraped from the discs, vigorously vortexed, and washed three times in PBS. 
Cell pellets were resuspended in 300 µl PBS and viewed under a x100 oil 
immersion lens using a fluorescence microscope (Zeiss Axioimager M1; Fig. 18). 
Fluorescein diacetate stains dead yeast cells with a green fluorescence while 
live cells remain unstained (LaFleur et al., 2006). 
 
11  Apoptosis in Candida biofilms 
11.1  SR-FLICA apoptosis detection assay 
 An SR-FLICA kit was used to detect active caspase enzymes within 
biofilm cells. The SR-FLICA reagent was reconstituted in 50 µl DMSO, as 
recommended by the manufacturers, to form a stock concentrate. The 
concentrate was further diluted with 200 µl PBS to produce the working 
solution. Mature (48-h) biofilms of C. albicans strains GDH2346 and SC5314, C. 
parapsilosis, and C. krusei were submerged in buffered YNB glucose medium 
containing amphotericin B (50µg/ml) and incubated for 5 h or 24 h at 37ºC. The 
biofilms were washed gently in PBS and the cells were resuspended to a 
concentration of approximately 107/ml. SR-FLICA working solution (10 µl) was 
then added to 200 µl of biofilm cell suspension and the mixtures were 
incubated for 1 h at 37ºC in the dark. The cells were washed twice by spinning 
in a microfuge for 5 min using a wash buffer provided in the kit. Cell pellets 
were resuspended in 300 µl wash buffer and examined under a x100 oil 
immersion lens using a fluorescence microscope (Zeiss Axioimager M1) with a 
bandpass filter (excitation 550 nm, emission >580 nm). Apoptotic cells with 
active caspase enzymes fluoresced red. 
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Figure 18. Fluorescence microscope (Zeiss Axioimager M1) used to examine 
biofilm cells stained with fluorescein diacetate, or with FLICA or D2R 
reagents 
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In addition, further investigations were carried out on the effect of pre-
treating biofilm cells with unlabelled general caspase inhibitor Z-VAD-FMK 
before the addition of the FLICA reagent. Mature (48-h) biofilms were treated 
with amphotericin B (50 µg/ml) for 24 h at 37ºC and then exposed to the 
unlabelled general caspase inhibitor Z-VAD-FMK (2.5 µM), 1 h prior the addition 
of the FLICA reagent.  In another experiment the unlabelled general caspase 
inhibitor Z-VAD-FMK was added to biofilms along with the inducer of apoptosis 
(i.e. amphotericin B). The biofilms were incubated for 24 h at 37ºC and then 
analysed by the FLICA assay. 
11.2   D2R apoptosis detection assay 
 A CaspSCREENTM kit was also used to detect caspase activity. Mature (48-
h) biofilms were submerged in buffered YNB glucose medium containing 
amphotericin B (50 µg/ml) and incubated for 24 h at 37ºC. Biofilm cells were 
washed gently in PBS and centrifuged to give a pellet (105 cells) which was 
resuspended in D2R incubation buffer (0.3 ml). Dithiothreitol (1 M; 3 µl) and D2R 
reagent (1µl) were then added and the mixture was incubated for 45 min at 
37ºC in the dark. Resuspended cells were observed under a x100 oil immersion 
lens using a fluorescence microscope (Zeiss Axioimager M1) with a bandpass 
filter (excitation 488 nm, emission 530 nm). Apoptotic cells with active caspase 
enzymes fluoresced green. 
 Further investigations were carried out on the effect of pre-treating 
biofilm cells with unlabelled general caspase inhibitor Z-VAD-FMK before the 
addition of the D2R reagent. Mature (48-h) biofilms were treated with 
amphotericin B (50 µg/ml) for 24 h at 37ºC and then exposed to the unlabelled 
general caspase inhibitor Z-VAD-FMK (2.5 µM), 1 h prior the addition of D2R 
reagent.  In another experiment the unlabelled general caspase inhibitor Z-
VAD-FMK was added to biofilms along with the inducer of apoptosis (i.e. 
amphotericin B). The biofilms were incubated for 24 h at 37ºC and then 
processed with the D2R reagent. 
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11.3   Effect of caspase inhibitors 
11.3.1  Effect on biofilm growth 
 To investigate the effect of Z-VAD-FMK on biofilm growth and viability, 
48-h biofilms of C. albicans strains GDH2346 and SC5314, C. parapsilosis, and C. 
krusei were washed gently with PBS and submerged in YNB glucose medium 
(1ml) buffered with MOPS and containing different concentrations (2.5, 5, 10, 
and 20 µM) of Z-VAD-FMK. Control biofilms were transferred to buffered 
medium without Z-VAD-FMK. Biofilms were incubated for 24 h at 37ºC and then 
cells were harvested and their numbers determined by viable counts (Section 
5.5). 
 Identical procedures were used to determine the effect on biofilm 
growth of specific inhibitors of caspases-1, -2, -3, -5, -6, -8, and -9 (Caspase 
Inhibitor Set III), at a concentration of 2.5 µM. 
11.3.2   Effect on antifungal activity 
 Mature (48-h) Candida biofilms were submerged in buffered YNB glucose 
medium containing Z-VAD-FMK (2.5, 5, 10, or 20 µM) and amphotericin B (50 
µg/ml). The final concentration of DMSO in assay mixtures ranged from 0.12 % 
to 0.26 %. Control biofilms were transferred into buffered medium containing 
amphotericin B only. Biofilms were incubated for 24 h at 37ºC and cell survival 
was determined by viable cell counts (Section 5.5). 
 Specific inhibitors of caspases-1, -2, -3, -5, -6, -8, and -9 (Caspase 
Inhibitor Set III), at a concentration of 2.5 µM, were also tested for their 
effects on the activity of amphotericin B (50 µg/ml) against Candida biofilms. 
The final DMSO concentration in the buffered medium was 0.25 %.  
 The effect of pepstatin A, an inhibitor of acid proteases (aspartyl 
peptidases) which are known to be produced by Candida species, was also 
tested. Mature (48-h) biofilms of C. albicans strains GDH2346 and SC5314 were 
submerged in buffered YNB glucose medium containing amphotericin B (50 
µg/ml) and pepstatin A (2.5 µM). Biofilms were then incubated at 37ºC for 24 h 
and cell survival was determined by viable cell counts (Section 5.5). Control 
biofilm discs without pepstatin A were also included. 
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11.4  Effect of histone deacetylase (HDA) inhibitors 
 A variety of histone deacetylase inhibitors (sodium butyrate, sodium 
valproate, apicidin, and trichostatin A) were tested against different Candida 
isolates (C. albicans strains GDH2346 and SC5314, C. parapsilosis, and C. 
krusei). The effect of HDA inhibitors on biofilm growth and viability was 
investigated at two stages: at time zero of biofilm formation, and after 48 h of 
biofilm formation. The effect of HDA inhibitors was determined by the XTT 
reduction assay (Section 3.2) and/or viable cell counts (Section 5.5). XTT assays 
were carried out in triplicate and done twice on different days. Viable cell 
counts were performed twice, in duplicate. 
11.4.1  Effect on biofilm growth 
11.4.1.1 Addition at time zero of biofilm formation 
 A standardized cell suspension (80 µl) was applied to each PVC disc, 
incubated for 1 h at 37ºC, and washed gently with PBS to remove non-adherent 
cells. Each disc was then submerged in 1ml YNB glucose medium buffered with 
MOPS and containing different concentrations of HDA inhibitors (2, 8 or 32 
µg/ml; 2, 8, or 32 mM for sodium butyrate). Discs were incubated for 48 h at 
37ºC for biofilm formation. The final concentration of DMSO in all cases was 
less than 0.5 %. Control biofilms were transferred to buffered medium without 
HDA inhibitor. 
11.4.1.2  Addition to mature biofilms 
 Mature (48-h) biofilms of Candida isolates were washed gently with PBS 
and submerged in YNB glucose medium (1 ml) containing different 
concentrations of HDA inhibitors (2, 8 or 32 µg/ml; 2, 8, or 32 mM for sodium 
butyrate). Biofilms were incubated for a further 24 h at 37ºC. Control biofilms 
were transferred to buffered medium without HDA inhibitor. 
11.4.2  Effect on antifungal activity 
 The effects of HDA inhibitors on the activity of amphotericin B and 
fluconazole against Candida species were assessed under two sets of 
conditions. First, mature (48-h) biofilms grown in the presence of different 
concentrations of HDA inhibitors (2, 8 or 32 µg/ml; 2, 8, or 32 mM for sodium 
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butyrate) were washed gently with PBS and submerged in 1 ml buffered YNB 
glucose medium containing different concentrations of antifungal agents (10 or 
50 µg/ml). Discs were then incubated for further 24 h at 37ºC. Secondly, 
mature (48-h) biofilms grown in HDA inhibitor-free medium were washed gently 
with PBS and submerged in 1 ml buffered YNB glucose medium containing 
different concentrations of antifungal agents (10 or 50 µg/ml) and HDA 
inhibitors (2, 8 or 32 µg/ml; 2, 8, or 32 mM for sodium butyrate). The final 
concentration of DMSO in the medium was less than 0.5 %. Discs were then 
incubated for further 24 h at 37ºC. Control biofilms were incubated in medium 
without HDA inhibitor, or without both HDA inhibitor and amphotericin B. 
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1 Activity of amphotericin B and caspofungin on 
planktonic cells of Candida species 
1.1 Minimum inhibitory concentration of both drugs for various 
Candida species 
 Antifungal susceptibility testing was performed by the broth microdilution 
method according to the Clinical and Laboratory Standards Institute (CLSI; 
formerly NCCLS) recommendations (National Committee for Clinical Laboratory 
Standards, 1995). The MIC endpoint was defined as the lowest concentration of 
the drug that produced optically clear wells (100% inhibition). Amphotericin B 
and caspofungin drug concentrations initially ranged from 0.06 to 8 µg/ml, plus 
16 µg/ml for caspofungin (Tables 4 and 6). The concentration range for each 
drug was then expanded to reach an exact endpoint (Tables 5 and 7).  The 
planktonic MICs of five Candida isolates are summarised in Table 8. The majority 
of the isolates were relatively resistant to amphotericin B; normally endpoints 
for Candida species are tightly clustered between 0.25 and 1.0 µg/ml (National 
Committee for Clinical Laboratory Standards, 1995). The MICs ranged between 
0.8 and 2.3 µg/ml, with C. albicans SC5314 being the isolate most susceptible to 
amphotericin B, at an MIC of 0.8 µg/ml. However, all five isolates showed 
greater susceptibility to caspofungin; the MICs for this antifungal agent ranged 
from 0.3 to 0.8 µg/ml (Table 8). 
1.2 Paradoxical effect of caspofungin 
 The paradoxical effect consists of reduced activity of the drug at high 
concentrations, above the minimum inhibitory concentration. This phenomenon 
has been reported recently for caspofungin by several different research groups 
(Arikan et al., 2005; Ostrosky-Zeichner et al., 2003; Ramage et al., 2002c; 
Stevens et al., 2004; Stevens et al., 2005). In this study, five Candida isolates 
were screened at caspofungin concentrations up to 16 µg/ml by the broth 
microdilution method. Three isolates only demonstrated the paradoxical effect 
at different concentrations of the drug; these were C. albicans (both strains) and 
C. tropicalis.  The MICs for all three isolates were < 0.45 µg/ml. However, 
reduced activity of caspofungin was observed at high drug concentrations: at 4  
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Table 4. MIC determinations for amphotericin B against planktonic cells of 
different Candida species: drug concentrations of 0.06 to 8 µg/ml 
 
 
 
 
Growth at amphotericin B concentration (µg/ml) of:* Isolate 
0 0.062 0.125 0.25 0.5 1 2 4 8 
C. albicans 
GDH2346 4+ 4+ 4+ 3+ 2+ 2+ 0 0 0 
C. albicans 
SC5314 4+ 4+ 4+ 3+ 2+ 0 0 0 0 
C. tropicalis 
AAHB73 4+ 4+ 4+ 4+ 3+ 2+ 1+ 0 0 
C. glabrata 
AAHB12 4+ 4+ 4+ 4+ 3+ 1+ 0 0 0 
C. parapsilosis 
AAHB4479 4+ 4+ 4+ 4+ 4+ 3+ 1+ 0 0 
  
                  
 
* 4+ = no reduction in turbidity relative to control; 3+ = slight reduction in 
turbidity; 2+ = prominent decrease in turbidity; 1+ = slightly hazy; and 0 = 
optically clear well. ND= not done. Assays were performed two or three times in 
duplicate. 
 
  
Table 5. MIC determinations for amphotericin B against planktonic cells of different Candida species: drug concentration 
range expanded from 0.5 to 2.6 µg/ml 
 
 
Growth at amphotericin B concentration (µg/ml) of:* 
Isolate 
0 0.5 0.6 0.7 0.8 0.9 1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 1.9 2 2.1 2.2 2.3 2.4 2.6 
C. albicans 
GDH2346 4+ 2+ ND ND ND ND 2+ 2+ 0 0 0 0 0 0 0 0 0 0 0 0 0 
C. albicans 
SC5314 4+ 2+ 1+ 1+ 0 0 0 0 ND 0 ND 0 ND ND ND 0 0 0 0 0 0 
C. tropicalis 
AAHB73 4+ 3+ ND ND ND ND 2+ 2+ 2+ 2+ 2+ 2+ 2+ 2+ 2+ 1+ 1+ 1+ 0 0 0 
C. glabrata 
AAHB12 4+ 3+ 2+ 2+ 2+ 2+ 1+ 0 ND 0 ND 0 ND ND ND 0 0 0 0 0 0 
C. parapsilosis 
AAHB4479 4+ 4+ 4+ 4+ 4+ 4+ 3+ 2+ ND 1+ ND 1+ ND ND ND 1+ ND 0 0 0 0 
                                            
 
 * 4+ = no reduction in turbidity relative to control; 3+ = slight reduction in turbidity; 2+ = prominent decrease in turbidity;         
 1+ = slightly hazy; and 0 = optically clear well. ND= not done. Assays were performed two or three times in duplicate. 
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Table 6. MIC determinations for caspofungin against planktonic cells of 
different Candida species: drug concentrations of 0.06 to 16 µg/ml 
 
 
 
 
 
Growth at caspofungin concentration (µg/ml) of:* Isolate 
0 0.062 0.125 0.25 0.5 1 2 4 8 16 
C. albicans 
GDH2346 4+ 4+ 2+ 1+ 0 0 0 1+ 2+ 2+ 
C. albicans 
SC5314 4+ 4+ 3+ 1+ 0 0 0 0 1+ 1+ 
C. tropicalis 
AAHB73 4+ 4+ 3+ 1+ 0 0 0 2+ 2+ 2+ 
C. glabrata 
AAHB12 4+ 4+ 3+ 3+ 2+ 0 0 0 0 0 
C. parapsilosis 
AAHB4479 4+ 4+ 3+ 3+ 3+ 0 0 0 0 0 
  
                    
 
 
* 4+ = no reduction in turbidity relative to control; 3+ = slight reduction in 
turbidity; 2+ = prominent decrease in turbidity; 1+ = slightly hazy; and 0 = 
optically clear well. ND= not done. Assays were performed two or three times in 
duplicate. 
  
Table 7. MIC determinations for caspofungin against planktonic cells of different Candida species: drug concentration range 
expanded from 0.5 to 2.6 µg/ml 
 
Growth at caspofungin concentration (µg/ml) of:* 
 
Isolate 
0 0.25 0.3 0.35 0.4 0.45 0.5 0.55 0.6 0.65 0.7 0.8 0.9 1 2 3 3.5 4 5 6 7 8 
C. albicans 
GDH2346 4+ 1+ 1+ 1+ 0 0 0 0 0 0 0 0 0 0 0 0 0 1+ 2+ 2+ 2+ 2+ 
C. albicans 
SC5314 4+ 1+ 0 ND 0 0 0 ND 0 ND 0 0 0 0 ND ND ND 0 ND ND ND 1+ 
C. tropicalis 
AAHB73 4+ 1+ 1+ 1+ 1+ 0 0 0 0 0 0 0 0 0 0 1+ 2+ 2+ 2+ 2+ 2+ 2+ 
C. glabrata 
AAHB12 4+ 3+ 3+ ND 3+ 3+ 2+ ND 1+ ND 0 0 0 0 ND ND ND 0 ND ND ND 0 
C. parapsilosis 
AAHB4479 4+ 3+ 3+ ND 3+ 3+ 3+ ND 3+ ND 2+ 0 0 0 ND ND ND 0 ND ND ND 0 
 
                      
* 4+ = no reduction in turbidity relative to control; 3+ = slight reduction in turbidity; 2+ = prominent decrease in turbidity; 1+ = 
slightly hazy; and 0 = optically clear well. ND= not done. Assays were performed two or three times in duplicate. 
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Table 8. Summary of the MICs of amphotericin B and caspofungin for 
planktonic cells of different Candida isolates 
 
 
MIC (µg/ml)  Isolate 
 
Amphotericin B Caspofungin 
C. albicans GDH2346 1.3 0.4 
C. albicans SC5314 0.8 0.3 
C. tropicalis AAHB73 2.3   0.45 
C. glabrata AAHB12 1.2 0.7 
C. parapsilosis AAHB4479 2.2 0.8 
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to 16 µg/ml, 8 to 16 µg/ml and 3 to 16 µg/ml for C. albicans GDH2346, C. 
albicans SC5314 and C. tropicalis, respectively (Tables 6 and 7). 
 
2 Fungicidal activity of amphotericin B against 
planktonic cells of C. albicans GDH2346 
 The in vitro fungicidal activity of amphotericin B was measured for 
planktonic cells of C. albicans GDH2346 by two methods (Barchiesi et al., 2004; 
Barchiesi et al., 2005; Di Bonaventura et al., 2004): assays for the minimum 
fungicidal concentration and time-kill curves. 
2.1 Minimum fungicidal concentration 
 After the minimum inhibitory concentration of amphotericin B for C. 
albicans GDH2346 was determined, 100 µl samples from each well at or above 
the MIC were plated on to SDA agar plates and incubated for 48 h at 37ºC. The 
minimum fungicidal concentration (MFC) was defined as the lowest drug 
concentration that caused total killing of cells. The minimum inhibitory 
concentration of amphotericin B for C. albicans GDH2346 was 1.3 µg/ml; the 
MFC occurred at the MIC end point.  
2.2  Time-kill curves 
 To investigate the fungicidal activity of amphotericin B against C. albicans 
GDH2346, three to five colonies were picked from a 48-h plate culture, 
suspended in sterile distilled water, and the optical density was adjusted to 0.5 
at 530 nm. An aliquot (1ml) of the adjusted suspension was added to 9 ml of 
growth medium plus the appropriate amount of drug. Amphotericin B was used 
at concentrations of one-half, one, two, and four times the MIC. The suspensions 
were placed on a shaker and incubated at 37ºC. At time points 0, 2, 6, and 24 h, 
100 µl of the suspension was removed, diluted in growth medium, and plated on 
to SDA plates. The number of CFU on each plate was determined after 48 h of 
incubation. Amphotericin B at 0.5 times the MIC exhibited some fungicidal 
activity (55% killing after 24 h), whereas complete fungicidal activity against C. 
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albicans was observed at a drug concentration equal to the MIC. Amphotericin B 
at 4 times the MIC was fungicidal after 2 h of incubation while drug 
concentrations equal to, or double the MIC were fungicidal after 6 h (Fig. 19). 
 
3 In vitro activity of amphotericin B and caspofungin at 
different developmental phases of Candida biofilms 
 Previous studies of C. albicans biofilm formation (Chandra et al., 2001a; 
Hawser & Douglas, 1994) showed that it occurs in several distinct developmental 
phases, resulting in a highly heterogeneous architecture of well-defined cellular 
communities enclosed in a thick polysaccharide matrix. These phases are: (i) 
early phase (0 to 11 h) involving the initial attachment of yeast cells to the disc 
material, (ii) intermediate phase (12 to 30 h) involving aggregation of the yeast 
cells and the formation of hyphae, and (iii) maturation phase (31 to 72 h) 
involving the production of the extracellular matrix. 
 In this investigation, the effects of three factors on drug resistance were 
examined: i) the Candida species; ii) the developmental stage of the biofilm; 
and iii) the drug concentration. Candida biofilms were grown on polyvinyl 
catheter discs. Different concentrations of amphotericin B and caspofungin (two 
times and five times the MIC for each isolate) were introduced at different 
stages of biofilm development (after 8, 17, 24, and 35 h). The efficacy of both 
drugs was measured after 48 h using the tetrazolium XTT reduction assay.  
3.1 8-h Candida biofilms 
 For most Candida isolates, biofilms in the early stage of development (i.e. 
8-h biofilms) were relatively resistant to amphotericin B at a concentration of 
two times the MIC, whereas at five times the MIC, metabolic activity was 
reduced significantly (P< 0.01; Fig. 20). However, amphotericin B at both 
concentrations was highly effective against C. albicans SC5314, with a 99% 
reduction in metabolic activity. On the other hand, caspofungin at two times the  
  
                                                                                                                                      Results 
 
 
 
87 
 
 
 
 
 
 
 
Figure 19. Time-kill study conducted against C. albicans GDH2346 planktonic 
cells 
 
Amphotericin B was used at concentrations equal to 0.5, 1, 2, and 4 times the 
MIC. Control (♦); 0.5X MIC (ο); 1X MIC (▲); 2X MIC (■); 4X MIC (×). Results are 
from one experiment, carried out in duplicate. 
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Figure 20. Effect of amphotericin B (      ) and caspofungin (       ) at 2x (A) or 
5x (B) the MIC on 8-h Candida biofilms. Data represent the mean + standard 
error for one experiment carried out with three replicates. 
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MIC showed higher activity than amphotericin B, except with C. parapsilosis 
biofilms where there was little effect. However, at the higher concentration, 
caspofungin was less effective against C. albicans SC5314 and C. tropicalis than 
amphotericin B. Also, the higher concentration of caspofungin was less effective 
at reducing the metabolic activity of C. albicans SC5314 and C. tropicalis 
biofilms than the lower drug concentration. 
3.2 17-h Candida biofilms 
 With the exception of C. albicans SC5314, biofilms grown for 17 h were 
more susceptible to amphotericin B at twice the MIC than biofilms grown for 8 h 
(Fig. 21). However, at this stage of biofilm development, biofilms were more 
resistant to the higher drug concentration. Caspofungin, at both concentrations, 
exhibited a greater effect than amphotericin B. Biofilms were more resistant to 
caspofungin at a concentration of twice the MIC than the biofilms grown for 8 h, 
with the exception of C. parapsilosis biofilms which were more sensitive. The 
greatest reduction in metabolic activity was observed with the higher drug 
concentration, with the exception of C. tropicalis biofilms. 
3.3 24-h Candida biofilms 
 Increased resistance to both antifungal drugs was observed in 24-h old 
biofilms of some Candida species (Fig. 22). At this stage of biofilm development, 
amphotericin B at the lower concentration had little effect on the metabolic 
activity of both C. albicans strains but showed greater activity against biofilms 
of C. parapsilosis, compared with earlier stages of development. Biofilms of 
both C. albicans strains also showed increased resistance to the higher drug 
concentration than at the earlier stages. Caspofungin was more effective at 
inhibiting biofilm growth than amphotericin B, except with C. parapsilosis 
biofilms. Caspofungin was more effective at the higher concentration than at the 
lower concentration, except with C. tropicalis biofilms. Its greatest effect was 
against C. glabrata biofilms. 
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Figure 21. Effect of amphotericin B (    ) and caspofungin (    ) at 2x (A) 
or 5x (B) the MIC on 17-h Candida biofilms.  Data represent the mean + 
standard error for one experiment carried out with three replicates. 
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Figure 22. Effect of amphotericin B (    ) and caspofungin (    ) at 2x (A) 
or 5x (B) the MIC on 24-h Candida biofilms.  Data represent the mean + 
standard error for one experiment carried out with three replicates. 
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3.4 35-h Candida biofilms 
 Mature (35-h) biofilms showed a susceptibility pattern similar to that of 
the 24-h biofilms. Both antifungal drugs were least effective against C. albicans 
SC5314. Caspofungin at the lower concentration was more effective than 
amphotericin B against biofilms of C. albicans, C. tropicalis, and C. glabrata, but 
not C. parapsilosis. However, caspofungin at the higher concentration showed 
more activity than amphotericin B against C. albicans GDH2346, C. tropicalis, 
and C. glabrata, but not against C. albicans SC5314 and C. parapsilosis. At this 
phase of development, all species showed increased resistance to caspofungin, 
at five times the MIC, as compared with 17-h and 24-h biofilms. Moreover, some 
Candida biofilms were more resistant to caspofungin at a concentration of five 
times the MIC than to the lower concentration; this was observed with biofilms 
of C. albicans SC5314 and C. tropicalis (Fig. 23). 
3.5 Overall conclusions 
 In summary, amphotericin B at two times the MIC had the least effect on 
Candida biofilms. However, when the drug concentration was increased to five 
times the MIC, the effect of amphotericin B increased. Amphotericin B at the 
higher concentration showed relatively high activity against C. parapsilosis and 
C. glabrata biofilms, especially at the late development phase (Fig. 23B). 
Biofilms of both strains of C. albicans were more resistant to amphotericin B 
throughout development (except for the earliest stage) than the other Candida 
species. 
 Caspofungin, at two times the MIC, generally exhibited a greater effect on 
Candida biofilms than amphotericin B although this was not observed with C. 
parapsilosis biofilms in some development phases (i.e. 24-h and 35-h biofilms). 
Caspofungin, at five times the MIC, was slightly less efficacious than at the lower 
concentration against C. tropicalis in all development phases tested (Figs. 20-23) 
and against C. albicans SC5314 in some phases (Figs. 20 and 23). In no case were 
biofilm cells of any Candida species completely killed by either amphotericin B 
or caspofungin, both of which are fungicidal agents, at either concentration 
used. The species most susceptible to caspofungin (at both concentrations) 
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Figure 23. Effect of amphotericin B (    ) and caspofungin (    ) at 2x (A) 
or 5x (B) the MIC on 35-h Candida biofilms.  Data represent the mean + 
standard error for one experiment carried out with three replicates. 
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throughout biofilm development was C. glabrata (Figs. 20-23); C. albicans 
GDH2346 was susceptible in the early phase (Fig. 20). 
 
4 Penetration of antifungal agent (caspofungin) through 
Candida biofilms 
 This penetration assay was a modification of the filter disc method 
described previously for bacterial biofilms. Biofilms were grown on 
polycarbonate membrane filters resting on YNB agar plates containing 50mM 
glucose for 48 h. A second smaller filter was placed on top of the 48 h biofilm 
and finally a moistened concentration disc was positioned on top of the second 
filter. The whole assembly was then transferred to antifungal containing agar. 
Plates were incubated at 37°C for specific time periods (60, 90, 120, 180, 240, 
or 360 min). Drug concentrations were selected based on their ability to produce 
large zones of growth inhibition in control assays for drug penetration; 
caspofungin was tested at a concentration of 60 times the MIC for C. albicans 
GDH2346 (i.e. 24 µg/ml). The amount of antifungal agent that diffused out of 
the agar and through the biofilm ‘sandwich’ to the concentration disc was 
determined by using the disc in a standard drug diffusion assay. The diameters 
of zones of growth inhibition were measured and used to determine the 
concentration of active antifungal agent in the discs by reference to a standard 
curve prepared using drug solutions of different concentrations but fixed 
volumes.  
4.1 Penetration of caspofungin through biofilms of C. albicans 
strains 
 Although caspofungin is a large polypeptide molecule with a molecular 
mass of 1213 Da, it penetrated Candida biofilms well. Different levels of 
penetration were demonstrated with biofilms of different Candida species. 
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4.1.1 Susceptibility of C. albicans to caspofungin 
 The MIC of caspofungin for planktonic C. albicans GDH2346 is 0.4 µg/ml, 
as determined previously (section 1.1). In this assay, biofilms of C. albicans were 
challenged with 60 times the MIC of caspofungin (i.e. 24 µg/ml).  
4.1.2 Caspofungin penetration through biofilms of C. albicans GDH2346 
 Caspofungin penetration through C. albicans GDH2346 biofilms was zero 
after 60 min but increased gradually to 28 % of the control value after 90 min.  
Within 360 min, the drug concentration (C) at the distal edge of the biofilm had 
reached 70.8 % of the control value (C0) (Fig. 24). 
4.1.3 Caspofungin penetration through biofilms of C. albicans SC5314 
 Diffusion of caspofungin through biofilms of C. albicans SC5314 was also 
zero after 60 min but then rose gradually to 38.6 % after 90 min. After 360 min, 
it had reached 57.8 % of that of the control value (Fig. 25). 
4.2 Penetration of caspofungin through biofilms of non-C. 
albicans species 
4.2.1 Caspofungin penetration through C. glabrata AAHB12 biofilms 
 Caspofungin penetration through C. glabrata biofilms was rapid, reaching 
54.8 % of the control value after 60 min.  Within 360 min it had reached 81.2 % 
of the control value (Fig. 26). 
4.2.2 Caspofungin penetration through C. parapsilosis AAHB4479 biofilms 
 The rate of penetration of caspofungin through C. parapsilosis biofilms 
was also fast, reaching 39.4 % of the control value after 60 min.  After 360 min, 
it had reached 73.3 % of the control value (Fig. 27). 
4.2.3 Caspofungin penetration through C. tropicalis AAHB73 biofilms 
 Caspofungin diffusion through biofilms of C. tropicalis was zero after 60 
min but rapidly reached 25.6 % of the control value after 90 min. It then levelled  
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Figure 24. Penetration of caspofungin through biofilms of C. albicans 
GDH2346 with time 
The drug concentration that diffused through the biofilm (C) was divided by the 
drug concentration for the control (C0). Error bars indicate the standard errors of 
the means for two independent experiments carried out in duplicate. 
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Figure 25. Penetration of caspofungin through biofilms of C. albicans SC5314 
with time 
 
The drug concentration that diffused through the biofilm (C) was divided by the 
drug concentration for the control (C0). Error bars indicate the standard errors of 
the means for two independent experiments carried out in duplicate. 
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Figure 26. Penetration of caspofungin through biofilms of C. glabrata with 
time 
The drug concentration that diffused through the biofilm (C) was divided by the 
drug concentration for the control (C0). Error bars indicate the standard errors of 
the means for two independent experiments carried out in duplicate. 
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Figure 27. Penetration of caspofungin through biofilms of C. parapsilosis 
with time 
The drug concentration that diffused through the biofilm (C) was divided by the 
drug concentration for the control (C0). Error bars indicate the standard errors of 
the means for two independent experiments carried out in duplicate. 
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off but increased again to reach 49.9 % of the control value after 360 min (Fig. 
28). 
4.2.4 Caspofungin penetration through C. krusei (Glasgow) biofilms 
 There was zero drug penetration through C. krusei biofilms after 90 min. 
After 120 min, the caspofungin concentration had risen rapidly to 34.6 %. Within 
360 min, it had reached 44.2 % of the control value (Fig. 29).  
4.3 Comparison of caspofungin penetration through biofilms of 
different Candida species  
 Both C. albicans GDH2346 and C. albicans SC5314 biofilms showed zero 
diffusion of caspofungin after 60 min of exposure (Fig. 30). Subsequently, drug 
diffusion was initially faster through biofilms of strain SC5314 but then levelled 
off. After 360 min, drug penetration was greater (70.8% of the control value) 
with biofilms of strain GDH2346.  
 The initial rate of drug penetration after 60 min through biofilms of C. 
glabrata AAHB12 and C. parapsilosis AAHB 4479 was faster than that seen with 
the other species (54.8 % and 39.4 % of the control value, respectively) (Fig. 31). 
The slowest diffusion was through C. krusei biofilms; it was zero after 90 min 
and then increased rapidly to 34.6 % after 120 min. Biofilms of this species 
showed the lowest drug penetration overall (44.2 % after 360 min). Biofilms of C. 
tropicalis were also penetrated poorly, with zero penetration after 60 min and 
then a gradual increase to 49.9 % of the control value after 360 min. The highest 
drug penetration overall was observed with C. glabrata and C. parapsilosis, at 
81.2 % and 73.3 % of the control value after 360 min, respectively (Fig. 31). 
4.4 Effect of antifungal agents on the viability of biofilm cells 
 After incubation of biofilms sandwiched between the two membranes on 
antifungal agent-containing agar, as in the penetration assay, the effects of 
antifungal agents on the viability of biofilm cells were assessed. Biofilms were 
incubated for 6 h (the time period during which drug penetration was 
determined) or 24 h at 37°C and viable counts were then carried out. Antifungal 
agents (amphotericin B or caspofungin) were present at concentrations similar to  
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Figure 28. Penetration of caspofungin through biofilms of C. tropicalis with 
time 
The drug concentration that diffused through the biofilm (C) was divided by the 
drug concentration for the control (C0). Error bars indicate the standard errors of 
the means for two independent experiments carried out in duplicate. 
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Figure 29. Penetration of caspofungin through biofilms of C. krusei with time 
 
The drug concentration that diffused through the biofilm (C) was divided by the 
drug concentration for the control (C0). Error bars indicate the standard errors of 
the means for two independent experiments carried out in duplicate. 
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Figure 30. Penetration of caspofungin through biofilms of C. albicans 
GDH2346 (■) and C. albicans SC5314 (♦) with time 
 
The drug concentration that diffused through the biofilm (C) was divided by the 
drug concentration for the control (C0). Error bars indicate the standard errors of 
the means for two independent experiments carried out in duplicate. 
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Figure 31. Penetration of caspofungin through biofilms of C. glabrata (×), C. 
parapsilosis (■), C. tropicalis (▲), and C. krusei (●) with time 
 
The drug concentration that diffused through the biofilm (C) was divided by the 
drug concentration for the control (C0). Error bars indicate the standard errors of 
the means for two independent experiments carried out in duplicate. 
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those in the drug penetration assay (i.e. 60 times the MIC of C. albicans 
GDH2346). 
4.4.1 Amphotericin B 
 Amphotericin B at 60 times the MIC (78 µg/ml) showed relatively poor 
activity against biofilms of all five Candida species (Table 9). C. glabrata and C. 
parapsilosis biofilms were the most affected, with cell viabilities of 3 % and 43 
%, after 6 h, and 0.1 % and 7 % after 24 h, respectively. The two C. albicans 
strains were the least susceptible, retaining 48 % viability after 24 h. Biofilms of 
C. tropicalis and C. krusei had intermediate viabilities of 38 % and 36 %, 
respectively, following drug treatment for 24 h (Table 9). 
4.4.2 Caspofungin  
 In general, Candida biofilms were less susceptible to caspofungin than to 
amphotericin B when treated at high drug concentrations (Table 9). After 6 h of 
exposure to caspofungin at 24 µg/ml (60 times the MIC), biofilms of all species 
showed a similar effect, with 67 to 76 % viability. Biofilm cells of C. glabrata 
were the most susceptible to caspofungin after 24 h of exposure, with 32 % 
viable cells. However, biofilms of this species were even more susceptible to 
amphotericin B (Table 9). Overall caspofungin treatment, like amphotericin B 
treatment, failed to result in complete killing of biofilm cells.  
 The paradoxical effect of caspofungin (reduced activity at high 
concentrations) was observed in previous work with planktonic cultures of some 
species, i.e. C. albicans (both strains) and C. tropicalis, but not C. parapsilosis 
or C. glabrata (Section 1.2). Therefore, biofilm cells of all six Candida isolates in 
this study were examined further for the paradoxical phenomenon. The biofilms 
were challenged with 5 or 10 times the MIC of caspofungin (2 or 4 µg/ml, 
respectively). The paradoxical effect was demonstrated in biofilms of C. 
glabrata and C. parapsilosis after either 6 h or 24 h (C. parapsilosis only) 
exposure time (Table 10). A caspofungin concentration of 4 µg/ml had a lesser 
effect on C. glabrata than a concentration of 2 µg/ml after 6 h of exposure 
(P<0.001). Similarly, biofilms of C. parapsilosis were more susceptible (P<0.006) 
to a concentration of 2 µg/ml than to one of 4 µg/ml after either 6 h or 24 h  
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Table 9. Viability of biofilm cells of Candida spp. after exposure to 
amphotericin B (78 µg/ml) or caspofungin (24 µg/ml) for 6 or 24 h * 
 
 
  Viability (%) 
Organism Amphotericin B (78 µg/ml)  Caspofungin (24 µg/ml) 
  6 h 24 h   6 h 24 h 
 
C. albicans 
GDH2346 65.6 + 1.8  48.0 + 0.5  71.3 + 3.6 44.9 + 2.7 
C. albicans 
SC5314 54.3 + 1.5 48.2 + 1.3  75.9 + 1.6 42.0 + 2.2 
C. tropicalis 
AAHB73 57.1 + 1.5 38.3 + 2.4  73.8 + 2.7 49.7 + 2.7 
C. glabrata 
AAHB12 2.8 + 0.7 0.1 + 0.1  70.5 + 2.8 32.2 + 1.5 
C. parapsilosis 
AAHB4479 43.1 + 1.7 6.6 + 0.9  75.9 + 3.3 52.6 + 1.5 
C. krusei 
Glasgow 63.7 + 2.8 35.6 + 1.8  66.6 + 2.6 58.5 + 2.1 
            
 
* Viability is expressed as percentage of that of control cells. Data represent the 
means + standard errors for two experiments carried out in duplicate. All results 
were significantly different at P < 0.006 from that of control.  
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Table 10. Viability of biofilm cells of Candida spp. after exposure to 
caspofungin (2 or 4 µg/ml) for 6 or 24 h * 
 
 
  Viability (%) 
Organism Caspofungin (2 µg/ml)   Caspofungin (4 µg/ml) 
  6 h 24 h  6 h 24 h 
 
C. albicans 
GDH2346 84.8 + 3.2 b 44.3 + 1.9 a  79.5 + 3.2 a 43.7 + 1.8 a 
C. albicans 
SC5314 77.4 + 3.0 a 39.7 + 3.7 a  76.7 + 2.0 a 36.8 + 2.0 a 
C. tropicalis 
AAHB73 79.3 + 2.8 a 62.3 + 4.4 a  57.9 + 3.4 a 49.9 + 2.1 a 
C. glabrata 
AAHB12 47.7 + 3.2 a 11.1 + 0.5 a  59.9 + 2.5 a 7.9 + 0.7 a 
C. parapsilosis 
AAHB4479 77.1 + 3.0 a 61.2 + 4.5 a  83.9 + 3.9 a 70.4 + 3.0 a 
C. krusei 
Glasgow 91.6 + 4.5 c 58.4 + 3.7 a  65.4 + 3.8 a 38.0 + 4.0 a 
            
 
* Viability is expressed as a percentage of that of control cells. Data represent 
the means + standard errors for two independent experiments carried out in 
duplicate.  
a Value significantly different at P < 0.006 from that of control 
b Value significantly different at P < 0.012 from that of control 
c Value not significantly different at P > 0.087 from that of control 
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exposure (Table 10). The paradoxical phenomenon complicates the evaluation of 
caspofungin activity against biofilms. Nevertheless, caspofungin clearly showed 
high activity at low concentrations against biofilms of several Candida species. 
4.5 Scanning electron microscopy of Candida biofilms before 
and after penetration by antifungal agents 
 Membrane-supported biofilms were fixed and processed for scanning 
electron microscopy (SEM) according to the method described by Erlandsen et 
al. (2004) who had used this procedure previously to investigate the presence of 
bacterial glycocalyx. Here, the presence of acidic polysaccharides and the 
effects of two antifungal drugs (amphotericin B and caspofungin) on biofilm 
structure and morphology were investigated.  After air drying, biofilms were 
more easily detached from the membrane filter and this allowed examination of 
three areas: (i) the top surface of the biofilm; (ii) the bottom surface of the 
biofilm (biofilms were turned upside down); and (iii) the membrane-attached 
basal region of the biofilm. Using cationic dyes (alcian blue or ruthenium red) in 
the primary fixation significantly improved the visualization of 
exopolysaccharides in the biofilm samples. Procedures with either dye gave good 
preservation of cell morphology and matrix material. However, with the 
exception of C. tropicalis and C. krusei biofilms, ruthenium red treatment 
produced a weakly held biofilm that broke easily into pieces. Because of this, all 
the biofilms shown in micrographs presented here were stained with alcian blue. 
4.5.1 Effects of amphotericin B and caspofungin on biofilm structure of 
different Candida species 
 The effects of amphotericin B (78 µg/ml) and caspofungin (24 µg/ml) on 
the structure of the biofilms were studied. The areas of the biofilm were 
examined as described above. 
4.5.1.1 The top surface of the biofilm 
 SEM observations of the top surface of the biofilm showed that the 
untreated control biofilm was, in some cases, covered with a slime-like material 
in which yeasts and filaments were completely embedded. This type of material 
was visualized in abundance in C. tropicalis and C. krusei biofilms (Fig. 32, E1 
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and F1). The other species failed to exhibit the slime-like material and only 
relatively sparse amounts of matrix material were seen (Figs. 32, A1, C1, D1 and 
33, A1-D1). Biofilms formed by C. albicans GDH2346 consisted of a dense 
network of yeast cells only (Figs. 32 and 33, A1), whereas those of C. albicans 
SC5314 consisted of both yeast and filamentous forms (Fig. 32, B1). C. glabrata 
and C. parapsilosis formed biofilms containing densely packed yeast cells (Figs. 
32 and 33, C1 and D1); in the case of C. parapsilosis, some of the cells were 
rather elongated (Figs. 32 and 33, D1). 
  
 After 24 h of exposure to amphotericin B, the top surface of the biofilms 
seemed largely unaffected and the cells retained the morphology of those found 
in the controls (Fig. 32, A2, B2, C2, D2, and F2), although in C. tropicalis 
biofilms the slime-like material was less evident (Fig. 32, E2). Caspofungin, on 
the other hand, affected the morphology of C. parapsilosis biofilms; some cells 
were damaged and appeared to be spherical and enlarged compared with those 
found in the control (Fig. 33, D2). Moreover, following caspofungin treatment, C. 
tropicalis and C. krusei biofilms contained less matrix material and were devoid 
of the slime-like component (Figs. 33, E2 and F2). However, caspofungin did not 
appear to affect the top surface of C. albicans biofilms (Figs. 33, A2 and B2), nor 
that of C. glabrata biofilms (Fig. 33, C2). 
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Figure 32. Scanning electron micrographs of the top layers of biofilms of 
Candida species exposed to amphotericin B  
Biofilms were grown on polycarbonate membrane filters for 48 h, and then 
treated with amphotericin for 24 h. The figure shows control biofilms (1) and 
biofilms grown in the presence of amphotericin B (78 µg/ml) (2). Arrows in A 
indicate matrix material; arrow in B1 indicates hyphae. 
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Figure 32 
(continued) 
 
Arrows indicate matrix material 
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Figure 32 
(continued) 
 
Arrows in E1, F1 and F2 indicate slime-like matrix material; arrow in E2 indicates 
matrix material 
 
E. C. tropicalis  
F. C. krusei  
E1 E2 
F1 F2 
   5 µm 
    10 µm     10 µm 
     10 µm 
                                                                                                                                      Results 
 
 
 
113 
 
 
Figure 33. Scanning electron micrographs of the top layers of biofilms of 
Candida species exposed to caspofungin 
Biofilms were grown on polycarbonate membrane filters for 48 h, and then 
treated with caspofungin for 24 h. The figure shows control biofilms (1) and 
biofilms grown in the presence of caspofungin (24 µg/ml) (2). Arrows indicate 
matrix material. 
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Figure 33 
(continued) 
 
Arrows in C1 and C2 indicate matrix material; arrows in D2 indicate spherical, 
enlarged, and damaged cells. 
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Figure 33 
(continued) 
 
Arrows in E1 and F1 indicate slime-like matrix material; arrows in E2 and F2 
indicate matrix material 
 
E. C. tropicalis  
F. C. krusei  
E1 
F1 
E2 
F2 
   5 µm 
  2 µm   2 µm 
   10 µm 
                                                                                                                                      Results 
 
 
 
116 
4.5.1.2 The bottom surface of the biofilm 
 The bottom surface of the untreated control biofilms showed different 
types of matrix material. These appeared as strands (Figs. 34, C1 and 35, F1) 
attached to the cell surface and forming a complex meshwork between cells, or 
as slime-like material (Figs. 34, D2 and 35, E1). Globule-like matrix particles 
were also seen on cell surfaces (Figs. 34, A1, B1 and 35, A1, B1). 
 After 24 h of amphotericin B treatment, some damage to the biofilm 
structure, at the bottom surface, was clearly seen in C. krusei biofilms; the 
meshwork structure was almost completely destroyed (Fig. 34, F2) and relatively 
little matrix remained. Amphotericin B also caused elongated cells in biofilms of 
C. krusei to become shorter and more spherical (Fig. 34, F2). In contrast, no 
change in biofilm structure or cell morphology was apparent in biofilms of the 
other Candida species (Fig. 34, A2-E2).  
 Caspofungin caused much more damage to the bottom surface of the 
biofilm. Severe destruction of the bottom surface meshwork structure was 
observed with biofilms of C. glabrata, C. tropicalis, and C. krusei (Figs. 35, C2, 
E2, and F2). In addition, many yeast cells in the biofilm had lost their surface 
matrix coat; this was visualized clearly with C. albicans and C. tropicalis (Fig. 
35, A2, B2, and E2). Caspofungin also caused cell rupture in biofilms of C. 
tropicalis and C. krusei (Fig. 35, E2 and F2). However, no such changes were 
apparent with biofilms of C. parapsilosis (Fig. 35, D2). 
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Figure 34. Scanning electron micrographs of the bottom layers of biofilms of 
Candida species exposed to amphotericin B 
Biofilms were grown on polycarbonate membrane filters for 48 h, and then 
treated with amphotericin for 24 h. The figure shows control biofilms (1) and 
biofilms grown in the presence of amphotericin B (78 µg/ml) (2). Arrows indicate 
globule-like matrix particle. 
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Figure 34 
(continued) 
 
Arrows in C indicate matrix material; arrows in D indicate slime-like matrix 
material. 
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Figure 34 
(continued) 
 
Arrows in E and F1 indicate matrix material; arrows in F2 indicate remaining 
matrix material and spherical yeast cells. 
 
E. C. tropicalis  
F. C. krusei  
 
E1 E2 
F1 F2 
    2 µm 
  10 µm 10 µm 
   2 µm 
                                                                                                                                      Results 
 
 
 
120 
 
 
Figure 35. Scanning electron micrographs of the bottom layers of biofilms of 
Candida species exposed to caspofungin 
Biofilms were grown on polycarbonate membrane filters for 48 h, and then 
treated with caspofungin for 24 h. The figure shows control biofilms (1) and 
biofilms grown in the presence of or caspofungin (24 µg/ml) (2). Arrows in A1 
and B1 indicate globule-like matrix; arrows in A2 and B2 indicate yeast cells 
without surface matrix material. 
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Figure 35 
(continued) 
 
Arrows in C2 indicate severe destruction of matrix material; arrows in C1 and D 
indicate matrix material. 
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Figure 35 
(continued) 
 
Arrow in E1 indicates slime-like matrix material; arrows in E2 indicate damaged 
yeast cells; arrows in F2 indicate severe destruction of the meshwork structure 
and damaged yeast cells.  
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4.5.1.3 The membrane-attached basal region of the biofilm 
 SEM observations of the membrane-attached basal region of control 
biofilms showed, in most cases, yeast cells submerged in a dense slime-like 
material. This was clearly visualized in C. albicans GDH2346 (Figs. 36 and 37, 
A1), C. albicans SC5314 (Figs. 36 and 37, B1), C. glabrata AAHB12 (Fig. 36 and 
37, C1), C. parapsilosis (Fig. 36, D1), and C. krusei (Figs. 36 and 37, F1). On the 
other hand, C. tropicalis showed a thick meshwork of matrix material connecting 
cells and attaching them to the surface (Figs. 36 and 37, E1) in addition to the 
slime-like material (Fig. 36, E1) 
 After treatment with amphotericin B, the slime-like material which was 
covering the basal region disappeared in most Candida biofilms. The removal of 
this type of material in C. albicans GDH2346 biofilms revealed a thick network of 
strands that seemed to anchor the cells to the substrate (Fig. 36, A2). The slimy 
material was also absent in amphotericin-treated biofilms of C. glabrata and C. 
parapsilosis but here no strands were apparent (Figs. 36, C2 and D2). On the 
other hand, C. albicans SC5314 biofilms retained a little slimy matrix material 
(Fig. 36, B2), whereas C. krusei biofilms appeared to retain as much intact slimy 
material as control biofilms (Fig. 36, F2). The basal region of amphotericin-
treated C. tropicalis biofilms had a thick meshwork of strands connecting cells 
together and to the substrate (Fig. 36, E2). In some cases, yeast cells at the 
basal region were elongated, as in C. glabrata (Fig.36, C2) or shortened and 
ballooned as C. krusei (Fig. 36, F2).  
 Caspofungin caused a high degree of damage to biofilm cells as well as 
damage to the biofilm structure of all six Candida isolates. The basal slime-like 
material was completely removed in all those Candida species that appeared to 
have it (Fig. 37, A2, B2, C2, and F2). The removal of this slimy material revealed 
a thick network of matrix strands as in C. albicans SC5314 (Fig. 37, B2) or short 
fibrils of matrix material surrounding single yeast cells as in C. glabrata (Fig. 37, 
C2), C. parapsilosis (Fig. 37, D2), and C. krusei (Fig. 37, F2). The meshwork 
structure of C. tropicalis was highly damaged (Fig. 37, E2). Caspofungin had also 
caused some damage to the yeast cells at the basal region and cell ‘footprints’ 
were found which are presumably due to lysed cells (Fig. 37, C2, D2, F2). 
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Figure 36. Scanning electron micrographs of the membrane-attached basal 
region of biofilms of Candida species exposed to amphotericin B 
Biofilms were grown on polycarbonate membrane filters for 48 h, and then 
treated with amphotericin for 24 h. The figure shows control biofilms (1) and 
biofilms grown in the presence of amphotericin B (78 µg/ml) (2). Arrow in A1 
indicates slime-like matrix material; arrows in A2 indicate thick strands of 
matrix material; arrow in B2 indicates remaining slime-like material. 
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Figure 36 
(continued) 
 
Arrows in C1 and D1 indicate slime-like material; arrows in C2 indicate elongated 
yeast cells. 
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Figure 36 
(continued) 
 
Arrows in E1 indicate thick meshwork of strands as well as slime-like material; 
arrows in E2 indicate thick meshwork of strands attached to the surface; arrows 
in F1 indicate control elongated yeast cell; arrows in F2 indicate shortened, 
ballooned cells. 
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Figure 37. Scanning electron micrographs of the membrane-attached basal 
region of biofilms of Candida species exposed to caspofungin 
Biofilms were grown on polycarbonate membrane filters for 48 h, and then 
treated with caspofungin for 24 h. The figure shows control biofilms (1) and 
biofilms grown in the presence of or caspofungin (24 µg/ml) (2). Arrow in A1 
indicates slime-like matrix material; arrows in B2 indicate a thick network of 
strands attached to the surface. 
A. C. albicans GDH2346 
B. C. albicans SC5314 
B1 B2 
A1 A2 
    10 µm    10 µm 
        5 µm       2 µm 
                                                                                                                                      Results 
 
 
 
128 
 
 
Figure 37 
(continued) 
 
Arrow in C1 indicates slime-like material; arrows in C2 and D2 indicate damaged 
yeast cells and ‘cell footprints’; arrows in D1 indicate strands of matrix material 
attached to the surface. 
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Figure 37 
(continued) 
 
Arrows in E1 and E2 indicate thick meshwork of strands of matrix material; 
arrows in F2 indicate damaged yeast cells and ‘cell footprints’. 
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 In summary, cells in both the membrane-attached basal region and the 
bottom surface of the biofilms (close to the drug-containing agar surface) were 
more affected by antifungal drugs than those at the top surface, which were 
more likely to be found intact. Caspofungin caused more damage to the biofilm 
structure and biofilm cell morphology than did amphotericin B. Moreover, the 
highest degree of damage overall was caused by caspofungin, and was observed 
in biofilms of C. krusei and C. glabrata. 
 
5 Persister cells in planktonic cultures and biofilms of 
different Candida species 
 Planktonic cultures (exponential and stationary-phase) and biofilms 
(grown on catheter discs for 48 h) of six isolates (i.e. C. albicans GDH2346, C. 
albicans SC5314, C. glabrata AAHB12, C. parapsilosis AAHB4479, C. krusei 
Glasgow and C. tropicalis AAHB73) were exposed to different concentrations of 
antifungals (amphotericin B and caspofungin; 5 µg – 100 µg/ml) for 24 h and 
examined for the presence of persister cells using standard viable cell counts. 
Caspofungin was tested against both strains of C. albicans but showed limited 
effects on stationary-phase cells and biofilms, producing at most only a 10-fold 
decrease in viability (Figs. 38 and 39).  Planktonic cells in exponential growth 
phase were rather more susceptible to caspofungin (Figs. 38 and 39). On the 
basis of these preliminary studies it was decided that caspofungin was an 
unsuitable antifungal agent for use in investigations on persister cells, and 
further experiments were carried out with amphotericin B only. 
5.1 Persister cells in planktonic cultures of Candida species 
5.1.1 Persister cells in planktonic cultures of C. albicans strains 
 Planktonic cells of strain GDH2346, in both exponential and stationary 
growth phases were effectively killed by a low concentration of amphotericin B 
(5 µg/ml) with no detectable survivors (Fig. 40); the MIC for this strain is 1.3 
µg/ml. Planktonic cells of strain SC5314 in exponential and stationary growth  
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Figure 38. Survival of biofilm cells (▲), planktonic exponential-phase cells 
(●), and planktonic stationary-phase cells (□) of C. albicans GDH2346 
exposed to different concentrations of caspofungin 
Biofilms were grown on PVC catheter discs for 48 h in YNB medium containing 50 
mM glucose and caspofungin at the concentration indicated, and then processed 
for viable cell counts. Exponential- and stationary-phase planktonic cultures 
were grown in the same medium. Results are means + standard errors of two 
independent experiments carried out in duplicate. 
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Figure 39. Survival of biofilm cells (▲), planktonic exponential-phase cells 
(●), and planktonic stationary-phase cells (□) of C. albicans SC5314 exposed 
to different concentrations of caspofungin 
Biofilms were grown on PVC catheter discs for 48 h in YNB medium containing 50 
mM glucose and caspofungin at the concentration indicated, and then processed 
for viable cell counts. Exponential- and stationary-phase planktonic cultures 
were grown in the same medium. Results are means + standard errors of two 
independent experiments carried out in duplicate. 
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Figure 40. Survival of biofilm cells (▲), planktonic exponential-phase cells 
(●), and planktonic stationary-phase cells (□) of C. albicans GDH2346 
exposed to different concentrations of amphotericin B 
Biofilms were grown on PVC catheter discs for 48 h in YNB medium containing 50 
mM glucose and amphotericin B at the concentration indicated, and then 
processed for viable cell counts. Exponential- and stationary-phase cultures 
were grown in the same medium. Results are means + standard errors of two 
independent experiments carried out in duplicate. 
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phases were also completely eliminated at this low concentration of 
amphotericin B (Fig. 41). The MIC for strain SC5314 is 0.8 µg/ml. 
5.1.2 Persister cells in planktonic cultures of non-C. albicans species 
 Planktonic cells of non-C. albicans species were also susceptible to 
amphotericin B. Exponentially growing cells of C. glabrata, C. tropicalis and C. 
krusei were killed by amphotericin B at a concentration of 5 µg/ml (Figs. 42-44) 
whereas those of C. parapsilosis were relatively more resistant (Fig. 45). 
Stationary-phase cells of C. tropicalis, C. krusei and C. parapsilosis were less 
susceptible than exponentially growing cells (Figs. 43-45), while stationary-phase 
cells of C. krusei showed a distinct tolerance to amphotericin B (Fig. 44). 
Overall, there was no indication of persisters among planktonic cells of any 
Candida species tested since all of these cells were eliminated completely at an 
amphotericin B concentration of 100 µg/ml. 
5.2 Persister cells in biofilms of Candida species 
5.2.1 Persister cells in biofilms of C. albicans strains 
 Unlike planktonic cells, biofilms of C. albicans GDH2346 seemed to 
contain a small fraction (0.01 %) of cells tolerant to amphotericin B at 
concentration of 100 µg/ml (Fig. 40), i.e. drug-tolerant persister cells. 
Unexpectedly, biofilms of C. albicans SC5314 appeared to lack such tolerant 
cells as no cells survived exposure to 100 µg/ml amphotericin B (Fig. 41). 
Nevertheless, in this strain, as in strain GDH2346, biofilm cells were more drug 
resistant than planktonic cells. 
5.2.2 Persister cells in biofilms of non-C. albicans species 
 Although biofilms of all four non-C. albicans species were considerably 
more resistant to amphotericin B than planktonic cells, only biofilms of C. krusei 
and C. parapsilosis gave biphasic killing curves indicative of the presence of 
persisters (Figs. 44 and 45). These biofilms, unlike those of C. glabrata and C. 
tropicalis, still showed some viability even after exposure to a drug 
concentration of 100 µg/ml. However, for both species the persister population  
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Figure 41. Survival of biofilm cells (▲), planktonic exponential-phase cells 
(●), and planktonic stationary-phase cells (□) of C. albicans SC5314 exposed 
to different concentrations of amphotericin B 
Biofilms were grown on PVC catheter discs for 48 h in YNB medium containing 50 
mM glucose and amphotericin B at the concentration indicated, and then 
processed for viable cell counts. Exponential- and stationary-phase cultures 
were grown in the same medium. Results are means + standard errors of two 
independent experiments carried out in duplicate. 
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Figure 42. Survival of C. glabrata biofilm cells (▲), planktonic exponential-
phase cells (●), and planktonic stationary-phase cells (□) exposed to different 
concentrations of amphotericin B 
Biofilms were grown on PVC catheter discs for 48 h in YNB medium containing 50 
mM glucose and amphotericin B at the concentration indicated, and then 
processed for viable cell counts. Exponential- and stationary-phase cultures 
were grown in the same medium. Results are means + standard errors of two 
independent experiments carried out in duplicate. 
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Figure 43. Survival of C. tropicalis biofilm cells (▲), planktonic exponential-
phase cells (●), and planktonic stationary-phase cells (□) exposed to different 
concentrations of amphotericin B 
Biofilms were grown on PVC catheter discs for 48 h in YNB medium containing 50 
mM glucose and amphotericin B at the concentration indicated, and then 
processed for viable cell counts. Exponential- and stationary-phase cultures 
were grown in the same medium. Results are means + standard errors of two 
independent experiments carried out in duplicate. 
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Figure 44. Survival of C. krusei biofilm cells (▲), planktonic exponential-
phase cells (●), and planktonic stationary-phase cells (□) exposed to different 
concentrations of amphotericin B 
Biofilms were grown on PVC catheter discs for 48 h in YNB medium containing 50 
mM glucose and amphotericin B at the concentration indicated, and then 
processed for viable cell counts. Exponential- and stationary-phase cultures 
were grown in the same medium. Results are means + standard errors of two 
independent experiments carried out in duplicate. 
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Figure 45. Survival of C. parapsilosis biofilm cells (▲), planktonic 
exponential-phase cells (●), and planktonic stationary-phase cells (□) 
exposed to different concentrations of amphotericin B 
Biofilms were grown on PVC catheter discs for 48 h in YNB medium containing 50 
mM glucose and amphotericin B at the concentration indicated, and then 
processed for viable cell counts. Exponential- and stationary-phase cultures 
were grown in the same medium. Results are means + standard errors of two 
independent experiments carried out in duplicate. 
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was small, representing approximately 0.001% and 0.07% of the total cell count 
of biofilms of C. krusei and C. parapsilosis, respectively. C. tropicalis and C. 
glabrata biofilm cells were eliminated at amphotericin concentrations of 30 
µg/ml and 100 µg/ml, respectively (Figs. 42 and 43). 
5.3 Live-dead staining of persister cells 
 To confirm the existence of persister cells in some Candida isolates but 
not in others, a live-dead staining procedure with fluorescein diacetate was used 
(LaFleur et al., 2006).  
5.3.1 Staining with fluorescein diacetate 
 Fluorescein diacetate was used to discriminate between live and dead 
yeast cells; this dye specifically stains dead yeast cells with a bright green 
fluorescence. Mature (48-h) Candida biofilms (C. albicans GDH2346 and SC5314, 
C. krusei Glasgow, and C. parapsilosis AAHB4479) were treated with a high 
concentration of amphotericin B (100 µg/ml) for 24 h at 37°C and stained with 
fluorescein diacetate. A small number of unstained cells (live) were detected in 
three of the isolates. These cells appeared to have normal morphology similar to 
that of untreated control cells and their numbers varied among the different 
Candida species. C. parapsilosis biofilms (Fig. 46) contained more of the live 
cells than did biofilms of C. albicans GDH2346 or C. krusei (Figs. 47 and 48, 
respectively). In contrast, C. albicans SC5314 failed to show live cells (Fig. 49). 
With all four isolates, fluorescence staining was rarely observed in untreated 
control cells (i.e. 72-h biofilm cells). These findings further confirm the earlier 
viability measurements which showed that persisters were present in biofilms of 
C. albicans GDH2346, C. krusei, and C. parapsilosis but absent from biofilms of 
C. albicans SC5314. 
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Figure 46. Live-dead staining of C. parapsilosis biofilm cells with fluorescein 
diacetate 
Biofilms (48-h) were incubated with amphotericin B (100 µg/ml) and fluorescein 
diacetate (100 µg/ml) for 24 h at 37ºC. Washed, resuspended biofilm cells were 
then examined by fluorescence microscopy. Differential interference contrast 
(DIC), fluorescence, and overlaid images are shown of untreated biofilm cells (A) 
and biofilm cells treated with amphotericin B (B). Dead cells fluoresce green. 
Bar, 13 µm 
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Figure 47. Live-dead staining of C. albicans GDH2346 biofilm cells with 
fluorescein diacetate  
Biofilms (48-h) were incubated with amphotericin B (100 µg/ml) and fluorescein 
diacetate (100 µg/ml) for 24 h at 37ºC. Washed, resuspended biofilm cells were 
then examined by fluorescence microscopy. Differential interference contrast 
(DIC), fluorescence, and overlaid images are shown of untreated biofilm cells (A) 
and biofilm cells treated with amphotericin B (B). Dead cells fluoresce green. 
Bar, 13 µm 
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Figure 48. Live-dead staining of C. krusei biofilm cells with fluorescein 
diacetate 
Biofilms (48-h) were incubated with amphotericin B (100 µg/ml) and fluorescein 
diacetate (100 µg/ml) for 24 h at 37ºC. Washed, resuspended biofilm cells were 
then examined by fluorescence microscopy. Differential interference contrast 
(DIC), fluorescence, and overlaid images are shown of untreated biofilm cells (A) 
and biofilm cells treated with amphotericin B (B). Dead cells fluoresce green. 
Bar, 13 µm 
 
DIC 
images 
DIC 
 images 
Fluorescence 
images 
Fluorescence 
images 
Overlaid 
images 
                                                                                                                                      Results 
 
 
 
144 
 
 
 
 
 
 
 
 
 B   
 
 
 
  
 
 
 
 
 
 
 
Figure 49. Live-dead staining of C. albicans SC5314 biofilm cells with 
fluorescein diacetate 
Biofilms (48-h) were incubated with amphotericin B (100 µg/ml) and fluorescein 
diacetate (100 µg/ml) for 24 h at 37ºC. Washed, resuspended biofilm cells were 
then examined by fluorescence microscopy. Differential interference contrast 
(DIC), fluorescence, and overlaid images are shown of untreated biofilm cells (A) 
and biofilm cells treated with amphotericin B (B). Dead cells fluoresce green. 
Bar, 13 µm 
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6 Apoptosis in Candida biofilms 
6.1  Detection of apoptotic cells in Candida biofilms 
6.1.1 Caspase detection using a polycaspase SR-FLICA reagent 
 The FLICA reagent (for fluorochrome-labelled inhibitor of caspase) was 
used to detect the presence of caspases in Candida biofilm cells. When the 
reagent enters a cell, any active caspases present will bind covalently to the 
peptide inhibitor sequence of FLICA (VAD). As a result, the fluorescent label, 
sulforhodamine (SR) is retained within the cell which fluoresces red. Here, 48-h 
biofilms of C. krusei, C. parapsilosis and both strains of C. albicans were treated 
with amphotericin B (10 or 50 µg/ml) for 5 h or 24 h. The cells were then 
labelled with the reagent and viewed under a fluorescence microscope. 
 Exposure of biofilms of C. albicans SC5314 to amphotericin B at a 
concentration of 10 µg/ml for 5 h resulted in relatively few cells that were 
stained with FLICA reagent (Fig. 50, A2) while biofilms exposed to a higher 
concentration of AMB (i.e. 50 µg/ml) showed slightly more stained cells, 
indicating a higher level of caspase activity (Fig. 50, A3). Considerably more 
stained cells resulted after 24 h of exposure (Fig. 50, B2 and 3).  Similarly, 
exposing biofilms of C. albicans GDH2346 to amphotericin B at a concentration 
of 50 µg/ml for 5 h resulted in relatively few cells that were stained with the 
FLICA reagent (Fig. 51, A2 and 3). Again, considerably more stained cells (93%) 
were seen in biofilms that had been exposed to the drug for 24 h (Fig. 51, B2 and 
3), suggesting an ongoing process of apoptosis induction. After such treatment, 
higher numbers of apoptotic cells appeared to be present in biofilms of C. 
albicans (both strains) and C. krusei (Fig. 52, A2 and 3) than in biofilms of C. 
parapsilosis (Fig. 52, B2 and 3). Some cells were faint red which may indicate a 
lower concentration of active caspase; these cells were probably just beginning 
to enter apoptosis at the time the reagent was added. Unstained, non-apoptotic 
cells appeared to be intact and had a morphology similar to that of untreated 
control cells.  
 Pre-treatment of biofilm cells with unlabelled caspase inhibitor Z-VAD-
FMK for 1h before the addition of FLICA failed to block the caspase-like protease  
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Figure 50. Caspase detection using a polycaspase SR-FLICA reagent: C. 
albicans SC5314  
Biofilms (48-h) of C. albicans SC5314 were treated with AMB (10 or 50 µg/ml) for 
5 h or 24 h. Biofilm cells were then labelled with the SR-VAD-FMK reagent for 60 
min at 37°C and examined by fluorescence microscopy. DIC and fluorescence 
images of C. albicans SC5314 exposed to AMB for 5 h (A) or 24 h (B) are shown:  
(1) untreated control biofilm cells; (2) biofilm cells treated with AMB (10 µg/ml); 
and (3) biofilm cells treated with AMB (50 µg/ml). Orange/red fluorescence 
indicates caspase activity. Bar, 13 µm. 
3 2 
3 
1 
1 2 
DIC image 
DIC image 
Fluorescence 
image 
Fluorescence 
image 
A 
B 
                                                                                                                                      Results 
 
 
 
147 
 
 
 
 
    
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 51. Caspase detection using a polycaspase SR-FLICA reagent: C. 
albicans GDH2346 
Biofilms (48-h) of C. albicans GDH2346 were treated with AMB (50 µg/ml) for 5 h 
or 24 h. Biofilm cells were then labelled with the SR-VAD-FMK reagent for 60 min 
at 37°C and examined by fluorescence microscopy. DIC and fluorescence images 
of C. albicans GDH2346 exposed to AMB for 5 h (A) or for 24 h (B) are shown: (1) 
untreated control biofilm cells; (2 and 3) treated biofilm cells. Orange/red 
fluorescence indicates caspase activity. Bar, 13 µm. 
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Figure 52. Caspase detection using a polycaspase SR-FLICA reagent: C. krusei 
and C. parapsilosis 
Biofilms (48-h) of C. krusei and C. parapsilosis were treated with AMB (50 µg/ml) 
for 24 h. Biofilm cells were then labelled with the SR-VAD-FMK reagent for 60 
min at 37C and examined by fluorescence microscopy. DIC and fluorescence 
images of C. krusei (A) and C. parapsilosis (B) are shown: (1) untreated control 
biofilm cells; (2 and 3) treated biofilm cells. Orange/red fluorescence indicates 
caspase activity. Bar, 13 µm. 
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binding sites. Furthermore, subsequent binding of FLICA was not completely 
prevented by addition of the unlabelled caspase inhibitor at the time of 
apoptosis induction; the number of stained cells did not significantly decrease 
(94 % of 1300 cells counted, P<0.37). 
6.1.2 Caspase detection using a D2R reagent 
 To confirm the results with the FLICA reagent, the presence of active 
caspase-like proteases was investigated using another method. This assay is 
based on the cleavage of (aspartyl)2-Rhodamine 110 (D2R) which is a substrate 
for caspases.  D2R is non-fluorescent but when it enters the cell it can be 
cleaved by active caspases to green fluorescent monosubstituted rhodamine 110 
and free rhodamine (Hug et al., 1999). With biofilms exposed to amphotericin B 
(50 µg/ml) for 24 h, the number of cells stained by D2R was high (96%; Figs. 53 
and 54); cells from untreated biofilms, however, were rarely stained. 
 Pre-treating biofilm cells of C. albicans GDH2346 with unlabelled Z-VAD-
FMK for 1h prior to the addition of D2R reagent did not prevent subsequent 
binding of D2R. Furthermore, addition of the unlabelled caspase inhibitor along 
with the inducer of apoptosis (AMB) also did not completely prevent the 
subsequent binding of D2R. Nevertheless, the number of stained cells was 
significantly lower (81% of 600 cells counted; P<0.035) than the number of 
stained cells in biofilms exposed to the apoptosis inducer only (97 % of 600 cells 
counted). 
 
 
 
 
 
 
 
 
 
                                                                                                                                      Results 
 
 
 
150 
 
 
 
  
 
 
 
    
    
    
 
 
 
 
 
 
 
 
 
 
Figure 53. Caspase detection using a D2R reagent: C. albicans strains 
GDH2346 and SC5314 
Candida biofilms (48-h) were treated with AMB (50 µg/ml) for 24 h at 37 °C. 
Biofilm cells were then labelled with D2R for 45 min at 37 °C and examined by 
fluorescence microscopy. DIC and fluorescence images of C. albicans GDH2346 
(A) and C. albicans SC5314 (B) are shown: (1) untreated control biofilm cells; (2 
and 3) treated biofilm cells. Green fluorescence indicates caspase activity. Bar,  
5 µm. 
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Figure 54. Caspase detection using a D2R reagent: C. krusei and C. 
parapsilosis 
Candida biofilms (48-h) were treated with AMB (50 µg/ml) for 24 h at 37 °C. 
Biofilm cells were then labelled with D2R for 45 min at 37 °C and examined by 
fluorescence microscopy. DIC and fluorescence images of C. krusei (A) and C. 
parapsilosis (B) are shown: (1) untreated control biofilm cells; (2 and 3) treated 
biofilm cells. Green fluorescence indicates caspase activity. Bar, 5 µm. 
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6.2 Effects of caspase inhibitors on Candida biofilms 
 The effects of caspase inhibitors on amphotericin B activity against 
Candida biofilms were investigated using a broad spectrum caspase inhibitor (Z-
VAD-FMK) and a variety of specific caspase inhibitors. Drug action was 
determined by viable cell count assays. The concentration of the solvent DMSO 
was maintained as low as possible (< 0.26 %) since higher concentrations were 
found to interfere with the inhibitors and to increase the number of dead cells in 
the presence of amphotericin B; examples of this effect are shown in Figs. 55 
and 56. Furthermore, according to the manufacturer of the inhibitors 
(Calbiochem), ‘a final DMSO concentration should not exceed 0.2% as higher 
levels may increase the risk of cellular toxicity which may mask the effect of the 
caspase inhibitor’. 
6.2.1 Effect of a general caspase inhibitor (Z-VAD-FMK) 
 Mature (48-h) biofilms of C. albicans GDH2346, C. krusei Glasgow, and C. 
parapsilosis AAHB4479 were incubated for 24 h at 37ºC in fresh growth medium 
in the presence of different concentrations of the caspase inhibitor Z-VAD-FMK 
(2.5, 5, 10, and 20 µM) alone or together with amphotericin B (50 µg/ml). 
6.2.1.1 Effect of Z-VAD-FMK on viability of Candida biofilms 
 Addition of the caspase inhibitor, Z-VAD-FMK, had no significant effect on 
biofilm viability (P>0.05) for any of the three Candida species at any 
concentration tested (Fig. 57). 
6.2.1.2 Effect of Z-VAD-FMK on amphotericin B activity against Candida 
biofilms 
 When Z-VAD-FMK was added at a concentration as low as 2.5 µM together 
with amphotericin B (50 µg/ml), it significantly reduced the effect of the drug 
on Candida biofilms. Biofilm viability was increased by 11.5-fold (P<0.001) and 
1.6-fold (P<0.05) for C. albicans GDH2346 and C. parapsilosis, respectively. 
However, Z-VAD-FMK (2.5 µM) produced no significant increase in biofilm 
viability with C. krusei (Fig. 58).  In contrast, Z-VAD-FMK at high concentrations 
(10 µM to 20 µM) was ineffective in preventing cell death; a dramatic increase in 
the number of dead cells was observed instead. The proportion of dead cells was 
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Figure 55. Effect of Z-VAD-FMK on amphotericin B (50µg/ml) activity against 
C. albicans GDH2346 in the presence of DMSO at 0.5-1.4% (♦) or 0.12-0.26% 
(■) 
Data represent the means + standard errors of two independent experiments 
carried out in duplicate. 
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Figure 56. Effect of Z-VAD-FMK on amphotericin B (50µg/ml) activity against 
C. parapsilosis in the presence of DMSO at 0.5-1.4% (♦) or 0.12-0.26% (■) 
Data represent the means + standard errors of two independent experiments 
carried out in duplicate.  
1.E+00
1.E+01
1.E+02
1.E+03
1.E+04
1.E+05
2.5 5 10 20
Lo
g 1
0
CF
U/
10
0µ
l
Control
(AMB only)
Lo
g 1
0
CF
U/
10
0µ
l
Z-VAD-FMK (µM) 
                                                                                                                                      Results 
 
 
 
155 
  
         
 
   
Figure 57. Effect of general caspase inhibitor Z-VAD-FMK on the viability of 
biofilms of C. albicans GDH2346 (♦), C. krusei (■), and C. parapsilosis (∆) 
 
Biofilms (48-h) were incubated with ZVAD-FMK for 24 h at 37°C and cell survival 
was determined by viable counts. Results are the means + standard errors of two 
independent experiments carried out in duplicate. Final DMSO concentration, < 
0.014%.  
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Figure 58. Effect of general caspase inhibitor Z-VAD-FMK on amphotericin B 
activity against biofilms of C. albicans GDH2346 (♦), C. parapsilosis (∆), and 
C. krusei (■) 
Biofilms (48-h) were incubated with Z-VAD-FMK and amphotericin B (50 µg/ml), 
together with Z-VAD-FMK at the concentration indicated, for 24 h at 37°C and 
cell survival was determined by viable counts. Results are the means + standard 
errors of two independent experiments carried out in duplicate. Final DMSO 
concentration, 0.12-0.26%. 
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highest at a concentration of 20 µM: 41 %, 57 %, and 94 % for C. albicans 
GDH2346, C. parapsilosis and C. krusei, respectively (Fig. 58).   
 The effect of combined treatment with Z-VAD-FMK and amphotericin B 
was also investigated with biofilms of C. albicans SC5314.  This strain seems to 
lack persisters, and biofilms lose all viability after exposure to amphotericin B at 
a concentration of 30 µg/ml (Section 5.2.1). When Z-VAD-FMK (2.5 µM) was 
added to 48-h biofilms along with amphotericin B (50 µg/ml), after incubation 
for 24 h at 37ºC there was a complete loss of viability like that observed with 
control biofilms exposed only to the antifungal agent. On the other hand, 
treating biofilms with Z-VAD-FMK and a lower concentration of amphotericin B 
(10 µg/ml) resulted in an 11.9-fold increase in viability (P<0.001). 
 The specificity of the effect noted with the general caspase inhibitor was 
investigated using pepstatin A, an inhibitor of aspartic proteinases which are 
known to be produced by Candida species. Mature (48-h) biofilms of C. albicans 
GDH2346 and C. albicans SC5314 were exposed to pepstatin A (2.5 µM) plus 
amphotericin B (50 µg/ml) for 24 h at 37ºC. Pepstatin A, with either C. albicans 
strain, had no significant effect in improving cell survival (Fig. 59). As noted 
above, C. albicans SC5314 biofilms produce no persisters and are completely 
eliminated at concentrations of amphotericin B >30 µg/ml (Section 5.2.1). 
6.2.2 Effect of some specific caspase inhibitors 
 A set of specific caspase inhibitors, active individually against caspases-1, 
-2, -3, -5, -6, -8, and -9, was also tested against C. albicans GDH2346 biofilms, 
at a concentration of 2.5 µM. 
6.2.2.1 Effect of specific caspase inhibitors on viability of Candida biofilms 
 Mature (48-h) biofilms of C. albicans were incubated for 24 h at 37ºC in 
fresh growth medium in the presence of specific caspase inhibitors (2.5 µM). 
None of the inhibitors showed a significant effect (P>0.05) on biofilm viability 
asdetermined by viable counts (Fig. 60). 
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Figure 59. Effects of pepstatin A on amphotericin B activity against biofilms 
of C. albicans GDH2346 and C albicans SC5314 
Biofilms (48-h) were incubated with pepstatin A (2.5 µM) and amphotericin B 
(50µg/ml) for 24 h at 37°C. Cell survival was determined by viable counts. 
Control (AMB only) (  ); pepstatin A + AMB (  ). Results are means + standard 
errors of two independent experiments carried out in duplicate.   
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Figure 60. Effects of specific inhibitors of caspases-1, -2, -3, -5, -6, -8, and -9 
on viability of C. albicans GDH2346 biofilms 
Biofilms (48-h) were incubated with inhibitor (2.5 µM) for 24 h at 37°C. Cell 
survival was determined by viable counts. Results are means + standard errors of 
two independent experiments carried out in duplicate. Final DMSO 
concentration, 0.125%.  
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6.2.2.2 Effect of specific caspase inhibitors on amphotericin B activity 
against Candida biofilms 
 When specific caspase inhibitors (2.5 µM) were added along with 
amphotericin B (50 µg/ml) to 48-h C. albicans biofilms, some of the inhibitors 
significantly enhanced the survival of biofilm cells. Caspase-1 inhibitor VI 
produced in a 40-fold increase in biofilm cell survival (P<0.001) compared with 
amphotericin B-treated controls. Similarly, inhibitors of caspases -9, -5, -3, and  
-2 increased cell survival 8-fold (P<0.001), 3.5-fold (P<0.001), 1.9-fold (P<0.001), 
and 1.7-fold (P<0.01), respectively. In contrast, caspase-6 and caspase-8 
inhibitors decreased biofilm cell survival as compared with the amphotericin-
treated controls (Fig. 61). 
6.3 Effects of histone deacetylase (HDA) inhibitors on Candida 
biofilms 
 The effects of four HDA inhibitors, namely sodium butyrate, sodium 
valproate, apicidin, and trichostatin A, on Candida biofilms were investigated 
using two methods. Initial experiments were carried out using a tetrazolium salt 
reduction (XTT) assay. However, very low XTT readings were obtained with one 
Candida species (C. parapsilosis). Additional experiments were therefore carried 
out using a viable cell count assay. In preliminary experiments, HDA inhibitors 
were added at time zero of biofilm formation but this procedure produced 
biofilms that were fragile, loosely adherent to PVC discs and difficult to handle 
(especially with trichostatin A and apicidin). In all subsequent experiments, the 
effects of HDA inhibitors were tested on mature (48-h) Candida biofilms instead. 
6.3.1 Effects of HDA inhibitors on growth and viability of Candida biofilms 
6.3.1.1 Tetrazolium salt reduction (XTT) assays 
 HDA inhibitors (sodium butyrate, sodium valproate, apicidin, and 
trichostatin A) at different concentrations (2 to 32 µg/ml, or 2 to 32 mM for 
sodium butyrate) were added to incubation mixtures at time zero of biofilm 
production. Incubation was continued for 48 h at 37 ºC. Sodium valproate had no 
significant effect on the growth of C. albicans GDH2346 biofilms, whereas 
sodium butyrate and apicidin reduced growth by 8 to 15 % (P<0.05). On the other  
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Figure 61. Effects of specific inhibitors of caspases-1, -2, -3, -5, -6, -8, and -9 
on amphotericin B activity against biofilms of C. albicans GDH2346 
Biofilms (48-h) were incubated with inhibitor (2.5 µM) and amphotericin B 
(50µg/ml) for 24 h at 37°C. Cell survival was determined by viable counts. 
Results are means + standard errors of two independent experiments carried out 
in duplicate. Final DMSO concentration, 0.25%.  
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hand, trichostatin A seemed to enhance growth slightly at low concentrations 
(Fig. 62).  
 Growth of C. krusei and C. parapsilosis biofilms was reduced by all four 
HDA inhibitors by 10 to 36% (Fig. 63 and 64). Using the XTT assay, low metabolic 
activity was consistently observed with C. parapsilosis biofilms. The reason for 
this is not clear; similar observations have been made by a colleague working in 
this laboratory (Filip Ruzicka, personal communication). Kuhn and co-workers 
have reported that XTT readings in this assay can vary in accordance with the 
sensitivity of different strains and species of Candida to tetrazolium salts.  They 
have also demonstrated decreased XTT activity with C. parapsilosis (strains 
P/A71 and P92) compared to C. albicans strains (Kuhn et al., 2002a; Kuhn et al., 
2002b; Kuhn et al., 2003). 
6.3.1.2 Viable cell counts 
 Mature (48-h) biofilms of C. albicans GDH2346, C. parapsilosis and C. 
krusei were incubated for 24 h at 37ºC in fresh growth medium in the presence 
of different concentrations of the HDA inhibitors.  None of the inhibitors 
affected the viability of any of the Candida species (Figs. 65, 66, and 67). 
6.3.2 Effects of HDA inhibitors on fluconazole activity against Candida 
biofilms 
 The effects of HDA inhibitors on fluconazole activity against C. albicans 
biofilms were evaluated by the XTT metabolic assay. The addition of HDA 
inhibitors (2 to 32 µg/ml, or 2 to 32 mM for sodium butyrate) at time zero of 
biofilm formation increased the action of fluconazole, at either 10 or 50 µg/ml, 
against biofilms of C. albicans GDH2346. The greatest effect on viability was 
observed in the presence of sodium butyrate (32 mM); biofilm viability was 
reduced by 36 % and 26 % (P< 0.001) at fluconazole concentrations of 10 and 50 
µg/ml, respectively (Fig. 68 and 69).  Valproate, apicidin, and trichostatin A at 
their highest concentration (32 µg/ml) also produced a significant effect on 
biofilm viability at a fluconazole concentration of 10 µg/ml; viability decreased 
by 28 %, 28 %, and 23.8 %, respectively (P< 0.001) (Fig. 68). Interestingly, 
valproate and apicidin at the higher concentration of fluconazole (50 µg/ml)  
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Figure 62. Effects of HDA inhibitors on the growth of biofilms of C. albicans 
GDH2346 as determined by XTT assays 
HDA inhibitors (2, 8, 32 µg/ml or mM) were added at time zero of biofilm 
formation. Incubation was for 48 h at 37°C.  Results are means + standard errors 
of two independent experiments carried out in triplicate. Sodium butyrate (mM; 
□), sodium valproate (µg/ml; ■), apicidin (µg/ml; ▲), and trichostatin A (µg/ml; 
○).  
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Figure 63. Effects of HDA inhibitors on the growth of C. krusei biofilms as 
determined by XTT assays 
HDA inhibitors (2, 8, 32 µg/ml or mM) were added at time zero of biofilm 
formation. Incubation was for 48 h at 37°C.  Results are means + standard errors 
of two independent experiments carried out in triplicate. Sodium butyrate (mM; 
□), sodium valproate (µg/ml; ■), apicidin (µg/ml; ▲), and trichostatin A (µg/ml; 
○). 
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Figure 64. Effects of HDA inhibitors on the growth of C. parapsilosis biofilms 
as determined by XTT assays 
HDA inhibitors (2, 8, 32 µg/ml or mM) were added at time zero of biofilm 
formation. Incubation was for 48 h at 37°C.  Results are means + standard errors 
of two independent experiments carried out in triplicate. Sodium butyrate (mM; 
□), sodium valproate (µg/ml; ■), apicidin (µg/ml; ▲), and trichostatin A (µg/ml; 
○). 
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Figure 65. Effect of HDA inhibitors on the viability of C. albicans GDH2346 
biofilms 
Biofilms (48-h) were incubated with HDA inhibitors for 24 h at 37°C. Results are 
means + standard errors of two independent experiments carried out in 
triplicate. Sodium butyrate (mM; □), sodium valproate (µg/ml; ■), apicidin 
(µg/ml; ▲), and trichostatin A (µg/ml; ○).  
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Figure 66. Effect of HDA inhibitors on the viability of C. krusei biofilms  
Biofilms (48-h) were incubated with HDA inhibitors for 24 h at 37°C. Results are 
means + standard errors of two independent experiments carried out in 
triplicate. Sodium butyrate (mM; □), sodium valproate (µg/ml; ■), apicidin 
(µg/ml; ▲), and trichostatin A (µg/ml; ○). 
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Figure 67. Effect of HDA inhibitors on the viability of C. parapsilosis biofilms 
Biofilms (48-h) were incubated with HDA inhibitors for 24 h at 37°C. Results are 
means + standard errors of two independent experiments carried out in 
triplicate. Sodium butyrate (mM; □), sodium valproate (µg/ml; ■), apicidin 
(µg/ml; ▲), and trichostatin A (µg/ml; ○). 
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Figure 68. Effects of HDA inhibitors on fluconazole (10 µg/ml) activity against 
biofilms of C. albicans GDH2346 
HDA inhibitors were added at time zero of biofilm formation. After incubation 
for 48 h, biofilms were exposed to fluconazole (10 µg/ml) for 24 h at 37°C. Cell 
viability was measured by the XTT assay. Sodium butyrate (SB; mM), sodium 
valproate (VAL; µg/ml), apicidin (AP; µg/ml), and trichostatin A (TSA; µg/ml) 
were used at concentrations of     2;    8;    32 µg/ml or mM. Results are 
means + standard errors of two independent experiments carried out in 
triplicate. 
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were less effective (10.5 % and 19 %, respectively), whereas trichostatin A 
appeared to enhance growth (Fig. 69). 
 A similar experiment was performed in which the HDA inhibitors were 
added to mature (48-h) biofilms of C. albicans GDH2346 rather than at time zero 
of biofilm formation. All four HDA inhibitors at their highest concentration (32 
µg/ml or mM) had a marked effect on biofilm viability at both fluconazole 
concentrations (10 or 50 µg/ml); however, sodium butyrate (32 mM) had the 
greatest effect and reduced biofilm viability by 40 % and 24 %, at fluconazole 
concentrations of 10 and 50 µg/ml, respectively (P< 0.01) (Figs. 70 and 71). 
6.3.3 Effect of HDA inhibitors on amphotericin B activity against Candida 
biofilms 
 Similar experiments were carried out to investigate the effects of HDA 
inhibitors (sodium butyrate, sodium valproate, apicidin, and trichostatin A) at 
different concentrations on the activity of amphotericin B against Candida 
biofilms. Tetrazolium reduction (XTT) and viable cell count assays were again 
used to assess the effects.  
6.3.3.1 Tetrazolium salt reduction (XTT) assays  
 The addition of HDA inhibitors at time zero of biofilm formation produced 
varied effects on amphotericin B activity. Sodium butyrate at all concentrations 
(2 to 32 mM) significantly enhanced the activity of amphotericin B against C. 
albicans GDH2346 biofilms. Sodium butyrate at concentrations of 2, 8, and 32 
mM with amphotericin B (10 µg/ml) reduced biofilm viability by 34 %, 56 %, and 
68 %, respectively (P<0.001; Fig. 72), and in the presence of a higher 
concentration of amphotericin B (50 µg/ml) by 47%, 59.7%, and 76%, respectively 
(P<0.001; Fig. 73). In contrast, valproate and apicidin at all concentrations (2 to 
32 mM) with amphotericin B (50 µg/ml) had no significant effect on C. albicans 
biofilm viability (P>0.05; Fig. 73). However, significant effects on viability 
(decreases of 37% and 31%, respectively) were observed when these inhibitors 
were used at a concentration of 32 µg/ml with amphotericin B at 10 µg/ml 
(P<0.001; Fig. 72).  Results with trichostatin A were not reliable in this assay; it 
was noticed that this inhibitor in the presence of amphotericin B causes 
detachment of C. albicans biofilms from the PVC discs. Surprisingly, 
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Figure 69. Effects of HDA inhibitors on fluconazole (50 µg/ml) activity against 
biofilms of C. albicans GDH2346 
HDA inhibitors were added at time zero of biofilm formation. After incubation 
for 48 h, biofilms were exposed to fluconazole (50 µg/ml) for 24 h at 37°C. Cell 
viability was measured by the XTT assay. Sodium butyrate (SB; mM), sodium 
valproate (VAL; µg/ml), apicidin (AP; µg/ml), and trichostatin A (TSA; µg/ml) 
were used at concentrations of     2;    8;    32 µg/ml or mM. Results are 
means + standard errors of two independent experiments carried out in 
triplicate.
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Figure 70. Effects of HDA inhibitors on fluconazole (10 µg/ml) activity against 
biofilms of C. albicans GDH2346: inhibitors added to mature biofilms 
Biofilms (48-h) were incubated with HDA inhibitors and fluconazole (10 µg/ml) 
for 24 h at 37°C. Cell viability was measured by the XTT assay. Sodium butyrate 
(SB; mM), sodium valproate (VAL; µg/ml), apicidin (AP; µg/ml), and trichostatin 
A (TSA; µg/ml) were used at concentrations of   2;   8;  32 mM or µg/ml. 
Results are means + standard errors of two independent experiments carried out 
in triplicate.  
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Figure 71. Effects of HDA inhibitors on fluconazole (50 µg/ml) activity against 
biofilms of C. albicans GDH2346: inhibitors added to mature biofilms 
Biofilms (48-h) were incubated with HDA inhibitors and fluconazole (50 µg/ml) 
for 24 h at 37°C. Cell viability was measured by the XTT assay. Sodium butyrate 
(SB; mM), sodium valproate (VAL; µg/ml), apicidin (AP; µg/ml), and trichostatin 
A (TSA; µg/ml) were used at concentrations of    2;     8;    32 mM or µg/ml. 
Results are means + standard errors of two independent experiments carried out 
in triplicate. 
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Figure 72. Effects of HDA inhibitors on amphotericin B (10 µg/ml) activity 
against biofilms of C. albicans GDH2346  
HDA inhibitors were added at time zero of biofilm formation. After incubation 
for 48 h, biofilms were exposed to amphotericin B (10 µg/ml) for 24 h at 37°C. 
Cell viability was measured by the XTT assay. Sodium butyrate (SB; mM), sodium 
valproate (VAL; µg/ml), apicidin (AP; µg/ml), and trichostatin A (TSA; µg/ml) 
were used at concentrations of    2;    8;    32 µg/ml or mM. Results are 
means + standard errors of two independent experiments carried out in 
triplicate. 
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Figure 73. Effects of HDA inhibitors on amphotericin B (50 µg/ml) activity 
against biofilms of C. albicans GDH2346 
HDA inhibitors were added at time zero of biofilm formation. After incubation 
for 48 h, biofilms were exposed to amphotericin B (50 µg/ml) for 24 h at 37°C. 
Cell viability was measured by the XTT assay. Sodium butyrate (SB; mM), sodium 
valproate (VAL; µg/ml), apicidin (AP; µg/ml), and trichostatin A (TSA; µg/ml) 
were used at concentrations of    2;   8;   32 µg/ml or mM. Results are means 
+ standard errors of two independent experiments carried out in triplicate. 
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the XTT readings for trichostatin A were significantly higher than that of the 
control (P<0.001); the reason for this result is unclear. However, since biofilm 
cells are enclosed in an extracellular polymeric matrix, detachment of the 
biofilm could expose cells directly to the XTT reagent which in turn might result 
in higher readings.  
 Biofilms of C. krusei and C. parapsilosis were also examined for the 
effects of HDA inhibitors on amphotericin B activity. With biofilms of C. krusei, 
sodium butyrate (32 mM) together with amphotericin B (10 or 50 µg/ml) 
decreased viability by 50% and 66%, respectively (P< 0.001; Figs. 74 and 75). 
Valproate and apicidin had their greatest effects at a concentration of 32 µg/ml 
with amphotericin B at 10 µg/ml (i.e. decreases of 37% and 45%, respectively; 
P<0.001). In contrast, trichostatin A, produced no significant effect at any 
concentration tested. With biofilms of C. parapsilosis, on the other hand, results 
were less striking overall. Biofilms treated with a high concentration of HDA 
inhibitors (32 µg/ml or mM) and amphotericin B (10 µg/ml) showed decreases in 
viability of 23%, 18%, and 10% with valproate, apicidin, and sodium butyrate, 
respectively (P<0.05; Fig. 76). At the higher concentration of amphotericin B (50 
µg/ml), there was no significant effect with any of the inhibitors used (Fig. 77). 
6.3.3.2  Viable cell counts 
 Mature (48-h) biofilms of C. albicans GDH2346, C. parapsilosis and C. 
krusei were incubated for 24 h at 37ºC in fresh growth medium in the presence 
of different concentrations of the HDA inhibitors plus amphotericin B (10 or 50 
µg/ml).  HDA inhibitors had a marked effect on biofilm viability in the presence 
of the drug. Biofilm populations of C. albicans were completely eliminated by 
sodium butyrate (8 or 32 mM) at low concentrations of amphotericin B (10 
µg/ml; Fig. 78), and by even lower concentrations of butyrate (2 mM) at higher 
concentrations (50 µg/ml) of the drug (Fig. 79). In the absence of butyrate, 
biofilms of this strain of C. albicans produce persisters which remain viable at 
amphotericin B concentrations of up to 100 µg/ml (Section 5.2.1). Biofilms of C. 
krusei and C. parapsilosis, which also produce persisters, were rather less 
susceptible; combined treatment with butyrate (32 mM) and amphotericin B (50 
µg/ml) reduced biofilm viability by 66% and 75%, respectively (Fig. 80 and 81). 
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Figure 74. Effects of HDA inhibitors on amphotericin B (10 µg/ml) activity 
against biofilms of C. krusei 
HDA inhibitors were added at time zero of biofilm formation. After incubation 
for 48 h, biofilms were exposed to amphotericin B (10 µg/ml) for 24 h at 37°C. 
Cell viability was measured by the XTT assay. Sodium butyrate (SB; mM), sodium 
valproate (VAL; µg/ml), apicidin (AP; µg/ml), and trichostatin A (TSA; µg/ml) 
were used at concentrations of    2;      8;      32 µg/ml or mM. Results are means 
+ standard errors of two independent experiments carried out in triplicate. 
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Figure 75. Effects of HDA inhibitors on amphotericin B (50 µg/ml) activity 
against biofilms of C. krusei 
HDA inhibitors were added at time zero of biofilm formation. After incubation 
for 48 h, biofilms were exposed to amphotericin B (50 µg/ml) for 24 h at 37°C. 
Cell viability was measured by the XTT assay. Sodium butyrate (SB; mM), sodium 
valproate (VAL; µg/ml), apicidin (AP; µg/ml), and trichostatin A (TSA; µg/ml) 
were used at concentrations of   2;     8;   32 µg/ml or mM. Results are 
means + standard errors of two independent experiments carried out in 
triplicate. 
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Figure 76. Effects of HDA inhibitors on amphotericin B (10 µg/ml) activity 
against biofilms of C. parapsilosis 
HDA inhibitors were added at time zero of biofilm formation. After incubation 
for 48 h, biofilms were exposed to amphotericin B (10 µg/ml) for 24 h at 37°C. 
Cell viability was measured by the XTT assay. Sodium butyrate (SB; mM), sodium 
valproate (VAL; µg/ml), apicidin (AP; µg/ml), and trichostatin A (TSA; µg/ml) 
were used at concentrations of    2;    8;  32 µg/ml or mM. Results are means 
+ standard errors of two independent experiments carried out in triplicate. 
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Figure 77. Effects of HDA inhibitors on amphotericin B (50 µg/ml) activity 
against biofilms of C. parapsilosis 
HDA inhibitors were added at time zero of biofilm formation. After incubation 
for 48 h, biofilms were exposed to amphotericin B (50 µg/ml) for 24 h at 37°C. 
Cell viability was measured by the XTT assay. Sodium butyrate (SB; mM), sodium 
valproate (VAL; µg/ml), apicidin (AP; µg/ml), and trichostatin A (TSA; µg/ml) 
were used at concentrations of    2;       8;      32 µg/ml or mM. Results are 
means + standard errors of two independent experiments carried out in 
triplicate. 
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Figure 78. Effects of HDA inhibitors on amphotericin B (10 µg/ml) activity 
against biofilms of C. albicans GDH2346 
Biofilms (48-h) were incubated with amphotericin B (10 µg/ml) and sodium 
butyrate (mM; ♦) or valproate (µg/ml; □) or apicidin (µg/ml; ▲) for 24 h at 37°C 
and cell survival was determined by viable counts. Results are means + standard 
errors of two independent experiments carried out in duplicate. 
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Figure 79. Effects of HDA inhibitors on amphotericin B (50 µg/ml) activity 
against biofilms of C. albicans GDH2346 
Biofilms (48-h) were incubated with amphotericin B (50 µg/ml) and sodium 
butyrate (mM; ♦) or valproate (µg/ml; □) or apicidin (µg/ml; ▲) for 24 h at 37°C 
and cell survival was determined by viable counts. Results are means + standard 
errors of two independent experiments carried out in duplicate. 
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Figure 80. Effects of HDA inhibitors on amphotericin B activity against 
biofilms of C. krusei 
Biofilms (48-h) were incubated with amphotericin B (50 µg/ml) and sodium 
butyrate (mM; ♦) or valproate (µg/ml; □) or apicidin (µg/ml; ▲) or trichostatin A 
(µg/ml; x) for 24 h at 37°C and cell survival was determined by viable counts. 
Results are means + standard errors of two independent experiments carried out 
in duplicate. 
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Figure 81. Effects of HDA inhibitors on amphotericin B activity against 
biofilms of C. parapsilosis 
Biofilms (48-h) were incubated with amphotericin B (50 µg/ml) and sodium 
butyrate (mM; ♦) or valproate (µg/ml; □) or apicidin (µg/ml; ▲) or trichostatin A 
(µg/ml; x) for 24 h at 37°C and cell survival was determined by viable counts. 
Results are means + standard errors of two independent experiments carried out 
in duplicate. 
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 A second HDA inhibitor, sodium valproate, also effectively eliminated 
biofilm populations of C. albicans when used at a concentration of 32 µg/ml with 
amphotericin B at 50 µg/ml (Fig. 79). Biofilms of C. krusei were even more 
sensitive to this inhibitor and lost all viability after treatment with 8 µg/ml 
valproate and 50 µg/ml amphotericin B (Fig. 80). On the other hand, biofilms of 
C. parapsilosis lost only 43% of their viability when treated in an identical 
manner (Fig. 81).  
 The other HDA inhibitors, apicidin and trichostatin A, both significantly 
reduced biofilm viability of all species tested (P<0.002) when used in 
conjunction with amphotericin B, although neither inhibitor produced complete 
killing of the biofilm population. Apicidin at a concentration of 32 µg/ml and 
amphotericin B (50 µg/ml) effectively reduced biofilm viability of C. albicans, C. 
krusei, and C. parapsilosis by 96 %, 87 %, and 74 %, respectively (Figs. 79, 80, 
and 81). Biofilms of C. krusei and C. parapsilosis were similarly sensitive to 
trichostatin A and viability was reduced by 97 % and 87 %, respectively (Fig. 80 
and 81). Trichostatin A was not tested against C. albicans since it was noted that 
this inhibitor used in combination with amphotericin B caused some detachment 
of C. albicans biofilms from PVC discs. 
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1 In vitro activity of amphotericin B and caspofungin at 
different developmental phases of Candida biofilms 
 Candida cells within biofilms are much more resistant to a variety of  
antimicrobial agents than are their planktonic counterparts (Hawser & Douglas, 
1995; Kuhn et al., 2002b; Mukherjee et al., 2003). These agents include the 
clinically important antifungal drugs amphotericin B, fluconazole, flucytosine, 
itraconazole and ketoconazole. More recently, however, it has been reported 
that some of the newer antifungal agents are active against Candida biofilms. 
Thus, while biofilms of C. albicans and C. parapsilosis were clearly resistant to 
the new triazoles, voriconazole and ravuconazole, there appeared to be some 
antibiofilm activity with lipid formulations of amphotericin B and two 
echinocandins (caspofungin and micafungin) (Kuhn et al., 2002b). Caspofungin 
was the first echinocandin to be licensed for clinical use. It acts on planktonic 
cells by inhibiting the synthesis of β-1,3-D-glucan in fungal cell walls. However, 
its action against Candida biofilms is not well characterized.  
 In the present study, the efficacy of amphotericin B and caspofungin 
against biofilms of different Candida species, at different stages of maturation, 
was compared. Biofilms of C. albicans (strains GDH2346 and SC5314), C. 
tropicalis, C. glabrata, and C. parapsilosis were allowed to develop over a series 
of time intervals (8, 17, 24, and 35 h). After each interval, antifungal drug at 
two or five times the MIC was added and the biofilms were further incubated for 
a total of 48 h. The ability of amphotericin B and caspofungin to inhibit fungal 
metabolism at the different stages of biofilm maturation was then evaluated 
using XTT reduction assays. Under the experimental conditions of this study, the 
activity of amphotericin B and caspofungin was assessed according to three 
parameters: (i) the Candida species; (ii) the maturation age of the biofilm; and 
(iii) the concentration of the antifungal drug.  
1.1 Activity of amphotericin B 
 Previous work by Chandra et al. (2001a) demonstrated that antifungal 
resistance of C. albicans biofilms increased in conjunction with the 
developmental phase of the biofilms; in other words, the progression of drug 
resistance was associated with the increase in metabolic activity of developing 
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biofilms. However, a recent study by Tobudic et al. (2009) failed to observe a 
correlation between the age of Candida biofilms and resistance to amphotericin 
B; the metabolic activity of biofilms grown for 24 h and 72 h was reduced 
significantly, but a lesser little effect was observed in 48-h biofilms.  
 In the present investigation, biofilms of both strains of C. albicans were 
more resistant to amphotericin B throughout development (except for the 
earliest stage) than the other Candida species. Amphotericin B at two times the 
MIC (ranging from 1.6 to 4.6 µg/ml) had the least effect on Candida biofilms. 
However, when the drug concentration was increased to five times the MIC 
(ranging from 4 to 11.5 µg/ml), the effect of amphotericin B increased. 
Amphotericin B concentration-dependent activity has been reported previously 
with C. albicans biofilms (Ramage et al., 2002c; Tobudic et al., 2009). 
Amphotericin B at the higher concentration showed relatively high activity 
against C. tropicalis, C. parapsilosis and C. glabrata biofilms, especially at the 
late development phase (35-h biofilms). Further, the least effect was observed 
in biofilms grown for 24 h, except with C. parapsilosis which showed the lowest 
metabolic activity in biofilms grown for 17 h.  
 Amphotericin B binds to the major sterol in the fungal cell membrane, 
ergosterol, and causes the death of the fungal cell (Slavin et al., 2004; Wingard 
& Leather, 2004). Mukherjee and colleagues analyzed the membrane sterols of 
C. albicans and revealed that the levels of ergosterol were substantially 
decreased in intermediate and mature stages compared with those in early-stage 
biofilms (Mukherjee et al., 2003). They also found that the levels of ergosterol 
biosynthetic intermediates varied among biofilm developmental stages. 
Alteration in sterol composition may result in membrane permeability changes 
that prevent or slow down the entry of antifungal drugs into the Candida cell. In 
addition to this mechanism, the absence of extracellular material in young (8-h) 
biofilms might play some role in their enhanced susceptibility to the higher 
concentration of amphotericin B and in the decreased susceptibility of biofilms 
at later stages of maturation. 
                                                                                                                              Discussion 
 
 
 
189
1.2  Activity of caspofungin  
 Data regarding the effect of caspofungin on biofilms of Candida species in 
vitro are rather contradictory. Previous studies have reported that caspofungin 
displays potent antibiofilm activity in vitro with decreases in biofilm metabolic 
activity of >50 % at concentrations similar to the MIC (Bachmann et al., 2002; 
Katragkou et al., 2008; Kuhn et al., 2002b; Tobudic et al., 2009). In contrast to 
these results, Cocuaud et al. (2005) found that caspofungin used at the MIC 
failed to modify the metabolic activity of C. albicans biofilms in all development 
phases tested. Nevertheless, the same concentration of caspofungin significantly 
reduced the metabolism of C. parapsilosis biofilms grown for 2 h or 48 h 
(Cocuaud et al., 2005). Related investigations have shown that when caspofungin 
is used at higher therapeutic concentrations (2 mg⁄l), it causes a significant 
reduction in biofilm metabolic activity of different Candida species, including 
both C. albicans and C. parapsilosis (Cateau et al., 2008; Cocuaud et al., 2005; 
Ferreira et al., 2009; Katragkou et al., 2008; Ramage et al., 2002c). However, 
Choi et al. (2007) have reported that caspofungin, at therapeutic 
concentrations, is active against biofilms formed by C. albicans and C. glabrata 
but not against those formed by C. tropicalis and C. parapsilosis. 
Although caspofungin is a fungicidal agent for planktonic cells of Candida 
species, it failed to show a fungicidal effect, defined as 95 % killing, on C. 
albicans biofilms tested in any of the developmental phases (Tobudic et al., 
2009). By contrast, Ramage et al. (2002c) found that caspofungin killed >99 % of 
biofilm cells of C. albicans at therapeutically attainable concentrations. 
Subsequent studies have shown that complete sterility of mature Candida 
biofilms is difficult to achieve (Bachmann et al., 2002; Katragkou et al., 2008). 
However, caspofungin has shown considerable efficacy in the treatment of C. 
albicans biofilms in vivo (Lazzell et al., 2009; Shuford et al., 2006).  
 In the current work, caspofungin, at two times the MIC (ranging from 0.6 to 
1.6 µg/ml), had a greater effect on Candida biofilms than did amphotericin B, 
although this was not seen with C. parapsilosis biofilms at some stages of 
development (i.e. 24-h and 35-h biofilms). Caspofungin, at five times the MIC 
(ranging from 1.5 to 4 µg/ml), was rather less effective than at the lower 
concentration against C. tropicalis in all development phases tested and against 
                                                                                                                              Discussion 
 
 
 
190
C. albicans SC5314 in some phases (i.e. 8-h and 35-h biofilms). The species most 
susceptible to caspofungin, at both concentrations and throughout biofilm 
development, was C. glabrata. 
Reduced activity of caspofungin at high concentrations, above the MIC, 
has been described for both planktonic and biofilm cells; this phenomenon is 
called the paradoxical effect or paradoxical growth. It has been reported for 
planktonic cells of different Candida spp. (Ostrosky-Zeichner et al., 2003; 
Stevens et al., 2004; Stevens et al., 2005) and for C. albicans biofilms (Ramage 
et al., 2002c; Tobudic et al., 2009). In a recent survey of five different Candida 
species (Melo et al., 2007) all isolates except those of C. tropicalis displayed 
paradoxical growth more frequently when they were grown as biofilms than 
when they were grown as planktonic cells. Moreover, paradoxical growth was 
undetectable among C. metapsilosis isolates grown planktonically but was 
present in 100% of isolates grown as biofilms. In a separate investigation 
(Ferreira et al., 2009)  paradoxical growth was confirmed in biofilms of C. 
albicans and C. tropicalis but not in those of C. parapsilosis. 
So far, the mechanism of the paradoxical effect of caspofungin has not 
been elucidated and its clinical significance is still unclear. In this study, 
paradoxical growth was detected in planktonic cells of some Candida isolates at 
different concentrations of the drug; these were C. albicans (both strains) and 
C. tropicalis. Reduced activity of caspofungin was observed at high drug 
concentrations: at 4 to 16 µg/ml, 8 to 16 µg/ml and 3 to 16 µg/ml for C. 
albicans GDH2346, C. albicans SC5314 and C. tropicalis, respectively. Among 
Candida biofilms tested, caspofungin at five times the MIC showed reduced 
activity against C. tropicalis at all developmental phases and against C. albicans 
SC5314 biofilms grown for 8 h and 35 h only. Recently, Tobudic et al. (2009) also 
demonstrated decreased caspofungin activity at high concentrations in C. 
albicans biofilms, particularly biofilms grown for 48 h. 
 Overall, this part of the study has demonstrated that amphotericin B has a 
concentration-dependent activity against Candida biofilms. Activity varied, 
depending on the Candida species and the development phase of the biofilm. 
Caspofungin, at two times the MIC, exhibited a greater effect on Candida biofilms than 
amphotericin B, except with C. parapsilosis biofilms grown for 24 h and 35 h. 
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The efficacy of caspofungin in inhibiting the metabolism of biofilm cells was 
dependent on the concentration of antifungal used, the Candida species, and 
the phase of biofilm development.  It was also complicated by the paradoxical 
effect. Several resistance mechanisms may be activated during the course of 
biofilm development. These could include the time-dependent production of 
quorum sensing molecules, activation of efflux pumps, alterations of cell wall 
assembly and the presence of persister cells (Tobudic et al., 2009). Further 
research is required to elucidate the role of these mechanisms over the various 
stages of biofilm maturation. 
 
2 Penetration of antifungal agent (caspofungin) through 
Candida biofilms 
 Biofilm-mediated antifungal resistance has been well documented and 
one of the mechanisms that may contribute to biofilm resistance is restriction of 
drug penetration through the biofilm matrix. The extracellular polymeric matrix, 
which envelops biofilm cells, may affect and limit the diffusion of solutes and 
antimicrobials. For example, the ability of a drug to penetrate the biofilm can 
be severely reduced if it is reactively neutralized as it diffuses into a cell 
cluster; this may involve enzymatic degradation or drug binding to charged 
extracellular polymers (Anderl et al., 2000; Stewart et al., 2001). Anderl et al. 
(2000) attributed the ability of ciprofloxacin to penetrate a bacterial biofilm 
faster than ampicillin to its low reactivity with the biofilm. A similar finding was 
reported by Stewart et al. (2001) who observed that chlorosulfamate penetrated 
bacterial biofilms more rapidly than hypochlorite due to a slower reaction rate 
with biofilm components. These results suggest that the extent of antibiotic 
penetration through bacterial biofilms depends greatly upon both the nature of 
the antimicrobial agent and the organism involved. 
 Most studies on drug penetration have been conducted with bacterial 
biofilms. However, three recent investigations (Al-Fattani & Douglas, 2004; 
Samaranayake et al., 2005; Subha & Gananamani, 2008) have evaluated the 
penetration of antifungals through Candida biofilms. These studies were carried 
out using an in vitro filter disc assay with commonly used antifungals such as 
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amphotericin B, fluconazole, itraconozole, ketoconazole, voriconazole, and 
flucytosine. Al-Fattani & Douglas (2004) showed that fluconazole diffused into 
single-species Candida biofilms more rapidly than flucytosine. Both drugs 
penetrated biofilms of C. glabrata and C. krusei faster than those of C. 
parapsilosis and C. tropicalis. Moreover, amphotericin B showed rapid 
penetration through C. albicans biofilms. In mixed-species biofilms containing C. 
albicans and S. epidermidis, the diffusion of the antifungal drugs was very slow. 
Subsequently, Samaranayake et al. (2005) reported that fluconazole and 
flucytosine demonstrated a similar degree of penetration through biofilms of C. 
albicans, C. parapsilosis, and C. krusei, while amphotericin B penetrated least 
well. Biofilms of all three Candida species showed a significant increase in drug 
penetration with increasing fluconazole and flucytosine concentrations but not 
with increasing concentrations of amphotericin B. In contrast to both these 
earlier studies, Subha & Gnanamani (2008) reported that all drugs tested 
(amphotericin B, fluconazole, itraconozole, ketoconazole) were unable to 
penetrate biofilms of C. albicans and C. tropicalis and reach the topmost disc 
(the concentration disc) even at concentrations as high as 2000 µg/ml. However, 
partial penetration by azoles was observed.  
 In this study, the penetration of caspofungin through biofilms of different 
Candida species was investigated using a similar model system. To date, the 
ability of this drug to penetrate Candida biofilms has not been reported. The 
rates of diffusion of caspofungin through biofilms of different strains of C. 
albicans were similar. Al-Fattani & Douglas (2004) described related findings 
with fluconazole and flucytosine; the rates of diffusion of either drug through 
biofilms of three strains of C. albicans were similar. However, different levels of 
penetration through biofilms of non-C. albicans species were observed. 
Caspofungin diffusion through biofilms of C. glabrata and C. parapsilosis was 
faster and greater than that through biofilms of C. krusei and C. tropicalis. 
Faster drug penetration through biofilms of C. glabrata and slower penetration 
through those of C. tropicalis was also reported by Al-Fattani & Douglas (2004).  
 The ability of antifungal agents to diffuse into Candida biofilms will 
depend on the chemical nature of the drug as well as the nature of the biofilm 
matrix material. In this connection, it is noteworthy that in biofilms of C. 
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albicans, C. parapsilosis and C. glabrata the major matrix component is 
carbohydrate, probably glucan, whereas in C. tropicalis biofilms, which are 
poorly penetrated by drugs, it is hexosamine (Al-Fattani & Douglas, 2006; Silva 
et al., 2009). Hexosamine is also present in the matrix of S. epidermidis biofilms 
in the form of a polysaccharide of ß-1,6-linked N-acetylglucosamine (Mack et al., 
1996); this polymer mediates cell-cell interaction within the biofilm  (Gotz, 
2002) and its production has been related to S. epidermidis virulence in 
catheter-infection models in animals. However, synthesis of glucan as a matrix 
component of some Candida biofilms could be inhibited by caspofungin and this 
might explain the rapid penetration of the drug through such biofilms. This is 
discussed further in Section 2.2. 
2.1 Effect of antifungal agents on the viability of biofilm cells 
The effect of antimicrobial agents on biofilm cell viability following drug 
penetration has been investigated previously. Anderl et al. (2000) reported that 
ciprofloxacin perfused bacterial biofilms within a few hours but bacteria were 
not killed even after 24 h of exposure. Likewise, a biofilm formed by a β-
lactamase deficient mutant was fully perfused by ampicillin but the cells were 
not effectively killed. Further, Stewart et al. (2001) demonstrated that both 
chlorosulfamate and hypochlorite completely penetrated bacterial biofilms after 
60 min of treatment but neither antimicrobial was able to kill biofilm cells very 
effectively. Similar findings were reported by Al-Fattani & Douglas (2004). After 
3 to 6 h, both fluconazole and flucytosine had fully penetrated biofilms of 
different Candida species, yet neither drug was able to produce complete killing 
of biofilm cells even after 24 h of treatment.  
In this study, the effect of caspofungin and amphotericin B on biofilm cell 
viability was assessed by viable counts. Biofilms ‘sandwiched’ between the two 
membranes were exposed to antifungal agent-containing agar for 6 h or 24 h. An 
earlier investigation in this laboratory showed rapid penetration of amphotericin 
B throughout C. albicans biofilms (Al-Fattani & Douglas, 2004); however, after 6 
h of amphotericin B and caspofungin penetration, about 70% of the biofilm cells 
remained viable. Both drugs failed to produce complete killing of biofilm cells 
even after 24 h. Indeed, caspofungin showed less activity than amphotericin B. 
This may be associated with the paradoxical effect of caspofungin at high 
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concentrations. A drug concentration of 24 µg/ml was used in this assay. Low 
drug concentrations are unsuitable as high concentrations are required to obtain 
well defined zones of growth inhibition. 
2.2 Scanning electron microscopy of biofilms 
An improved scanning electron microscopy technique was used in this work 
to visualize biofilm structural changes associated with antifungal penetration. 
Conventional SEM methods appear to severely distort biofilm architecture, due 
to the fixation and dehydration steps required (Chandra et al., 2008; Ferreira et 
al., 2009; Ramage et al., 2001a). It has been demonstrated recently that using 
cationic dyes during fixation improves preservation of biofilm exopolysaccharide 
matrix and protects it from collapse during the dehydration/critical point drying 
process. Moreover, various cationic dyes (such as alcian blue, safranin O, and 
ruthenium red) can dramatically increase visualization of the exopolysaccharide 
matrix structure, and different cationic dyes may selectively permit visualization 
of different components in the matrix (Di Bonaventura et al., 2006; Erlandsen et 
al., 2004b). For instance, the Gram-positive bacterium, Enterococcus faecalis, 
produces biofilms on cellulose tubing which have an extensive matrix (Erlandsen 
et al., 2004a). Fixation of these biofilms in aldehyde alone, without cationic 
dyes, allowed the visualization of a few surface fibrils that appeared to attach 
the cocci to the substratum, whereas addition of alcian blue to the aldehyde 
cocktail resulted in a different matrix; this consisted of a branching network of 
fibrils on the cell surface and a thick mat of fibrils on the substratum. However, 
when another cationic dye, safranin O, was used, fewer filaments were present 
and some of them formed a meshwork above cells anchored to the substratum. 
Variations in size, shape and charge density of the dyes appeared to account for 
these differences in matrix appearance (Erlandsen et al., 2004b). 
Previous work by Samaranayake et al. (2005), using conventional SEM 
procedures, demonstrated that biofilms grown on polycarbonate membrane 
filters are distinct from those on polymethyl methacrylate strips or silicone 
elastomer discs (Chandra et al., 2001a; Kuhn et al., 2002a). For example, 
mature biofilms of C. albicans contained very few hyphal forms on membrane 
filter discs in comparison to the abundant filamentation seen on polymethyl 
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methacrylate strips (Chandra et al., 2001a), silicone elastomer (Kuhn et al., 
2002a), or polyvinyl chloride discs (Hawser et al., 1998). 
In this study biofilms of six Candida isolates were examined using the 
cationic-dye procedure for SEM. The results revealed that C. albicans forms a 
dense biofilm consisting of mostly yeast cells on polycarbonate filters; 
occasional filamentous forms were embedded within the exopolymeric material, 
an observation similar to that of Samaranayake et al. (2005). On the other hand, 
C. parapsilosis and C. glabrata appeared to develop biofilms that were less 
dense than those of C. albicans; they contained mostly yeast cells, were devoid 
of hyphal forms and were covered by less matrix material. This was similar to 
the findings of Kuhn et al. (2002a). Subsequent observations of relatively sparse 
biofilm formation by C. parapsilosis on polycarbonate filters were made by 
Samaranayake et al. (2005). Recently, other research groups have reported that 
C. glabrata forms less extensive biofilms consisting of a multicellular structure 
packed with yeast cells but devoid of pseudohyphae and hyphae (Silva et al., 
2009; Thein et al., 2007). Based on biofilm dry weight, Hawser and Douglas 
(1994) showed that isolates of C. parapsilosis and C. glabrata produced 
significantly less biofilm growth on PVC catheter discs compared with C. 
albicans. However, C. tropicalis and C. krusei exhibited more extensive biofilm 
growth than did C. albicans (Hawser & Douglas, 1994). Recently, SEM studies by 
Al-Fattani and Douglas (2004) have revealed that C. tropicalis biofilms consist of 
a dense network of yeast cells and filamentous forms encased in a very slimy 
matrix material (Al-Fattani & Douglas, 2004; Al-Fattani & Douglas, 2006). 
In the current investigation, results similar to those in all of these earlier 
studies were obtained. Biofilms of C. parapsilosis and C. glabrata, formed on 
polycarbonate membrane filters, were less dense than those of C. albicans and 
consisted of yeast cells only. On the other hand, biofilms of C. tropicalis and C. 
krusei possessed a very extensive, slimy matrix material covering a dense 
network of yeast cells and filaments. The slowest rates and the lowest levels of 
caspofungin penetration were found with biofilms formed by C. tropicalis and C. 
krusei and it is possible that the complex structure with slimy matrix of these 
biofilms might retard antifungal penetration. In contrast, the biofilms showing 
the fastest rates, as well as the highest levels of caspofungin penetration were 
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those formed by C. parapsilosis and C. glabrata. One reason for this observation 
could be the formation of less extensive biofilms by both species. 
Previous SEM observations of antifungal-treated Candida biofilms 
demonstrated some obvious effects of the drugs on biofilm structure. 
Samaranayake et al. (2005) reported that although amphotericin B was the drug 
least penetrant through biofilms of C. albicans, C. parapsilosis, and C. krusei, it 
caused more structural damage to the superficial cells of the biofilm than either 
fluconazole or flucytosine. Further, Bachmann et al. (2002) examined the effect 
of caspofungin on biofilms of C. albicans and their results indicated that 
caspofungin significantly affected both cellular morphology and overall biofilm 
architecture. In the present study, an evaluation of the ultrastructural effects of 
antifungal penetration through Candida biofilms revealed that different drugs 
caused different degrees of damage among biofilms of different Candida species. 
SEM observations showed that caspofungin caused more damage to biofilms 
of all the Candida isolates tested than did amphotericin B. Caspofungin severely 
affected the matrix architecture as well as cell morphology. Caspofungin, a new 
lipopeptide antifungal, belongs to the echinocandin family that inhibits the 
synthesis of β-1,3-glucan, a major component of the fungal cell wall (Denning, 
2002; Georgopapadakou, 2001; Kauffman & Carver, 2008). β-Glucans are the 
main component of the C. albicans cell wall, accounting for approximately 60% 
of its weight (Chaffin et al., 1998; Klis et al., 2001).  Moreover, culture 
supernatants of Candida contain high amounts of β-glucans (Odabasi et al., 
2006). Interestingly, cell walls of C. albicans biofilm cells contain significantly 
greater concentrations of β-1,3-glucan than their planktonic counterparts; these 
glucans can also be found in the supernatants surrounding biofilms and in the 
matrix material (Nett et al., 2007a; Nett et al., 2007b). These observations 
would suggest that caspofungin exposure affects biofilm cell walls and matrix 
composition, which in turn change cell morphology and the architecture of the 
biofilm. 
 The chemical composition of matrix material could play a minor role in 
slowing the diffusion of antimicrobial agents. Biofilm cells of P. aeruginosa have 
been shown to contain periplasmic glucans which appear to interact physically 
with antibiotics and retard their diffusion (Mah et al., 2003). It has also been 
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suggested that the nature and the amount of extracellular glucans produced by 
Streptococcus mutans from sucrose in dental plaque play a role in slowing acid 
diffusion (Hojo et al., 1976). Previous work by Baillie and Douglas (2000) 
demonstrated that C. albicans biofilm matrix contains carbohydrate, protein, 
phosphorus, glucose and hexosamine. However, a considerable portion of the 
matrix material remains unidentified. These results were confirmed in recent 
work by Al-Fattani and Douglas (2006) on the chemical composition of the 
biofilm matrix. This study revealed that C. tropicalis biofilms, which are poorly 
penetrated by antifungal agents (Al-Fattani and Douglas, 2004; results of the 
present investigation), contain matrix material rich in hexosamine (27.4%), with 
smaller amounts of carbohydrate, protein, phosphorus, and uronic acid (3.3%, 
3.3%, 0.2%, and 1.6%, respectively). In contrast, C. albicans biofilms, which are 
more readily penetrated by drugs (Al-Fattani and Douglas, 2004; results of the 
present investigation), possess a matrix that consists mainly of carbohydrate 
(39.6%, including glucose 32.2%) with small amounts of protein, hexosamine, 
phosphorus, and uronic acid (5.0%, 3.3%, 0.5%, and 0.1%, respectively). It is 
possible that the slow rate of drug penetration through biofilms of C. tropicalis 
is due to the production of a hexosamine-containing matrix polymer. 
 The impact of several enzymes on biofilm matrix polymers has also been 
investigated (Al-Fattani & Douglas, 2006). The greatest effect was observed with 
lyticase (which hydrolyses β-1,3-glucan), which caused an 85% and 53% 
detachment of C. albicans and C. tropicalis biofilms, respectively. This result 
indicates that some of the glucose present in the C. albicans matrix could be 
present as β-1,3-glucan, a polysaccharide which is a major structural component 
of the cell wall (Al-Fattani & Douglas, 2006). Another study by Nett et al. 
(2007b) showed that the cell walls from biofilm cells of C. albicans contained 
significantly more total carbohydrate and β-1,3-glucan compared with walls from 
planktonic cells, and that these glucans could be found in the supernatant 
surrounding the biofilm and in the matrix. Moreover, cell walls from both 
planktonic and biofilm cells bound a measurable amount of fluconazole. 
However, four- to five-fold more compound was bound to the biofilm cell walls. 
The effect of β-1,3 glucanase on the susceptibility of biofilm cells to fluconazole 
and amphotericin B was also investigated. The enzyme markedly enhanced the 
activity of both drugs against C. albicans biofilm cells. These results suggest that 
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a cell wall component, such as glucan, may interact physically with the 
antifungal and retard penetration to the site of action (Nett et al., 2007b). 
 Recently, a study by Silva et al. (2009) attempted to characterized 
biofilms of non-C. albicans Candida species (NCAC). In this investigation, biofilm 
matrices of NCAC species were analyzed for carbohydrate and protein content. 
Consistent differences were found in the matrix composition of biofilms of the 
NCAC species.  Matrix material from C. tropicalis biofilms had low amounts of 
both carbohydrate and protein while that extracted from Candida parapsilosis 
biofilms had high amounts of carbohydrate with low amounts of protein. In 
contrast, C. glabrata matrix material had higher quantities of both protein and 
carbohydrate compared to the other species; protein levels were on average five 
times higher than those of C. parapsilosis and C. tropicalis (Silva et al., 2009). 
The results of this study are in accordance with previous work on C. tropicalis 
biofilms by Al-Fattani and Douglas (2006) which demonstrated that the matrix of 
this species contains mainly hexosamine, with smaller amounts of carbohydrate 
and protein. It also further supports the notion that biofilms which contain 
substantial amounts of matrix carbohydrate (those of C. albicans, C. 
parapsilosis, and C. glabrata) are more easily penetrated by antifungal agents, 
including caspofungin, than are hexosamine-rich biofilms such as those of C. 
tropicalis. 
 A non-destructive, in situ analysis by Raman microscopy was applied 
recently to multispecies biofilms (Ivleva et al., 2008; Ivleva et al., 2009; Wagner 
et al., 2009). Without staining the sample, this technique can provide detailed 
information about the chemical composition and the distribution of extracellular 
polymeric substances and microorganisms within such biofilms. Based on their 
specific Raman scattering signals, the various constituents in the biofilm matrix 
can be classified (e.g. polysaccharides, proteins) and detailed chemical 
information about them obtained. Raman microscopy is therefore a promising 
future tool for further characterization of different matrix constituents in 
Candida biofilms. 
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3 Persister cells in planktonic cultures and biofilms of 
different Candida species  
 The discovery of persister cells in bacterial biofilms helped to clarify the 
puzzling resistance of biofilms to killing by antimicrobial agents (Keren et al., 
2004b). Persisters were originally described as dormant or nongrowing cells 
(Lewis, 2007) but are now recognized as drug-tolerant cells – usually 1% or less of 
the overall population – which neither grow nor die in the presence of 
microbicidal antibiotics. The ability to avoid killing is their key characteristic 
(Keren et al., 2004a). The existence of such cells in biofilms of C. albicans (Khot 
et al., 2006; LaFleur et al., 2006; Lafleur et al., 2009; Tsang & Tang, 2009) has 
also been reported recently . LaFleur et al. (2006) demonstrated that exposure 
of C. albicans biofilms to amphotericin B or chlorhexidine resulted in biphasic 
killing indicative of the presence of a persister subpopulation capable of 
surviving high concentrations of these fungicidal agents. In contrast to bacterial 
species tested, planktonic cultures (exponential or stationary phase) of Candida 
species seemed to be devoid of persisters (LaFleur et al., 2006).  
 In this study, viability measurements and fluorescein staining were used 
to investigate the existence of persisters in planktonic cultures and biofilm cells 
of C. albicans, C. tropicalis, C. glabrata, C. krusei, and C. parapsilosis subjected 
to different concentrations of amphotericin B. Planktonic cultures of all these 
species appeared to lack persisters, in accordance with the earlier results of 
LaFleur et al. (2006). Similarly, using the criteria adopted previously for C. 
albicans (LaFleur et al., 2006), persisters were absent from biofilms of some 
species. Persisters were found in biofilms of C. albicans GDH2346, C. krusei, and 
C. parapsilosis in low numbers (0.001 to 0.07%), while biofilms of C. albicans 
SC5314, C. glabrata and C. tropicalis were devoid of such cells. It is unlikely that 
persister cells were mutants since acquired resistance to amphotericin B is rare. 
Moreover, LaFleur et al. (2006) in their study clearly demonstrated that C. 
albicans persisters were phenotypic variants, not mutants, of the wild type. 
 In addition to viability measurements, fluorescein diacetate was also used 
to discriminate between living and dead biofilm cells; this dye specifically stains 
dead cells green. Biofilms (48-h) of C. albicans (both strains), C. krusei and C. 
parapsilosis were treated with a high concentration (100 µg/ml) of amphotericin 
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B for 24 h at 37ºC and the cells were then stained with fluorescein diacetate. 
With most of these biofilms, small numbers of unstained (live) cells were 
detected. These cells appeared to have a normal morphology and their numbers 
varied according to the Candida species under investigation. C. parapsilosis 
biofilms contained more of the live cells than did biofilms of C. krusei or C. 
albicans GDH 2346. By contrast, no live cells were detected in biofilms of C. 
albicans SC5314 exposed to a high concentration of amphotericin B. 
Fluorescence was rarely observed in untreated, control cells (ie. 72-h biofilm 
cells). On the assumption that the unstained cells represent drug-tolerant 
persisters, these results with fluorescein staining confirmed the viability 
measurements, showing that persisters were present in biofilms of C. albicans 
GDH 2346, C. krusei and C. parapsilosis, but absent from biofilms of C. albicans 
SC5314.  
 A recent investigation by Khot et al. (2006) also identified a small 
subpopulation of cells in C. albicans biofilms showing increased tolerance to 
amphotericin B. The biofilms were cultured in a tubular flow cell and exhibited 
typical C. albicans biofilm architecture (Baillie & Douglas, 1999a; Douglas, 
2003), consisting of a thin basal yeast layer and an overlying thicker, partly 
filamentous layer. After growth, most of the biofilm was removed by draining 
and washing the tubing, but a monolayer of yeast cells remained on the surface. 
In dose-response experiments with amphotericin B, this yeast subpopulation 
showed greater tolerance of the drug than biofilm cells removed by washing. 
Metabolic activity, rather than viability, was measured after exposure to a range 
of amphotericin B concentrations for 1 h. The dose response curve for the basal 
yeast cells decreased to a plateau of approximately 50% metabolic activity 
between a drug concentration of 3.7 µg/ml_ and the highest concentration of 28 
µg/ml_. Whether these cells represent a population of persisters, as defined here 
is not clear. Conversely, it is not known whether the persister population 
identified in biofilms of C. albicans GDH2346 in the present study consisted 
entirely of yeast cells.  
 LaFleur et al. (2009) recently reported a study of Candida persister cells 
in the oral cavity of cancer patients undergoing treatment with chlorhexidine. 
Strains isolated from patients with long-term Candida carriage had high levels of 
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persisters. All of the high-persister isolates had an amphotericin B MIC that was 
the same as that for the wild type indicating that these strains were drug-
tolerant rather than drug-resistant mutants. This study suggests that persister 
cells are clinically relevant and that antimicrobial therapy selects for high-
persister strains in vivo.  
 Another study on the formation of Candida persister cells on titanium 
surfaces was reported recently (Tsang & Tang, 2009). Titanium discs were 
surface-treated by three different methods: group A, polishing; group B, 
sandblasting followed by acid-etching; and group C, sandblasting alone. Persister 
cells of two C. albicans strains (ATCC 90028 and HK30Aa), in planktonic and 
biofilm states, were measured by viable cell counts after 24 h of exposure to 
various concentrations of amphotericin B. No persister cells were detected in 
the planktonic cultures. However, persister cells were detected at a drug 
concentration of 64 µg/ml in all groups of both C. albicans strains. Nevertheless, 
group C of C. albicans ATCC 90028 appeared to provide a surface relatively 
unfavourable for the development of persister cells (Tsang & Tang, 2009). 
 The mechanisms by which Candida biofilms resist the action of antifungal 
agents are poorly understood. The biofilm matrix does not appear to form a 
major barrier to drug penetration since antifungal agents permeate Candida 
biofilms relatively easily (Al-Fattani & Douglas, 2004). However, under flow 
conditions resembling those found in catheter infections in vivo, increased 
production of matrix polymers can contribute to drug resistance (Al-Fattani & 
Douglas, 2006). Studies with a perfused biofilm fermenter (Baillie & Douglas, 
1998a) have shown that drug resistance is not simply due to a low growth rate, 
and a related investigation (Baillie & Douglas, 1998b) demonstrated that iron 
limitation of biofilm growth is not solely responsible. It is possible that 
expression of resistance genes is induced by contact with a surface. For 
example, genes encoding multidrug efflux pumps in C. albicans are upregulated 
during biofilm formation and development. However, mutants lacking these 
genes are drug sensitive when growing planktonically but still drug resistant 
during biofilm growth (Ramage et al., 2002a). The recent attractive suggestion 
that a small number of persister cells are responsible for resistance (LaFleur et 
al., 2006) is not wholly supported by the present study. Although persister 
                                                                                                                              Discussion 
 
 
 
202
populations are present in biofilms of several C. albicans isolates (LaFleur et al., 
2006; Tsang & Tang, 2009), the results described here demonstrate that 
persisters are absent from those of at least one well-characterized strain, C. 
albicans SC5314. Similarly, while biofilms of C. krusei and C. parapsilosis appear 
to harbour persister cells, biofilms of C. glabrata and C. tropicalis are devoid of 
such cells. Biofilm drug resistance in Candida species therefore remains 
unexplained and is most likely multifactorial in nature. 
 
4 Apoptosis in Candida biofilms 
 Apoptosis is one type of programmed cell death that serves to eradicate 
defective cells and is essential for the development and maintenance of 
multicellular organisms. It is defined by a series of biochemical and 
morphological changes, one of the most important of which is the activation of 
caspases (Leist & Jaattela, 2001). During the past decade, evidence of apoptosis 
in both yeasts and filamentous fungi has been obtained (Hamann et al., 2008; 
Madeo et al., 2004; Mazzoni & Falcone, 2008; Ramsdale, 2008). In C. albicans 
growing planktonically, exposure of the organism to a variety of environmental 
conditions such as weak acid stress, oxidative stress, or ultraviolet irradiation 
can produce characteristics typical of apopotosis.  These include externalization 
of phosphatidylserine, chromatin condensation, accumulation of reactive oxygen 
species, DNA degradation and caspase activation (Cao et al., 2009; Phillips et 
al., 2003; Shirtliff et al., 2009; Yang et al., 2010). The benefits of such a suicide 
process to unicellular organisms like yeasts are not immediately obvious. 
However, apoptosis could be highly advantageous for a biofilm community that, 
in many ways, resembles a multicellular organism. The self-destruction of 
damaged cells which consume scarce nutrients in a vain attempt to repair 
themselves could enhance the viability and reproductive success of healthier 
members of the community (Buttner et al., 2006; Lewis, 2000). This study has 
shown via specific staining and the use of caspase inhibitors that apoptosis does 
indeed occur in Candida biofilms during exposure to the antifungal agent, 
amphotericin B. 
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4.1  Detection of apoptotic cells in Candida biofilms 
 Caspase activity was monitored initially in biofilm cells by the binding of a 
specific fluorochrome-labelled inhibitor of caspases (FLICA). FLICAs have become 
widely used for the detection of active caspases in yeasts as well as in 
mammalian cells, although their use has sometimes been controversial 
(Pozarowski et al., 2003; Vachova & Palkova, 2007). Madeo et al. (2002) 
reported FLICA binding to active caspase in intact (propidium iodide-negative) 
cells of S. cerevisiae, and only in cells containing a functional YCA1 gene; no 
binding was detected in an yca 1 mutant. However, other studies have indicated 
nonspecific FLICA binding by heat-killed or ageing yeast cells (Vachova & 
Palkova, 2007; Wysocki & Kron, 2004). In the present investigation, fluorescent 
staining was rarely observed in control cells from biofilms not exposed to 
amphotericin B. Moreover, caspase activity, as detected by FLICA, increased 
with longer incubation times. However, to demonstrate unequivocally caspase 
activity in drug-treated biofilm cells, a second staining method was also used. 
This involves a non-fluorescent substrate, D2R (aspartyl2-Rhodamine 110), which 
enters intact yeast cells and is cleaved by the direct action of activated caspases 
to a green fluorescent compound. Our results with this staining method 
confirmed that drug-treated biofilm cells undergo apoptosis. Very recently, two 
separate research groups have demonstrated caspase activity in planktonic 
cultures of C. albicans by one or other of these staining protocols (Cao et al., 
2009; Shirtliff et al., 2009). 
4.2  Effects of caspase inhibitors on Candida biofilms 
 Synthetic caspase inhibitors have been developed both as research tools 
and with the hope that they may eventually be used clinically to prevent cell 
death. They act by binding to the active site of caspases either in a reversible or 
irreversible manner. The peptide recognition sequence of the inhibitor is 
attached to a functional group such as fluoromethylketone (FMK). FMK-
containing peptides are irreversible inhibitors; those synthesized with an 
additional benzyloxycarbonyl group (also known as Z) show enhanced cell 
permeability. In this study, low concentrations of the general caspase inhibitor, 
Z-VAD-FMK, significantly increased the viability of biofilms of C. albicans 
GDH2346 exposed to amphotericin B, suggesting that caspase activity had been 
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partially suppressed. This inhibitor has a broad specificity and is capable of 
inhibiting human caspases-1 to -9 to varying extents, with greatest activity 
against caspases-1, -5, -8 and -9. The half-life for irreversible inhibition at 1 µM 
inhibitor is < 40 min for all of these enzymes  (Garcia-Calvo et al., 1998). Some 
specific caspase inhibitors, each differing in the nature of its peptide recognition 
sequence, also increased the viability of biofilms of C. albicans GDH2346 treated 
with amphotericin B. The greatest effect, a 40-fold increase in viability, was 
observed with a caspase-1 inhibitor (Z-YVAD-FMK); there were also 8-fold and 
3.5-fold increases with a caspase-9 inhibitor (Z-LEHD-FMK) and a caspase-5 
inhibitor (Z-WEHD-FMK), respectively. 
 Partial suppression of caspase activity in C. albicans by mammalian 
caspase inhibitors is not wholly unexpected. To date, only one enzyme with 
caspase-like activity, CaMCA1, has been identified in C. albicans. This, like its 
homologue in S. cerevisiae, YCA1/MCA1, is a metacaspase (Cao et al., 2009). 
Mammalian caspases are cysteine proteases with a stringent specificity for 
cleaving protein substrates containing aspartic acid. Plant, protozoan and fungal 
metacaspases, on the other hand, display arginine and lysine protease specificity 
instead of the aspartic acid specificity characteristic of caspases. Nevertheless, 
Madeo et al. (2002) reported that extracts of a YCA1 overproducing strain of S. 
cerevisiae, which had been treated with H2O2 to induce apoptosis, showed a high 
proteolytic activity towards several substrates for mammalian caspases. Addition 
of the general caspase inhibitor, Z-VAD-FMK, to the extracts completely 
abrogated this catalytic activity. Mammalian caspase inhibitors, including Z-VAD-
FMK, are also known to be remarkably efficient at blocking programmed cell 
death in plants (Bonneau et al., 2008). However, there is some evidence that 
plant metacaspases do not cleave caspase substrates and are not inhibited by 
caspase inhibitors (Bonneau et al., 2008). It is therefore possible that other 
caspase-like activities are present in both plants and yeasts. In S. cerevisiae, for 
example, an MCA1/YCA1-independent caspase-like activity has been detected in 
an mca1 mutant using the D2R staining procedure (Vachova & Palkova, 2005). 
There are several other reports of MCA1-independent caspase-like activities in S. 
cerevisiae detected by different approaches (Vachova & Palkova, 2007). 
Moreover, very recently, Aerts et al. (2009) demonstrated that the antifungal 
plant defensin RsAFP2 induces apoptotic cell death in C. albicans that is 
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independent of CaMCA1, indicating the existence of at least one other 
unidentified caspase or caspase-like protease in this organism. 
4.3  Effects of histone deacetylase (HDA) inhibitors on Candida 
biofilms 
 There was a striking effect on viability when Candida biofilms were 
incubated with amphotericin B in the presence of HDA inhibitors. The addition of 
either sodium valproate or sodium butyrate to the incubation mixtures 
completely eliminated biofilm populations of C. albicans GDH2346 at 
amphotericin concentrations of 10 to 50 µg/ml. Without an inhibitor, biofilms of 
this strain of C. albicans remain viable at drug concentrations of up to 100 µg/ml 
due to the presence of persisters. HDA inhibitors are known to induce apoptosis 
in mammalian cells (Kawagoe et al., 2002; Medina et al., 1997). Recently, 
valproate was reported to induce YCA1-dependent apoptosis in S. cerevisiae; a 
yca1 mutant survived this treatment (Mitsui et al., 2005). It was subsequently 
shown that valproate also stimulated the accumulation of neutral lipids, mainly 
triacylglycerol, in the apoptotic wild-type cells (Sun et al., 2007). Valproic acid 
is a short-chain fatty acid widely used in humans as an anticonvulsant and has 
teratogenic  and anti-tumour activities. Whether it induces lipid accumulation in 
C. albicans is not known. Sodium butyrate was even more effective than 
valproate at eradicating biofilms of C. albicans GDH2346 when added to 
incubation mixtures together with amphotericin B. Butyrate inhibits germination 
in C. albicans (Noverr & Huffnagle, 2004); at concentrations of 4 to 8 mM, it also 
enhances the activity of fluconazole against planktonic C. albicans cells (Smith & 
Edlind, 2002). 
 Drug-tolerant persisters capable of withstanding high concentrations of 
amphotericin B have been detected in biofilms of many but not all strains of C. 
albicans tested. Biofilms of C. albicans SC5314, for example, appear to lack 
persisters as demonstrated by viable counts and by fluorescein staining. 
Similarly, while biofilms of C. krusei and C. parapsilosis produce persisters, 
biofilms of some strains of C. glabrata and C. tropicalis do not. The reasons for 
these differences are not clear. Moreover, the mechanisms by which Candida 
persisters tolerate high drug concentrations are not understood. This 
investigation has demonstrated that persisters capable of surviving amphotericin 
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B concentrations of 100 µg/ml are nevertheless eradicated at lower drug 
concentrations when simultaneously subjected to an HDA inhibitor such as 
valproate or butyrate. This finding implies that histone acetylation might 
somehow activate apoptosis in these cells. The HDA inhibitor, trichostatin A, is 
known to affect colony-type phenotypic switching in C. albicans. It causes a 
dramatic increase in the frequency of switching in the white-to-opaque 
transition but has no effect on the frequency of switching in the opaque-to-
white transition, suggesting that deacetylation through a trichostatin-sensitive 
deacetylase selectively suppresses switching in one direction (Klar et al., 2001). 
Targeted deletion of HDA1, which encodes a deacetylase sensitive to trichostatin 
A, had the same selective effect. Subsequent studies showed that a second 
histone deacetylase gene, RPD3, plays a role in suppressing the basic switch 
events in both directions (Srikantha et al., 2001). Whether these or any other 
histone deacetylase genes are involved in the regulation of caspase-like activity 
in C. albicans biofilms remains to be demonstrated. 
 Trichostatin A and other HDA inhibitors have also been shown to enhance 
the sensitivity of planktonic C. albicans to the azoles fluconazole, itraconazole 
and miconazole. Smith and Edlind (2002) reported that expression of ERG genes 
(encoding azole targets) and CDR/MDR1 genes (encoding multidrug transporters) 
was induced by fluconazole, but that trichostatin A reduced this upregulation by 
50 to 100%. The authors concluded that trichostatin A probably does not act 
directly on ERG and CDR gene promoters since decreased deacetylation (ie. 
increased acetylation) should enhance, not inhibit, transcriptional upregulation. 
Rather, azole treatment could be associated with histone deacetylation  of the 
promoter region of a transcriptional repressor. The resulting down-regulation of 
this repressor would lead to upregulation of ERG and CDR. However, HDA 
inhibition by trichostatin A would result in constitutive expression of this 
repressor, blocking ERG/CDR upregulation (Smith & Edlind, 2002). 
 Recent evidence suggests that the Ras-cAMP-PKA signalling pathway in C. 
albicans regulates programmed cell death induced by exposure to acetic acid or 
hydrogen peroxide, either by inhibiting antiapoptotic functions (such as stress 
responses) or by activating proapoptotic functions (Phillips et al., 2006). 
Mutations that block Ras signalling were shown to suppress or delay the 
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apoptotic response; in contrast, mutations that stimulate signalling accelerated 
the apoptotic response (Phillips et al., 2006). The role of histone acetylation or 
deacetylation, if any, in this regulatory process is not known, nor is it clear 
whether the Ras pathway is involved in amphotericin-induced apoptosis either in 
planktonic or biofilm cultures. However, treatment of C. albicans with 
trichostatin A has been reported to produce a significant reduction in 
transcription of EFG1, a gene which codes for a key regulatory protein in this 
pathway (Simonetti et al., 2007). Studies with biofilms of Ras mutants of C. 
albicans could therefore be instructive and might help to elucidate the 
mechanism by which drug-tolerant persisters resist programmed cell death.  
 
5 Concluding remarks 
 Implanted medical devices are at risk of Candida biofilm formation. 
Microorganisms in the biofilm environment exhibit an altered phenotype and are 
difficult to remove since they are both recalcitrant to antifungals and isolated 
from host immune components. Clinical guidelines recommend device removal in 
order to avoid progression to systemic disease, which has a mortality rate of up 
to 40%. Biofilm resistance to antifungal drugs is complex and involves more than 
one mechanism. This study has demonstrated that even the most effective 
fungicidal agents, amphotericin B and the newly introduced caspofungin, are 
unlikely to cure or eradicate a biofilm infection.  
 The extent to which the matrix acts as a barrier to drug diffusion would 
depend on the chemical nature of both antifungal drugs as well as the matrix 
material. Caspofungin penetration through biofilms of Candida varied among 
species. However, although caspofungin was able to penetrate biofilms of 
different Candida species with different diffusion rates, it failed to do so at 
rates appreciably different from those of other drugs (Al-Fattani & Douglas, 
2004) and it failed to result in complete killing of biofilm cells. These findings 
suggest that drug penetration is not a major factor in biofilm resistance. On the 
other hand, drug resistance of C. albicans biofilms is significantly enhanced by 
increased production of matrix material under flow conditions (Al-Fattani & 
Douglas, 2006). Thus, further detailed chemical analysis of biofilm matrix 
material is required to understand the nature of antifungal reactivity with 
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various biofilm components. For example, C. tropicalis matrix material, which 
contains significant amounts of hexosamine and appears to partially hinder the 
diffusion of several drugs, deserves further study. 
 The discovery of a persister cell population, which survives high 
concentrations of antifungal drugs, helps to explain the resistance of biofilms to 
killing. Surprisingly, in this study, not all Candida biofilms contained persisters 
which suggests that persisters cannot solely account for drug resistance. It would 
be interesting to carry out a more extensive survey of the existence of persisters 
in biofilms of different Candida species. Additional research aimed at 
determining the molecular mechanisms responsible for persister formation is 
also merited. 
 Amphotericin B induced apoptosis in Candida biofilms as detected by SR-
FLICA and D2R fluorochrome-based staining reagents. Mammalian general 
caspase inhibitor and some specific caspase inhibitors produced significant 
increases in the viability of drug-treated biofilms of C. albicans.  On the other 
hand, histone deacetylase inhibitors enhanced the activity of amphotericin B 
against biofilms of Candida species and in some cases even eradicated persister 
subpopulations. Persisters may therefore represent cells with a defective 
apoptosis mechanism and histone acetylation could activate apoptosis in these 
cells. These results suggest that it might be possible to kill all biofilms cells, 
including persisters, in vivo with a combination of antifungals and apoptosis 
activators (i.e. histone deacetylase inhibitors), if appropriate concentrations are 
used.  
 This study could be extended further by testing drug-tolerant biofilm cells 
for other apoptosis markers such as phosphatidylserine externalization, 
chromatin condensation, or reactive oxygen species accumulation. Recently, the 
isolation of a CaMCA1 null mutant has been reported (Cao et al., 2009) and 
biofilm experiments with this mutant would also be very informative. It now 
appears that C. albicans may contain a caspase activity that is distinct from the 
metacaspase (Aerts et al., 2009). Further investigations with the null mutant 
should establish the relative importance of these activities in Candida biofilms 
exposed to amphotericin B. 
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Appendix 1   Medium 
1.1 Yeast Nitrogen Base (YNB; Difco)  
___________________________________________________________________ 
  
Chemical   Weight/litre 
___________________________________________________________________ 
  
Ammonium sulfate  5.0 g 
Monopotassium phosphate 1.0 g 
Magnesium sulfate  0.5 g 
Sodium chloride 0.1 g 
Calcium chloride 0.1 g 
L-Histidine monohydrochloride 10.0 mg 
LD-Methionine      20.0 mg 
LD-Tryptophan     20.0 mg 
Biotin        2.0 µg 
Inositol     2000.0 µg   
Boric acid    500.0 µg 
Niacin (Nicotinic acid)  400.0 µg 
Manganese sulfate    400.0 µg 
Pyridoxine HCl    400.0 µg 
Zinc sulfate   400.0 µg 
Thiamine HCl    400.0 µg 
Calcium pantothenate (D-Pantothenic acid) 400.0 µg 
Ferric chloride    200.0 µg 
Sodium molybdate 200.0 µg 
Riboflavin    200.0 µg 
p-Aminobenzoic acid 200.0 µg 
Potassium iodide 100.0 µg 
Copper sulfate  40.0 µg 
Folic acid        2.0µg 
___________________________________________________________________ 
Final pH 5.4 ± 0.1 at 25 ˚C 
  
 
 
 
                                Appendices 
 
 
 
236 
1.2 Sabouraud Dextrose Agar (SDA; Oxoid) 
________________________________________________________________ 
Chemical   Weight (g/l) 
________________________________________________________________ 
Mycological peptone    10.0 
Glucose    40.0 
Agar      15.0 
________________________________________________________________ 
Autoclaved for 15 min at 15 lbs pressure (121˚C). Final pH 5.6 ± 0.2 at 25˚C 
 
 
Appendix 2  Buffers 
2.1 0.15 M Phosphate-buffered saline (PBS)  
 
Phosphate buffered saline tablet  
__________________________________________________________________ 
Chemical            Quantity 
___________________________________________________________________________ 
Phosphate buffered saline tablet   1.0 
Distilled water    200 ml 
__________________________________________________________________ 
Each tablet added to 200 ml distilled water yields 0.01 M phosphate buffer, 
0.0027 M potassium chloride and 0.137 M sodium chloride. The solution was 
autoclaved at 121˚C for 15 min. The pH of the subsequent solution was 7.2, at 
25˚C. 
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2.2 RPMI 1640 with HEPES (Sigma) 
 
 
Chemicals g/litre 
Calcium Nitrate 4H2O 0.1 
Magnesium Sulfate (anhydrous) 0.04884 
Potassium Chloride 0.4 
Sodium Chloride 6.0 
Sodium Phosphate Dibasic (anhydrous) 0.8 
L-Arginine (free base) 0.2 
L-Asparagine (anhydrous) 0.05 
L-Aspartic Acid 0.02 
L-Cystine 2HCL 0.0652 
L-Glutamic Acid 0.02 
L-Glutamine 0.3 
Glycine 0.01 
L-Histidine (free base) 0.015 
Hydroxy-L-Proline 0.02 
L-Isoleucine 0.05 
L-Leucine 0.05 
L-Lysine HCL 0.04 
L-Methionine 0.015 
L-Phenylalanine 0.015 
L-Proline 0.02 
L-Serine 0.03 
L-Threonine 0.02 
L-Tryptophan 0.005 
L-Tyrosine 2Na H2O 0.02883 
L-Valine 0.02 
D-Biotin 0.0002 
Choline Chloride 0.003 
Folic Acid 0.001 
myo-Inositol 0.035 
Niacinamide 0.001 
p-Amino Benzoic Acid 0.001 
D-Pantothenic Acid (hemicalcium) 0.00025 
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Final pH 7.0 
2.3 RPMI 1640 with L- Glutamine (Cambrex) 
 
Chemicals mg/L 
Inorganic Salts 
 
Ca(NO3)2•4H2O 100.00 
KCl 400.00 
MgSO4•7H2O 100.00 
NaCl 6000.00 
NaHCO3 2000.00 
Na2HPO4•7H2O 1512.00 
Other Components 
Glucose 2000.00 
Glutathione (reduced) 1.00 
Phenol Red•Na 5.00 
Amino Acids 
L-Arginine 200.00 
L-Asparagine•H2O 50.00 
L-Aspartic Acid 20.00 
L-Cystine 50.00 
L-Glutmaic Acid 20.00 
L-Glutamine 300.00 
Glycine 10.00 
L-Histidine 15.00 
Pyridoxine HCL 0.001 
Riboflavin 0.0002 
Thiamine HCL 0.001 
Vitamin B12 0.000005 
D-Glucose 2 
Glutathione (reduced) 0.001 
HEPES 5.958 
Phenol Red (sodium) 0.0053 
NaHCO3 2.0  
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Hydroxy L•Proline 20.00 
L-Isoleucine 50.00 
L-Leucine 50.00 
L-Lysine•HCl 40.00 
L-Methionine 15.00 
L-Phenylalanine 15.00 
L-Proline 20.00 
L-Serine 30.00 
L-Threonine 20.00 
L-Trypotophan 5.00 
L-Tyrosine 20.00 
L-Valine 20.00 
Vitamins 
p-Aminobenzoic Acid 1.00 
d-Biotin 0.20 
D-Ca Pantothenate 0.25 
Choline Chloride 3.00 
Folic Acid 1.00 
i-Inositol 35.00 
Nicotinamide 1.00 
Pyridoxine•HCl 1.00 
Riboflavin 0.20 
Thiamine•HCl 1.00 
Vitamin B12 0.01 
 
Final pH 7.0     
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